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Abstract 
Two or more forms of gonadotropin-releasing hormone (GnRH) have been isolated from 
most vertebrate species. In most species, GnRH variants have been shown to occur in 
distinct areas of the peripheral and central nervous systems, the gonads and other peripheral 
organs. Although GnRH is a primary regulator of gonadotropin secretion, it has been shown 
to have additional roles such as the regulation of growth hormone secretion in goldfish and 
the inhibition of a potassium current (M-current) in amphibian sympathetic ganglia. This 
raises the possibility of the occurrence of multiple GnRH receptor subtypes. This thesis 
describes the cloning and characterisation of GnRH receptor subtypes from two non-
mammalian vertebrates, the Amphibian , Xenopus laevis and the Osteichthyes, Carassius 
auratus (goldfish). Using degenerate primers designed to the mammalian GnRH receptors 
two putative receptor subtypes were identified from both X. laevis (X/a.1 and Xfo.1) and 
goldfish (GfA and GfB) genomic DNA The full-length cDNA for X/a.1, was cloned from pituitary 
cDNA. When transiently expressed in COS-1 cells, this clone showed a GnRH-dependent 
stimulation of inositol phosphates. No full-length clone for Xfo.1 could be isolated using cDNA 
from several different tissues. A partially processed transcript was, however, amplified from 
sympathetic ganglia cDNA. These ganglia showed specific binding to a chicken GnRH II 
(cGnRH II) agonist and cGnRH II immunoreactivity was also detected in extracts from the 
ganglia. The expression, function and pharmacology of clone Xfo.1, thus remains unknown, but 
the presence of cGnRH II-specific binding sites on membranes from the sympathetic ganglia 
with distinctly different pharamcology, implies the presence of a second GnRH receptor subtype 
in these neurons. Full-length cDNA clones of GfA and GfB were amplified from goldfish pituitary 
and brain cDNA respectively. These receptors had a 71% amino acid identity to each other and 
a 43% amino acid identity to the human GnRH receptor. The pharmacology of these two 
GnRH receptor subtypes was investigated by transient expression in COS-1 cells. The GfA 
and GfB receptors had different pharmacologies as demonstrated by their selectivities for 
GnRH analogues. In situ hybridisation revealed a distinct expression pattern of the goldfish 
GnRH receptor subtypes in the brain, gonads and liver (Dr R. Peter, University of Alberta). 
The full-length receptors cloned from the pituitaries and brain of X. /aevis and the goldfish 
have a low homology to the cloned mammalian GnRH receptors and have several different 
features, such as the presence of an intracellular carboxy-terminal tail. This thesis, 
describing the primary structure and characterisation of ligand selectivity of non-mammalian 
GnRH receptors, provides some useful foundations for future work towards understanding 
ligand recognition in the GnRH receptor. The description of multiple receptor subtypes in the 
goldfish and possibly in X. laevis also provides valuable information into alternative roles of 
GnRH and its receptor, which we are only beginning to understand. 
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Gonadotropin-releasing hormone (GnRH) is a decapeptide, which is synthesised in 
neurons of the hypothalamus. GnRH is secreted in a pulsatile manner directly into 
the hypophysioportal system. GnRH binds to a specific receptor on the surface of 
gonadotropes in the anterior pituitary, where it acts as a central regulator of 
reproductive function by stimulating the release of the heterodimeric gonadotropins 
luteinising hormone (LH) and follicle stimulating hormone (FSH). These hormones 
stimulate gonadal production of sex steroids resulting in gametogenesis. Twelve 
different forms of GnRH have been identified to date, and they are named from the 
species in which they were first identified. In most of the vertebrate species analysed 
to date two or more forms of GnRH occur. The highly conserved and widely 
distributed [His5,Trp7,Tyr~GnRH (chicken GnRH II; cGnRH II) usually co-occurs with 
one or more variable forms of GnRH. The physiological relevance of the occurrence 
of more than one form of GnRH in a single species is unknown, but implies a more 
widespread function , which correlates to its widespread distribution even in non-
reproductive tissues. GnRH has been shown to be important in reproductive 
behaviour and neuromodulation or neurotransmission. The GnRH receptors from 
several mammalian and one non-mammalian species have been cloned. The 
mammalian GnRH receptors, which are highly conserved have been shown to be 
more selective for mammalian GnRH (mGnRH), than the other endogenous forms of 
GnRH. These receptors are G-Protein coupled receptors (GPCRs) which couple to 
the Gq111 class of G-Proteins. 
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1.2 Introduction 
This introduction aims to give a brief background of the structures, evolution, function 
and regulation of gonadotropin-releasing hormone (GnRH) in vertebrates. The 
structure/activity relations and biologically relevant conformations will be discussed. 
Finally the GnRH receptor structure, function, signal propagation and termination, 
and receptor expression will be described for the mammalian system. 
1.3 The Primary Structure of GnRH 
Gonadotropin-releasing hormone (GnRH) is a decapeptide, which regulates the 
synthesis and release of luteinising hormone (LH) and follicle stimulating hormone 
(FSH) [for reviews, see Sch ally et al., 1971; Kiesel, 1993). GnRH was originally 
isolated from mammalian hypothalami [Matsuo et al. , 1971; Burgus et al., 1972), but 
structural variants have been identified in a range of vertebrates, including the 
primitive protochordates. Twelve forms of the peptide have been isolated to date, 
and named from the species in which they were first identified [Gothilf et al., 1995; 
Powell et al., 1996; Jimenez-Linan et al., 1997, for reviews, see Sherwood et al., 
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Trp Ser Tyr 
Trp Ser Tyr 
Trp Ser Tyr 
Trp Ser His 
Trp Ser Tyr 
Trp Ser His 
Trp Ser His 
Trp Ser Tyr 
Trp Ser His 
Tyr Ser Leu 
Trp Ser Asp 
Trp Ser Leu 
6 7 8 9 10 
Gly Leu Arg Pro Gly.NHi 
Gly Leu Gin Pro Gly.NJii 
Gly Leu Ser Pro Gly.NHi 
Gly Leu Asn Pro Gly.NHi 
Gly Trp Leu Pro Gly.NJii 
Gly Trp Leu Pro Gly.NHi 
Gly Trp Tyr Pro Gly.NHi 
Gly Val Arg Pro Gly.NJii 
Asp Trp Lys Pro Gly.NHi 
Glu Trp Lys Pro Gly.NHi 
Tyr Phe Lys Pro Gly.NJii 
Cys His Ala Pro Gly.NHi 
Figure 1.1. Primary structures of the twelve known forms of GnRH isolated from 
vertebrate and protochordate brains. Shaded boxes show highly conserved regions. 
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The primary structure of the different forms of GnRH reveals highly conserved NH2 
and COOH terminal sequences, with a variable domain from residues 5 to 8 (fig. 1.1). 
Position 8 is the most variable followed by positions 5, 7 and 6. Further structural 
variation in the peptide may result from post-translational modifications. The 
hydroxylation of the proline in position 9 of mammalian GnRH (mGnRH) has been 
demonstrated in rat and frog brains [Gautron et al., 1991) and proteolytic cleavage 
may create novel activities [Moss et al., 1973). 
In all species analysed to date, GnRH is encoded by a gene containing four exons. 
GnRH is synthesised as a precursor hormone, which is enzymatically processed to 
form the secreted decapeptide. The precursors of mGnRH [Seeburg and Adelman, 
1984; Adelman et al., 1986; Hayes et al., 1994) chicken GnRH I [Dunn et al., 1993), 
salmon GnRH [Bond et al., 1991; Suzuki et al., 1992; Klungland et al., 1992; Gothilf 
et al., 1995; Okuzawa et al., 1994), cGnRH II [Bogerd et al., 1994; Gothilf et al., 1995; 
White et al., 1994), catfish GnRH [Bogerd et al., 1994), and seabream GnRH [Gothilf 
et al., 1995; White et al., 1995) have been studied in several species of vertebrates 
[for review, see King and Millar, 1997). The mammalian hormone is synthesised in 
the hypothalamus as a preprohormone of 92 amino acids [Seeburg and Adelman, 
1984; Adelman et al., 1986). This precursor consists of a 21-23 amino acid signal 
sequence, followed by the decapeptide and a Gly-Lys-Arg sequence, which is 
required for enzymatic processing and amidation of Gly 10. The amino-terminal pyro-
glutamate forms by a spontaneous cyclisation of Gin 1. The remaining amino acids 
form the GnRH-associated peptide. The role of this peptide is unknown, but it was 
postulated to inhibit prolactin secretion [Nikolics et al., 1985) and increase 
gonadotropin secretion [Millar et al., 1986(a); Milton et al., 1986). This peptide is, 
however, quite conserved, even amongst the different forms of GnRH, therefore, 
inferring the possibility of a physiological role [for review, see King and Millar, 1995; 
1997]. 
1.4 The Evolution of GnRH Structural Variants 
Although the primary structure of GnRH has changed over more than 500 million 
years of evolution, it remains pivotal in controlling reproduction from protochordates, 
to higher vertebrates. The multiple forms of GnRH appear to have arisen by an early 
gene duplication of an ancestral GnRH gene [for reviews, see King and Millar, 1995; 
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1997; Sherwood et al., 1993; 1997). This ancestral molecule may have evolved to 
form the conserved cGnRH II on the one arm, while a further duplication, gave rise to 
the other GnRH isoforms (fig. 1.2). A recent phylogenetic analysis, predicts the 
existence of three evolutionarily distinct forms of GnRH as characterised in 
vertebrates by their brain distribution [White et al., 1998). These include those 
localised in the hypothalamic area (GnRH I), the mesencephalic area (GnRH II) and 
the telencephalic area (GnRH Ill). GnRH I functions mainly as a hypophysiotropic 
factor, and includes the mGnRH, Seabream GnRH (sbGnRH) and chicken GnRH I 
(cGnRH I) subtypes. The highly conserved GnRH II (cGnRH II) has an unknown 
function, but may act as a neuromodulator [Jan and Jan, 1980). The GnRH Ill 
subtype including the salmon GnRH isoform, which has been isolated in bony fish, 
may represent a class of GnRH only recently identified in mammals [Montaner et al., 
1997). These evolutionary schemes [White et al., 1998; King and Millar, 1997; 
Sherwood et al., 1997], all support the hypothesis of an early duplication of an 
ancestral gene before species divergence. 
Invertebrate 
Protochordat 
Jawless .... ................. ........................ .. ... ... ..... ... .... .... ..... ....... ..... ....... ..... 
Cartilaginous 







Figure 1.2. King and Millar (1995; 
1997) proposed a possible 
evolutionary scheme for the GnRH 
gene. The scheme involves the 
early duplication of an ancestral 
gene (A), which may have led to 
the other GnRH forms. Tl, 
Tunicate GnRH I; TII, Tunicate 
GnRH II; LIii, Lamprey GnRH Ill; 
LI, Lamprey GnRH I; Of, Dogfish 
GnRH; M, mammalian GnRH; Cf, 
catfish GnRH; S, salmon GnRH; 
Sb, Seabream GnRH; Cl, chicken 
I; Gp, guinea pig GnRH and CII, 
chicken GnRH II. 
been seen in the common carp, Cyprinus carpio [Lin et al. , 1993] and Tilapia hybrids 
[Melamed et al., 1995]. There is also some evidence, although unconfirmed for 
GnRH-stimulated GH secretion in the rainbow trout, Oncorhynchus mykiss [Blaise et 
al., 1995; for review, see LeGac et al., 1993]. In the African catfish, however, GnRH 
does not affect GH secretion [Bosma et al., 1997]. GnRH has also been shown to 
stimulate pituitary GH secretion in rat neonates [Andries and Denef, 1995]. The 
occurrence of salmon GnRH in the neurons of the olfactory bulb, with projections into 
the retina of the African catfish suggest that this peptide may also co-ordinate 
sensory input with reproductive behaviour [Van Weerd et al., 1991]. GnRH also 
plays an important role as a paracrine/autocrine regulator in the gonads. 
Transcription of the GnRH gene has been described in the ovaries [Oikawa et al., 
1990; Goubau et al., 1992], where it enhances the basal production of steroids, but 
attenuates the gonadotropin-induced cAMP steroidogenesis. This may occur, either, 
by increased degradation or decreased production of cAMP [Harwood et al., 1980; 
Knecht and Catt, 1981, Ranta et al., 1983]. The occurrence of GnRH and GnRH 
receptors in non-reproductive tissue, such as liver, heart kidney and skeletal muscle 
by Kakar and Jennes (1995) by reverse-transcriptase PCR, may implicate GnRH 
involvement in the . regulation of cellular functions unrelated, or related to 
reproduction. GnRH has also been shown to have an autocrine role in certain 
tumours, indicated by the presence of specific GnRH binding sites on prostrate 
tumours [Hierowski et al. , 1983], in breast carcinoma cell lines, which express mRNA 
of both GnRH and its receptor [Eidne et al., 1985; Eidne et al. , 1987; Harris et al., 
1988; Harris et al., 1991] and in tumours originating from the endometrium and ovary 
[Imai et al., 1994(a); 1994(b)]. 
1.6 GnRH regulation 
Tissue specific regulation of GnRH ·in mammals is currently an active area of 
research. The 5' flanking sequences of the rat [Kepa et al., 1992; Whyte et al., 1995] 
and human [Dong et al., 1993, 1997] GnRH genes have been well characterised. 
Both upstream sequences appear to contain several putative transcription factor 
recognition sequences, and both the rat and the human sequences appear to have 
neuron-specific recognition sequences, which infer tissue specificity. Interestingly the 
human promoter appears to have two independent promoter regions. Reproductive 
tissues for example the gonads, use a more 5' upstream promoter and trancription 
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1.5 The role of GnRH 
The physiological significance of the occurrence of multiple forms of GnRH within a 
single species is unclear. The hypothalamic form of GnRH is important for the 
regulation of pituitary gonadotropin release. The mesencephalic form of GnRH, 
namely, cGnRH II (GnRH II) has been highly conserved throughout vertebrate 
evolution. cGnRH II was originally not found in advanced eutherian species, but has 
recently been described in the brain of primitive placental mammals such as, the 
musk shrew [Dellovade et al., 1993; King et al., 1994(b)], and the tree shrew (Kasten 
et al., 1996) and more recently in the brain of primates [Lescheid et al., 1997) and 
human brain and kidneys [White et al., 1998). The role of this highly conserved form 
of GnRH, which predominates extra-hypothalamically is unknown. Although able to 
stimulate the release of gonadotropins, in some cases more potently than the 
hypothalamic GnRH I form [for reviews, see King and Millar, 1995; Sealfon et al., 
1997), it is thought that it may have an additional role in neuromodulation or 
neurotransmission. In amphibia, cGnRH II has been shown to potently inhibit the 
modulatory late-slow postsynaptic potential, known as M-current [Jan and Jan, 1980; 
1982; Jones 1987). It has also been implicated in the control of reproductive motor 
behaviour [Miller and Kriebel, 1986; Maney et al., 1997; for review, see Rissman et 
al., 1997). The high conservation and widespread distribution of cGnRH II may imply 
selective pressure from multiple functions, related to reproductive behaviour . and 
functioning. 
Behavioural interactions have also been shown to be important in the regulation of 
hypothalamic GnRH neuron size or number. Such interactions have been shown to 
alter LH-release [Bowman et al., 1987; Kaynard et al., 1990), which may be a 
reflection of the increase in GnRH immunoreactive neurons, observed after a 
behavioural stimulus [for review, see Rissman et al., 1997). This increase in GnRH 
neurons may be linked to steroid hormone level changes. An example of this is the 
inverse ratio between GnRH neuronal size arid cortisol levels, which is seen in the 
territorial African cichlid fish, Haplochromis burtoni [Fox et al., 1997; Fernald, 1997). 
GnRH can also stimulate the release of growth hormone in goldfish, Carassius 
auratus [Marchant et al., 1989) apparently through the stimulation of a different GnRH 
receptor subtype (Murthy and Peter, 1994). This additional role of GnRH has also 
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start site than do hypothalamic tissues, resulting in a smaller mRNA transcript in 
hypothalamic tissues [Dong et al., 1997]. This may, therefore, be an important 
mechanism for differential control and tissue specificity. The promoter regions also 
have an AP-1 site, which is a known site for the interaction of transcription factors 
such as c-fos. Several growth factors and tissue-specific enhancers may be involved 
in the regulation of the GnRH gene. For example, insulin-like growth factor I has 
been shown to increase both human and rodent GnRH gene expression via the AP-1 
site [Zhen et al., 1997]. 
In mammals, GnRH is released from the median eminence of the hypothalamus into 
the portal system, in a pulsatile manner. This pulsatile release is required to maintain 
gonadotropin secretion [for review, see Conn and Crowley, 1991]. The amplitude 
and frequency of these pulses vary with reproductive states, for example the 
frequency increases during the follicular phase and slows during the luteal phase of 
the human menstrual cycle [Reame et al., 1984]. There is also evidence to suggest 
that the frequency and amplitude of the GnRH pulses can regulate gonadotropin 
subunit gene expression [Daikin et al., 1989], possibly by increasing gene 
transcription [Haisenleder et al., 1991; 1993]. The regulation may also involve GnRH 
receptor number [Kaiser et al., 1997]. The pulsatile release of GnRH from stores in 
the hypothalamus may be under the control of several inhibitory and excitatory 
neurotransmitters. A putative model for the interaction of these neurotransmitters 
has been proposed by Brann and Mahesh (1997] (fig. 1.3). The neurotransmitters 
are regulated by the steroid hormones, estradiol and progesterone. The major 
inhibitory neurotransmitters are the endogenous opioid peptides, for example, p-
endorphin, and neuropeptide K. The opioid peptides, which are activated by the 
cytokine, interleukin-1 p [Kalra et al., 1990], have been shown to inhibit luteinising 
hormone secretion [Rivier and Vale, 1990]. The tachykinin, neuropeptide K-
containing neurons, which have been immunocytochemically co-localised with the 
hyphothalamic GnRH neurons [Valentino et al., 1986], have also been shown to have 
an inhibitory effect on luteinising hormone secretion [Sahu and Kalra, 1992]. These 
neurotransmitter systems act through the inhibition of the excitatory amino acid 
glutamate [Bonavera et al., 1993]. Gamma-aminobutyric acid (GABA), which is 
secreted by neurons in the hypothalamic area, is released episodically into the 
medial pre-optic area in synchrony with luteinising hormone pulses. GABA is thought 
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to restrain amplitude and duration of GnRH secretion. Glutamate along with nitric 
oxide (NO) [Bhat et al., 1995), neuropeptide Y (NPY), nor-epinephrine (NE) and 
galanin are thought to act alone or together to stimulate GnRH secretion [for review, 
see Kalra et al., 1997). 
In summary then, during non-surge conditions the inhibitors act by attenuating the 
effects of the stimulatory neurotransmitters. During surge conditions rising levels of 
steroid hormones are thought to inhibit opioid neurons thereby allowing the activation 
of the excitatory components [for review, see Brann and Mahesh, 1997). 
Estradiol + Progesterone 
~ =1!_ 
Inhibitory Signals 













Figure 1.3. A proposed model for the pulsatile control of GnRH secretion [Brann and 
Mahesh, 1997] 
1.7 GnRH as a gonadotropin-releasing factor 
The main target of GnRH is the anterior pituitary where it binds to GnRH receptors on 
the surface of gonadotropes. Once bound, the receptor, which is a G-Protein 
coupled receptor, is activated. The activated receptor in turn activates the Gq111 class 
of heterotrimeric GTP-binding proteins, which results in a cascade of intracellular 
signaling events, ultimately leading to the synthesis and release of LH and FSH. The 
activation of the G-Protein by the receptor is catalytic; thus several G-proteins can be 
activated by one receptor, thereby, amplifying the signal. 
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The intracellular signaling events leading to the release of the gonadotropins are 
summarised in fig. 1.4 [for reviews, see Kiesel, 1993; Stojilkovic et al., 1994]. Briefly, 
ligand binding to the GnRH receptor activates the G-protein, causing the a., p, and y 
subunits to dissociate and form the Ga-GTP and the G13y subunits. Both the Ga and 
G13r subunits are capable of regulating intracellular signaling. GTP is hydrolysed to 
GDP by the GTPase activity of the Ga subunit causing reassociation with the Gpy-
subunits and subsequent inactivation of the G-protein [for review, see Van Biesen et 
al., 1996]. Activation of the Gq111 class of G-proteins, in the gonadotrope cells in the 
anterior pituitary activates the phosphatidylinositol cycle. Phospholipase C131 (PLC), 
which is activated by the Ga- subunit to cleave phosphatidylinositol 4,5-bisphosphate 
(PIP2) to form inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [for review, 
see Exton, 1994]. Both of these products as well as calcium act as the most 
important second messengers in the GnRH response. IP3 stimulates the release of 
intracellular calcium from vesicular stores, by binding to its receptor. Two calcium 
responses can be induced by GnRH; a calcium spike/plateau or calcium oscillations. 
The calcium spike is thought to originate from the release of intracellular calcium, 
while the plateau phase may be a result of the influx of extracellular calcium. Low 
concentrations of GnRH seem to induce calcium oscillations, which elevate GnRH 
receptor numbers and enhance LH gene expression, without stimulating LH release. 
High concentrations of GnRH cause a calcium spike/plateau stimulus with hormone 
release, but a decrease in gonadotropin gene expression [Leong and Thorner, 1991]. 
DAG in combination with calcium and phosphatidylserine, activates protein kinase C 
(PKC) which phosphorylates serine and threonine residues on target proteins to 
facilitate gonadotropin release. DAG has also been proposed to be important in 
feedback control mechanisms, possibly contributing to the calcium oscillatory signal 
by attenuating PLC activity [Nishizuka, 1986]. PLC may also stimulate GTPase 
activity of Gq111 [Berstein et al. , 1992]. DAG also acts as a substrate of phospholipase 
A2 (PLA2), which synthesises arachidonic acid. PLA2 may be indirectly activated by 
PKC. Metabolites of arachidonic acid, for example leukotrienes, may be important in 
gonadotropin modulation [Kiesel et al., 1991]. The GnRH-stimulated release of 
gonadotropins is, therefore, a highly complex system, finely tuned by the interaction 
of a number of second messengers. 
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Figure 1.4. Diagram depicting the intracellular signaling events leading to the release 
of the gonadotropins, LH and FSH, from the anterior pituitary [Kiesel, 1993]. DAG, 
Diacylglycerol; IP3, Inositol 1,4,5-triphosphate; PIP2, Phosphoinositol 4,5-
bisphosphate; PS, phosphatidylserine; PLC, Phospholipase C; PKC, Protein Kinase 
C; PLA2, Phospholipase A2. 
1.8 Structure/Activity Relations in GnRH 
1.8.1 The conformation of GnRH 
Studies using nuclear magnetic resonance (NMR) [Deslauriers et al., 1975; Chary et 
al., 1986] and circular dichroism [Cann et al., 1979], revealed that GnRH is a highly 
flexible molecule in solution and may exist as a mixture of structural conformations. 
In order to have a high affinity for the receptor, the most abundant form of the peptide 
in solution should be the biologically active conformation [Morrison et al., 1987]. The 
abundant conformation should have the lowest free energy. Momany [1976(a); 
1976(b); 1978], used computational analyses of the free energy to predict the 
possible conformation of GnRH. Despite significant methodological limitations these 
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studies predicted a p-bend involving amino acids 5 to 8 of GnRH [for review, see 
Sealfon et al., 1997). 
The design of GnRH analogues with conformational constraints, which may stabilise 
the active conformation have been valuable in determining the biological active 
conformation [Freidinger et al., 1980). When the type-II p-turn proposed by Momany 
was stabilised by the incorporation of a y-lactam ring between Gly
6 and Leu7 of 
mGnRH, the analogue became much more potent. This confirms earlier studies 
where D-Ala6 , in place of the achiral Gly6 or L-Ala6 , was presumed to increase the 
activity of analogues by stabilising the p-11 type turn [Monahan et al., 1973). 
Two fields of research have contributed to our understanding of the structure and the 
activity of GnRH. Firstly the study of the activity of naturally occurring GnRHs and 
secondly the study of synthetic analogues. 
1.8.2 Activities of endogenous GnRHs 
All the GnRHs stimulate the release of gonadotropins, but the potencies differ 
considerably, in different vertebrate species (fig. 1.5). Non-mammalian GnRHs, with 
the exception of cGnRH II have been shown to have poor gonadotropin-releasing 
activity in mammals [Millar et al., 1986(b); 1989). The mammalian GnRH receptor, 
thus, seems to be highly selective for its endogenous ligand, mGnRH. The non-
mammalian GnRH receptors were, however, thought to be less selective for the 
different forms of GnRH, thus binding the structural variants equally [for reviews, see 
Peter, 1986; King and Millar, 1997). In general, these findings were, however, over 
simplified and incomplete, in that not all the endogenous forms of GnRH have been 
tested using comparable techniques [Peter et al., 1985; Licht et al., 1987; Millar et al., 
1989; Habibi et al., 1992). This will be discussed in light of the cloning of the non-















* * * * 
* * * * * * 
* * * * * 
Figure 1.5. Activities of some of the naturally occurring GnRHs in vertebrates, 
derived from King and Millar [1997]. Activity is shown from 0-100%, as summarised 
from studies on gonadotropin release from pituitary cells and receptor binding 
assays.* Represents not determined. 
1.8.3 The individual amino acids and GnRH activity 
The entire peptide is required for gonadotropin-releasing activity, as any truncations 
of GnRH result in a loss of activity [Sandow et al., 1978]. The conservation of the 
NH2 and COOH terminal domains throughout evolution indicates their importance in 
GnRH activity and function. While the variation in residues 5 to 8 may suggest that 
they are not important in GnRH activity, it may imply that they are important for 
receptor/ligand selectivity. The development and understanding of GnRH analogues, 
including both agonists and antagonists has been vital for understanding the 
importance of individual amino acids in GnRH activity [for reviews, see Rivier et al., 
1981; 1992]. 
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The NH2 terminal domain 
pGlu 1 is required for biological activity. Most substitutions at this position caused a 
loss of activity except analogues with substitutions resembling the pGlu structure, 
such as the cyclic (O=)Ser1 [Fujino et al., 1972], D-pGlu [Hirotsu et al., 1974], 
acylated Gly 1 and formyl Gly 1 [Okado et al., 1973]. Despite the similarity between 
pGlu 1 and Pro, however, substitutions by this amino acid, resulted in a loss of activity 
(Fujino et al., 1972]. pGlu 1 may also be important for receptor activation as 
demonstrated by its substitution in antagonists [for reviews, see Rivier et al., 1981; 
1992]. 
Several substitutions in position 2 of GnRH have indicated the importance of an 
aromatic amino acid in this position. This is confirmed by the high activity of 
[Trp2]GnRH [Monohan et al., 1973] and the relatively low activity of other 
substitutions [for reviews, see Karten and Rivier, 1986; Sealfon et al., 1997]. Further 
support for the importance of an aromatic amino acid at this position comes from the 
recent isolation of [Tyr2,Val7]GnRH (guinea pig GnRH) [Jimenez-Linan et al., 1997]. 
This change in GnRH may, however, be accommodated by changes in the guinea 
pig GnRH receptor. Bulky hydrophobic amino acid residues have replaced His2, 
resulting in antagonistic activity . . Recently His2 . has been suggested to interact 
directly with Lys121 [Zhou et al., 1995] and possibly Asp98 [Rodie et al., 1996] of the 
human GnRH receptor. His2 may, therefore, be important for direct interaction with 
the receptor, as well as being important for the intrinsic activity of the molecule [Vale 
et al., 1972]. 
Substitution studies have indicated the critical role, of an aromatic amino acid in 
position three of GnRH in receptor activation. This is also confirmed by the natural 
substitution of Trp3 by Tyr3 in lamprey GnRH (fig 1.1) [Powell et al., 1996]. Studies 
with the unnatural aromatic amino acids, 2-naphthyl-Ala and pentamethyl-Phe (Me5-
Phe), resulted in analogues with approximately half the activity [Sandow et al., 1978; 
Coy et al., 1974]. Since the only common feature of these amino acids is their ability 
to form 1t-1t interactions with certain aromatic compounds, Trp3 possibly interacts with 
an aromatic amino acid residue of the receptor. 
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Despite the total conservation of Ser4 in GnRH, substituted analogues at this position 
are relatively active [Sandow et al., 1978; for review, see Coy et al., 1975(a)]. The 
size of the substituted side chain, however, appears to be important, with larger 
substitutions such as Leu or Ser(But)decreasing activity [Sandow et al., 1978]. The 
high conservation and spatial constraints at this position may imply that Ser4 
occupies the binding pocket, where it may play a role as a Hydrogen-bond donor with 
the receptor [for review, see Sealfon et al., 1997). 
The central variable domain 
As implied by the high variability with endogenous GnRH peptides including Tyr, His, 
Leu, and Asp, substitutions at position 5 show a high tolerance, with only small loses 
in GnRH activity [Sandow et al., 1978; for review, see Coy et al., 1975(a)]. 
Gly6 is conserved in all the vertebrate GnRHs except the ancient Lamprey and the 
Tunicate isoforms. As discussed above, the presence of an achiral amino acid at this 
position is vital in supporting the biologically active conformation of GnRH, which 
requires a ~ II-type turn [Momany, 1976(a)]. D-amino acids enhance this 
conformation and thus have. a higher activity [Monohan et al., 1973). The Cys in 
position 6 of tunicate GnRH II (Leu5,Cys6,His7,Ala8]GnRH (fig 1.1) may result in the 
formation homodimers, via the formation of a disulphide bridge [Powell et al., 1996]. 
This may be important for decreasing enzymatic degradation. 
Most substitutions of Leu7, did not decrease the activity of GnRH, as suggested by 
the large variability of the natural GnRHs at this position. Analogues with small 
sidechains; such as Ala and Gly, or charged sidechains, such as Lys and Arg, were 
however, less active [Sandow et al., 1978). Thus large uncharged amino acids may 
be required at this position, as confirmed by the demonstration of the increase in LH-
releasing activity of [Trp7]GnRH in sheep [Millar et al., 1989]. 
Arg8 is important for high affinity binding of mGnRH to its receptor [Millar and King, 
1983; Millar et al., 1986(b); Millar et al., 1989]. The activity for several analogues, 
with substitutions at this position have been studied, and conclude that a basic amino 
acid at this position is required for activity [Hazum et al., 1977; Millar and King, 1983; 
for review, see Coy et al., 1975(a)]. In recent studies the acidic Glu301 in extracellular 
22 
loop Ill of the mouse GnRH receptor was shown to confer specificity for Arg8 GnRH 
[Flanagan et al., 1994]. The non-mammalian receptors do not appear to be selective 
for Arg8 GnRH. It was, therefore, proposed that they may not have an acidic amino 
acid in the corresponding position of extracellular loop Ill. This will, however, be 
discussed in greater detail in later chapters. 
The conserved COOH-terminal domain 
The rigidity imposed by the Pro in position 9 and its high conservation, suggest that it 
may be very important for both the structure and activity of GnRH. The substitutions, 
which have been tested decreased activity [Sandow et al., 1978]. 
The Gly-NH2 terminus, however, can be altered considerably without much change in 
activity, with substitutions such as Ala10 [Fujino et al., 1972] retaining 10% of activity. 
Potent analogues of GnRH, with prolonged activity have been made by replacing the 
COOH-terminal glycine amide with an ethylamide [Arimura et al., 1974] and 2,2,2-
trifluroethylamide [Coy et al., 1975(b )]. 
1.9 The GnRH receptor 
The initial cloning of the mouse GnRH receptor by PCR [Tsutsumi et al., 1992] and 
subsequent cloning by expression in Xenopus oocytes [Reinhart et al., 1992] and a 
mammalian cell line [Perrin et al., 1993] and cloning of the other mammalian 
receptors by several groups, including human [Kakar et al., 1992; Chi et al., 1993], 
rat [Eidne et al., 1992; Kaiser et al., 1992], ovine [llling et al., 1993; Brookes et al., 
1993], bovine [Kakar et al., 1993], and porcine [Weesner and Matteri, 1994], led to 
·the classification of the mammalian GnRH receptors as members of the G-protein 
coupled receptor (GPCR) superfamily. 
1.9.1 General characteristics of G-protein coupled receptors 
GPCRs represent the largest family of proteins, with over 300 known members, 
which have been cloned and characterised [for reviews, see Dohlman et al., 1991; 
Baldwin, 1993; Strader et al., 1994; 1995 and Van Biesen et al., 1996]. These 
receptors are grouped by their characteristic coupling to heterotrimeric GTP-binding 
proteins (G-proteins). They are important in conveying extracellular signals to the 
intracellular milieu of target cells, causing an appropriate response. GPCRs have 
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been classed into three major groups according to their sequence alignment: the 
large rhodopsin-like family, the secretin receptor group and the metabotropic 
glutamate receptors. They respond to a diverse array of signaling molecules ranging 
from photons of light hitting the retina, odorants, neurotransmitters, cations, lipids, 
cytokines, glycoprotein hormones, to peptides. Despite their diverse signaling 
mechanisms they have considerable homology. 
The most characteristic feature of G-protein coupled receptors are the 7 hydrophobic 
a-helical domains, which traverse the membrane, and are linked by alternating 
extracellular and intracellular loops. The transmembrane helices have the highest 
amino acid homology between receptors of the same and different subgroups. The 
two-dimensional electron crystallography of the bovine rhodopsin receptor, confirmed 
the hydrophobicity prediction of the arrangement of the 7 a-helical transmembrane 
domains [Schertler et al., 1993]. The transmembrane helices range in size from 18 
amino acids, which is the minimum number of residues required to span the cell 
membrane in an a-helical conformation, to 25 amino acids. Based on the 
assumption that the hydrophobic nature of the membrane will exclude any hydrophilic 
residues, the transmembrane domains can be assigned [Kyte and Doolittle, 1982; 
Chou and Fasman, 1978]. The positively charged Arg and Lys residues, when they 
occur on the cytoplasmic side of a transmembrane helix, may be predicted to lie 
outside the membrane by the hydrophobicity plot. These residues should, however, 
be incorporated into the transmembrane domain [Ballesteros and Weinstein, 1992]. 
They may in fact mark the boundary of the cytoplasmic end, by their ionic interaction 
with the negatively charged headgroups of the inner cell membrane [for review, see 
Ballesteros and Weinstein, 1995]. 
The extracellular and intracellular loops have a large variation both in size, ranging 
anywhere between 5 and 420 amino acids [Baldwin, 1993], and sequence. The 
extracellular loops along with the transmembrane helices are thought to be important 
for ligand recognition [for reviews, see Dohlman et al., 1991; Strader et al., 1994; 
Savarese and Fraser, 1994]. The intracellular loops, especially intracellular loop Ill 
are thought to be important for interaction with G-proteins, and may convey the 
specificity of this interaction. There are a large number of G-proteins, and GPCRs 
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seem to be specific in interacting with particular subtypes [for reviews, see Spiegel et 
al., 1992]. 
Characteristic postranslational modifications to G-protein coupled receptors include 
N-linked glycosylation of the N-terminal domain [Rands et al., 1990; Davidson et al., 
1995], disulphide bridge formation between extracellular loops II- and Ill [Dahlman et 
al., 1990] and the palmitoylation of cysteine residues in the carboxy-terminal domain 
[O' Dowd et al., 1989]. These modifications, may be important for optimal receptor 
expression, receptor conformation and G-protein interaction [for review, see Strader 
et al., 1994]. The phosphorylation of intracellular serine/threonine residues, may be 
important in receptor desensitisation [Lefkowitz et al., 1990]. 
1. 9.2 Structure and function of the mammalian GnRH receptors 
The mammalian GnRH receptor is a member of the rhodopsin family of GPCRs. It 
has, however, several features, which are uncharacteristic of this class of GPCRs, 
which will be discussed in detail in the following sections. Analogous to the studies 
on endogenous GnRH peptides, alignment of GPCRs has been invaluable in the 
study of the structure and function of these receptors, and has helped identify several 
sites important for structural integrity, ligand binding, agonist induced internalisation 
and G-protein coupling [Probst et al., 1992]. Further dissection of the relevance of 
these conserved/unconserved sites has been possible with the aid of site-directed 
mutagenesis. Although the results of such studies are complicated by the affect of 
the mutation on receptor expression, many valuable conclusions have been made. 
Postranslational processing of the mammalian GnRH receptors 
The rodent GnRH receptors have three glycosylation consensus sites, two in the 
amino-terminus and one in the extracellular loop I. The other mammalian GnRH-Rs 
have, however, only one potential site in the amino-terminus, and the other site in 
extracellular loop I. These sites were investigated in the mouse GnRH receptor, 
using a combination of site directed mutagenesis and photo-affinity labelling 
[Davidson et al., 1995; Arora et al., 1997]. Only the two amino-terminal sites were 
implicated. These two sites, when mutated, resulted in receptors with a lower 
expression, due to either decreased stability, membrane trafficking or expression. 
The binding affinity and signal transduction were, however, unaltered. The human 
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GnRH receptor has only one glycosylation site at Asn 18 in the amino-terminus. When 
an additional site was introduced into the amino-terminus by site directed 
mutagenesis, the receptor expression was increased [Davidson et al., 1996(a)]. 
Disulphide bridges between Cys residues create an internal scaffold within the 
receptor, stabilising _the receptor conformation. There is a conserved disulphide 
bridge between Cys residues in extracellular loops I and II, which is present in most 
GPCRs [for review, see Strader et al., 1994]. Disulphide bridges may be important for 
high affinity binding of GnRH because treatment with reducing agents decreases the 
affinity [Keinan and Hazum, 1985]. This disulphide bridge was demonstrated 
between Cys 104 and Cys 196 of the human GnRH receptor [Davidson et al., 1997] and 
Cys 114 and Cys 195 of the rat GnRH receptor [Cook and Eidne, 1997]. An additional 
disulphide bridge between the amino-terminus Cys 14 and Cys200 in extracellular loop 
II, has also been demonstrated in the human GnRH receptor [Davidson et al., 1997], 
but there is conflicting evidence for the occurrence of this disulphide bridge in the rat 
GnRH receptor [Cook and Eidne, 1997]. Cys 14 appears to be involved in the 
covalent binding to the photoreactive side chain of [azidobenzoyl-d-Lys6]GnRH 
resulting in the irreversible activation of the receptor [Davidson et al., 1997]. The 
interaction between the side chain and Cys 14 may, therefore, keep the photoreactive 
ligand in the correct orientation for receptor activation. However, mutants of Cys 14 
still exhibit reduced ligand binding and receptor activity [Cook and Eidne, 1997]. This 
interaction as well as the disulphide bridge between Cys 14 of the NH2-terminus and 
Cys200 of extracellular loop II may, therefore, not be vital for endogenous GnRH 
binding, but the disulphide bridge between extracellular loops I and II is essential for 
receptor function (Davidson et al., 1997; Cook and Eidne, 1997] (fig. 1.6). 
Transmembrane helices 
In the mammalian GnRH receptors transmembrane helices (TM) II and VII are the 
most conserved (96%), followed by TM Ill (93%), TM VI (80%), TM V (78%) TM I 
(70%) and TM IV (58%). A number of highly conserved amino acid residues in 
GPCRs occur in the transmembrane helices, including Pro residues in TM II and TM 
IV - TM VII, which are thought to produce kinks in the a-helices [Baldwin, 1993]. 
Other conserved residues in TM helices include Asn53 (TM I), Trp 164 and Ser167 (TM 
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Figure 1.6. Diagram showing the amino acid sequence of the human GnRH receptor 
and the putative two-dimensional arrangement of the seven transmembrane helices. 
Residues referred in the text are numbered. Residues involved in postranslational 
modifications (green), ligand binding (blue) G-Protein interaction (red) and interhelical 
interactions (white) are shown. 
V) , and Asn315 and Tyr323 (TM VII) [for review, see Davidson et al. , 1994(a)]. Asn87 
and Asp318 in TMs II and VII respectively, appear to have undergone a reciprocal 
exchange when compared to other GPCRs. Mutagenesis experiments of these two 
residues suggest that the reciprocal change seen in the mammalian GnRH receptors 
can be accommodated by the close association of TM helices II and VII [Zhou et al., 
1994). These mutagenesis experiments also suggested a possible role for Asp318 in 
receptor signal transduction [Zhou et al., 1994). 
The Ligand Binding Site 
Mutagenesis studies have been vital in understanding the ligand binding site of the 
receptor. Several GPCRs have been studied and the binding sites appear to be 
located in the TM domains of the receptors [for reviews, see Strader et al., 1994; 
Schwartz, 1994; Strader et al. , 1995). 
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Asp 113 of the ~-adrenergic receptor in TM Ill has been shown to form a salt bridge 
with the amine group of the ligand. Mutagenesis studies have confirmed its role in 
ligand binding. Lys 121 occurs at an analogous position in the human GnRH receptor. 
Mutation of Lys 121 resulted in a loss of agonist affinity, while high affinity antagonist 
binding was retained [Zhou et al., 1995]. GnRH agonists and antagonists differ 
substantially in the amino-terminal region, thus implicating this region for interaction 
with Lys 121 . This interaction may involve the imino group of His2 [Zhou et al., 1995]. 
Asp98, is also thought to interact with His2 of GnRH, as mutagenesis of this site had 
little effect on GnRH analogues with substitutions at position two [Rodie et al., 1996]. 
Asn 102, which is located at the top of TM II, has been shown to interact with the 
glycine amide of GnRH [Davidson et al., 1996(b)]. Combined mutagenesis and 
GnRH analogue studies involving substitutions at the COOH-terminal glycine amide 
were utilised. 
Mutation of Glu301 in extracellular loop Ill of the mouse GnRH receptor to a neutral 
Gin, resulted in the loss of selectivity for GnRH analogues with the positively charged 
Arg at position 8 [Flanagan et al., 1994]. The Gln301 mutant receptor, however, 
showed no loss in affinity for conformationally constrained analogues [Flanagan et 
al., 1994]. This implies that Glu301 in the mouse- or Asp302 in the human receptor 
may interact electrostatically with Arg8 of GnRH, inducing GnRH to assume the active 
conformation [Flanagan et al., 1994]. 
Thus, GnRH binding to the human GnRH receptor appears to involve Lys 121 in TM Ill, 
Asn 102 and Asp98 in TM II and Asp302 in TM VII. While Lys 121 docks the amino-
terminus, possibly His2, Asp98 interacts vyith His2, Asn 102 may bind to the glycine 
amide, and Asp302 may interact with Arg8, inducing GnRH to adopt the active 
conformation (fig. 1.6). 
G-Protein interaction and signal transduction 
Mutagenesis and chimeric receptor studies for different GPCRs have implicated the 
intracellular domains, particularly the second and third intracellular loops (IL) in G-
protein interactions [for reviews, see Doh Iman et al., 1991; Savarese and Fraser, 
1992; Strader et al., 1994]. 
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Alignment of GPCRs led to the identification of the highly conserved DRY motif, 
which is located at the border of TM Ill and IL II. The Asp and Arg residues have 
previously been shown to be important in G-protein coupling [for review, see 
Savarese and Fraser, 1992]. Uncharacteristically the conserved Tyr of this motif is a 
Ser in the cloned mammalian GnRH receptors. Mutational analysis of this motif 
implicated the Asp 138 and Arg 139 residues as important contributors of receptor 
expression, agonist induced activation and internalisation. Ser140, however, is 
unimportant [Davidson et al., 1994(a); Arora et al., 1997]. The Arg residue has been 
shown to interact with Asp 138 and lie 143, which would occur one turn away if 
intracellular loop II forms a a-helix [Ballesteros et al. , 1998]. These residues are 
thought to 'cage' the Arg appropriately for the active and inactive receptor 
conformations [Ballesteros et al., 1998]. 
Another uncharacteristic feature of the mammalian GnRH receptors is the GPCR 
conserved NPX2-3Y motif in TM VII. In the GnRH receptors this motif is DPLIY 
(Asp318, Pro319, Leu320, lle321, Tyr322}. The Asn is changed to an Asp, but the Pro and 
Tyr residues are conserved . Mutagenesis studies revealed the importance of Asp318 
in signal transduction [Zhou et al., 1993]. Mutations of Tyr322 showed the 
requirement of an aromatic amino acid at this position in the receptor, in receptor 
activation and signal transduction [Arora et al. , 1996]. 
Several residues in IL Ill of GPCRs have been mutated, rendering the receptor 
constitutively active. An example of such a mutation is, Ala293 of the a1 B-adrenergic 
receptor, which when mutated to any other amino acids, results in a receptor, which 
is contitutively active [Allen et al., 1991]. When Ala261 in the analogous position in the 
human GnRH receptor is mutated to an amino acid with a bulky side chain, the 
resulting receptor is unable to activate the G-protein, and is thus uncoupled [Myburgh 
et al. , 1998]. 
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Receptor desensitisation and internalisation 
One of the most remarkable features of the mammalian GnRH receptors is the 
absence of an intracellular COOH-terminal tail. The COOH-terminal tail of GPCRs 
has been shown to play an important role in homologous desensitisation, possibly via 
receptor phosphorylation [for review, see Lefkowitz et al., 1990]. The GnRH receptor 
does not show rapid homologous desensitisation in a-T3 cells [Davidson et al., 
1994(b); McArdle et al., 1995]. The GnRH receptor does, however, show a long term 
desensitisation to continuous GnRH stimulation [for review, see Clayton, 1989). This 
long-term desensitisation is both Ca
2
• [Smith and Conn, 1983) and inositol phosphate 
independent [Hawes and Conn, 1992) and may result in GnRH receptor expression 
being down regulated either by decreased efficiency of receptor mRNA translation 
[Tsutsumi et al., 1995) or regulation of gene expression [Lerrant et al., 1995]. The 
lack of short-term homologous desensitisation may be a critical feature of the GnRH 
receptor, which enables it to respond to a pulsatile stimulation of GnRH, ultimately 
leading to the LH-surge. Studies on a chimeric GnRH receptor with the cytoplasmic 
tail of thyrotropin-releasing hormone (TRH) receptor revealed that the lack of a 
cytoplasmic COOH-terminal tail in the GnRH receptor can account for part of the 
receptor's inability to undergo homologous desensitisation to short-term stimulation 
with GnRH [Heding et al, 1998). 
The presence of a COOH-terminal cytoplasmic tail may also be required for agonist-
stimulated receptor internalisation. This has been demonstrated for the TRH 
receptor [Nussenzveig et al., 1993], and will be discussed in greater detail in later 
chapters of this thesis. G-protein coupling and agonist-induced receptor 
internalisation appear to be closely linked, where mutations that affect coupling often, 
affect internalisation. Mutations of Ala
261 to amino acids with bulky side chains, which 
were uncoupled, showed a reduced ability to internalise [Myburgh et al, 1998]. 
Mutations of Asp 138 and Arg 139 of the DRY/S motif at the border of TM Ill and IL II 
also exhibit reduced internalisation [Arora et al., 1997). 
1.9.3 Expression and regulation of the GnRH receptor 
The mammalian GnRH receptors have a widespread distribution in both reproductive 
and non-reproductive tissues. GnRH receptors have been characterised in the 
pituitaries and brain [Millan et al., 1986) of several species [for review, see Stojilkovic 
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et al., 1994]. GnRH receptors have also been localised in the Leydig cells of the 
testis [Bourne et al., 1980; Millar et al., 1982], and the granulosa and luteal cells of 
the ovary [Harwood et al., 1980; Hazum and Nimrod, 1982; Seguin et al., 1982]. 
GnRH binding sites have been found in human breast, [Eidne et al., 1985; 1987], 
endometrial and ovary carcinomas [Imai et al., 1994(a); 1994(b)]. GnRH receptor 
mRNA has also been identified in non-reproductive tissues, by reverse transcriptase 
PCR [Kakar and Jennes, 1995]. 
The human GnRH receptor has been localised to chromosome 4q13.2-13.3 
[Morrison et a/.,1994]. The receptor is encoded by a 18.9 kb gene, which like the 
mouse GnRH receptor gene [Zhou and Sealfon, 1994], consists of three exons [Fan 
et al., 1994]. The GnRH receptor appears to be regulated by several different factors 
and expression may vary greatly during the estrous cycle [Clayton et al., 1980; 
Marian et al., 1981; Kaiser et al., 1993]. The GnRH receptor gene is under the 
homologous regulation of GnRH, as pulses of the hormone increase receptor 
expression, while a continuous administration of GnRH shows no change in receptor 
mRNA levels [Kaiser et al. , 1993; Bauer-Dantoin et al., 1995; Sakakibara et al., 
1996]. This increase in receptor expression may be as a result of estrogen [Bauer-
Dantoin et al., 1995]. Gonadal steroids such as estrogen as well as inhibin [Sealfon 
et al., 1990] appear to increase the GnRH response [Clayton et al., 1980; Duncan et 
al., 1986; Quinones-Jenab et al., 19961]. 
The mouse [Albarracin et al., 1994; Duval et al. , 1997(a)], and human [Fan et al., 
1995; Kakar, 1997] GnRH receptor gene promoters have been characterised [for 
reviews, see Eidne, 1994; Millar, 1997]. Both the mouse and human GnRH receptor 
promoters have multiple regulatory elements such as, Pit-1 (pituitary specific), AP-1 
and AP-2 (protein kinase responsiveness), SF-1 (steroidogenic factor), TRE (thyroid 
hormone response element), PRE/GRE (progesterone/glucocorticoid response 
element), and CRE (cAMP response element) [for review, see Millar, 1997]. The 
mouse GnRH receptor promoter has a novel GRAS (GnRH receptor activity 
sequence), which is the recognition sequences for a tripartite, cell specific enhancer 
[Duval et al., 1997(b)]. Regulation of the GnRH receptor may, therefore be a central 
mechanism in the complex signaling system regulating reproductive pathways. 
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1.10 Concluding remarks 
GnRH has been highly conserved throughout vertebrate evolution (some 500 million 
years), and plays a central role in the regulation of reproduction. Since its discovery 
in 1971 by Ors Schally and Guillemin, GnRH has been widely used as a therapeutic 
agent for reproductive disorders. Due to the nature of the action of GnRH, it is 
utilised to both restore fertility and to selectively suppress the pituitary gonadal axis. 
In order to restore fertility GnRH analogues are administered in a pulsatile manner so 
as to mimic the biological release of GnRH. This is used for the treatment of 
Kallmann's syndrome, pituitary tumours and hypogonadotropic hypogonadism. If 
GnRH is administered continually, by long acting GnRH analogues, the pituitary 
gonadal axis becomes suppressed via the down regulation of the GnRH receptor. 
This can be used to treat endometriosis, uterine fibroids and prostate cancer, where 
normal pituitary function must be suppressed [for review, see Conn and Crowley, 
1990]. The development of long-acting, enzyme resistant analogues would be useful 
for such therapies. Most of the therapeutic agents are confined to injectable 
preparations, thus the design of orally active (non-peptide) analogues would have a 
great impact in furthering the applications of GnRH-related therapies. An additional 
use of GnRH in this regard, includes antifertility agents or contraceptives. These 
would be more specific than the steroidal contraceptives, thus, having fewer side 
effects. 
The cloning of the mammalian GnRH receptors has been important for the 
delineation of ligand/receptor interactions. Several residues in the receptor have 
been identified as important for ligand recognition and receptor activation. A further 
understanding of these interactions may help in the design of therapeutic .agents, as 
described above. The mammalian GnRH receptors are highly conserved (>80% 
amino acid identity), thus the analysis of sequences from more evolutionarily distinct 
vertebrates which recognise the same ligand may be useful in determining both 
agonist and antagonist binding sites in the receptor. The recent cloning of the catfish 
GnRH receptor by Tensen and co-workers (1997] has already proved useful in this 
regard. This thesis describes the cloning and characterisation of GnRH receptors 
from the amphibian, X /aevis and the teleost, Carassius auratus. The primary 
structure and characterisation of ligand selectivity provides some useful foundations 
for future work towards understanding ligand recognition in the GnRH receptor. The 
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description of multiple receptor subtypes in the
 goldfish and possibly in X laevis also 
provides valuable information into alternative ro
les of GnRH and its receptor. The co-
occurrence of multiple GnRH receptors and lig
ands implicates a more diverse role of 




Molecular Cloning, Expression and Characterisation of a Gonadotropin-
Releasing Hormone Receptor from Xenopus laevis Pituitary 
2.1 Summary 
Mammalian GnRH ([Arg8]GnRH, mGnRH) and chicken GnRH II ([His5, Trp7, 
Tyr8]GnRH, cGnRH II) have been shown to be present in amphibia. mGnRH, which 
predominates in the preoptic area, is thought to act as the major hypophysiotropic 
factor, while cGnRH II, which has a widespread distribution, but predominates in the 
hindbrain, may have a role in neuromodulation or neurotransmission. A full-length 
cDNA for a putative gonadotropin-releasing hormone (GnRH) receptor was cloned 
from Xenopus laevis pituitary cDNA, using PCR-based methodology. The 1.1 kbp 
clone is encoded by an approximately 11.4 kbp gene containing two intrans. The 
cDNA encodes a receptor of 368 amino acids with the features of a typical G-protein 
coupled receptor. The amphibian receptor has a 46% amino acid identity to the 
human GnRH receptor [Kakar et al., 1992; Chi et al. , 1993] and a 55% amino acid 
identity to the catfish GnRH receptor [Tensen et al., 1997]. Unlike the mammalian 
GnRH receptors, but like the catfish GnRH receptor, the amphibian receptor has an 
intracellular carboxy-terminal tail [for review, see Sealfon et al., 1997]. The receptor 
was transiently transfected into COS-1 cells and inositol phosphate response 
monitored to characterise ligand specificity. Although previously mGnRH was 
reported to be equipotent to other naturally occurring GnRH subtypes in stimulating 
LH release from the amphibian pituitary, cGnRH II was found to be 2000-fold more 
potent than mGnRH. This contrasts with the mammalian GnRH receptors, which 
show a 10-fold preferential binding of mGnRH compared to cGnRH II. The 
differences in ligand selectivity are presumably a result of differences in amino acids 
making up the binding sites or alternatively, indirectly altering the conformation of the 
receptor such that the binding pocket is altered. This receptor thus offers the 
potential for delineating important conformational residues at a molecular level. 
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2.2 Introduction 
From an evolutionary perspective amphibians are progenitors of mammals via a 
mammal-like reptile and may, therefore, be considered to represent the primitive 
mammalian condition [Carter, 1967]. Amphibians are a useful model system for the 
study of the mammalian endocrine system, as the structures of the major regulatory 
components such as GnRH, thyrotropin-releasing hormone (TRH), corticotropin-
releasing factor (CRF), growth hormone-releasing hormone (GHRH) and 
somatostatin are conserved. Amphibians like mammals have the mammalian and 
chicken II isoforms of GnRH [King and Millar, 1986; Dellovade et al., 1993; King et 
al., 1994(b); Kasten et al., 1996; Lescheid et al., 1997; White et al., 1998 and for 
reviews, see King and Millar 1995; 1997; Sherwood et al., 1997]. The distribution of 
these peptides in amphibia has been intensely studied. While the general pattern of 
distribution between the amphibian genera, may differ slightly, the overall pattern 
seems to be conserved. mGnRH, which predominates in the preoptic area, with 
fibres extending into the hypothalamus and median eminence, appears to be the 
central hypophysiotropic regulator [di Meglio et al., 1991; Fasano et al., 1993; Muske 
et al., 1994; Licht et al., 1994; King et al., 1994(a); Collin et al., 1995; Di Matteo et al. , 
1996; Pinelli et al., 1997]. cGnRH II, however, appears to have a more widespread 
distribution and has a two-fold higher concentration than mGnRH in the brain [Licht et 
al., 1994]. cGnRH II distribution does overlap with mGnRH distribution in the 
preoptic and hypothalamic areas, but mGnRH predominates in these areas, by 
approximately 5-fold [Licht et al., 1994]. cGnRH II predominates in the hindbrain, 
particularly the medulla oblongata, telecephalon and spinal cord, which supports its 
putative role as a neuromodulator [King et al., 1994(a); Licht et al., 1994; Muske et 
al., 1994; Collin et al., 1995; Di Matteo et al., 1996]. 
Although several groups have reported the presence of salmon GnRH (sGnRH) in 
amphibia using immunocytochemistry [Fasano et al., 1993; Di Matteo et al. , 1996] 
this remains to be confirmed. Others have detected an unknown peptide with similar 
properties to sGnRH, but which does not show complete identity with sGnRH-specific 
antisera [Sherwood et al., 1986; Cariello et al., 1989; King et al., 1994(a)]. If sGnRH 
or a third unidentified form of GnRH with properties similar to sGnRH, is present, it 
does not, however, appear to be involved as a hypophysiotropic factor [Fasano et al., 
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1993]. A third form of GnRH, namely [Trp~GnRH, has recently been cloned from 
Rana dubowski [H. Kwon, University of Korea, unpublished]. In this species, mGnRH 
has not yet been identified and thus, this alternate form, may replace mGnRH, or 
may represent a third form of GnRH present in this species. Interestingly, this 
peptide ([Leu7, Trp8]GnRH, may have similar chromatographic properties to sGnRH 
([1Trp7, Leu~GnRH) and may be the third form of GnRH present in amphibia, which 
co-elutes with sGnRH in many species [Sherwood et al., 1986; Cariello et al., 1989; 
King et al., 1994(a)]. 
The cloning of the mammalian GnRH receptors has been valuable for the delineation 
of amino acid residues important in ligand binding, G-protein interaction and 
interhelical interactions. The exploitation of structural/functional evolution of GnRH 
receptors in other vertebrates, may help in this endeavour. The sequence of an 
evolutionarily distinct GnRH receptor, which responds to the same ligand may be 
helpful in furthering our understanding of structure-activity domains of GnRH 
receptors. We have, therefore, determined the sequence of the Xenopus laevis 
pituitary GnRH receptor and characterised its selectivity for different GnRH agonists. 
Amino acid residues which are conserved between the amphibian receptor and the 
mammalian receptors may be important for the receptor conformation, G-protein 
coupling or ligand induced receptor activation. Despite the similarities between 
amphibians and mammals, the amphibian pituitary GnRH receptor is, however, likely 
to be substantially different from several aspects. Firstly the mammalian receptor 
shows a high fidelity for mGnRH and a substantially lower affinity for cGnRH II and 
other GnRH isoforms, while the amphibian pituitary has been reported to not 
discriminate between different GnRH isoforms [Licht et al., 1984; 1987]. Secondly 
the mammalian pituitary requires a pulsatile input of GnRH to facilitate LH and FSH 
secretion, while the amphibian pituitary responds well to the chronic administration of 
GnRH [Licht and Potter, 1986]. GnRH receptor regulation and desensitisation may, 
therefore, be substantially different between the two vertebrates. 
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The cloning and characterisation of the X. laevis pituitary GnRH receptor, described 
in this chapter, however, reveals that these early reports are not correct. Firstly the 
amphibian receptor is highly selective for cGnRH II compared to mGnRH. The 
amphibian receptor also shows partial stimulation with a mammalian GnRH receptor 
antagonist. These differences in the pharmacology between the mammalian- and 
the amphibian GnRH receptors may be dictated by the differences in the primary 
structure of the receptors. The amphibian receptor also has a carboxy-terminal tail , 
which is absent in the mammalian GnRH receptors. This may imply an alternative 
mechanism of regulation and desensitisation. 
2.3 Materials and Methods 
2.3.1 GnRH analogues 
The following GnRH analogues were used: Mammalian GnRH; [Hiss, Trp
7
, 
Tyr8]GnRH (cGnRH II); [Trp7 , Leu8]GnRH (sGnRH); [Gln
8]GnRH (cGnRH I); [T-
BuSer6, Pro9NHEt]GnRH (buserelin) ; [Hiss]GnRH; [Trp
7
, Tyr8]GnRH; [Hiss, D-
Tyr6]GnRH; [Hiss, D-Arg6, Trp7, Tyr8]GnRH; [Hiss, D-Trp
6, Trp7 , Tyr8]GnRH; [Hiss, D-
Lys6, Trp7 , Tyr8]GnRH; [D-Ala6, N-Me-Leu7, Pro9-NHEt]GnRH; [Ac-D-Nal
1
, D-4-
CIPhe2, D-Pal3, lies, D-lsopropyllys6·8, D-Ala 
10 NH2]GnRH (antagonist 135-18); and 
[Ac-D-p-CIPhe 1·2, D-Trp3 , D-Lys6, D-Ala 
10 NH2]GnRH (antagonist 26) were prepared 
by solid-phase synthesis and purified by C-18 reversed-phase chromatography. 
2.3.2 Tissue dissection and isolation of total RNA and genomic DNA 
Adult male African clawed frogs were decapitated, and the cranial bone cut away to 
expose the brain and pituitary. The pituitaries from 10 frogs were pooled for RNA 
extraction. Total RNA was prepared by extraction with guanidinium thiocyanate 
[Chomczynski and Sacchi, 1987). The dissected tissues were placed in 500 µI of 
denaturing solution (4 M guanidinium thiocyanate; 25 mM sodium citrate, pH?; 0.5% 
sarcosyl; 0.1 % 2-mercaptoethanol) , frozen on dry ice and stored at -70°C until 
required. Tissues were homogenised prior to extraction using a sterile 2 ml syringe 
with a 0.8 x 40 mm needle (Promex). RNA was visualised on a 1 % formaldehyde-
agarose gel. To minimise RNA degradation by ribonucleases during extractions, 
solutions were treated with 0.1 % diethylpyrocarbonate (DEPC), prior to autoclaving. 
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solutions which could not be treated with DEPC, were made up with DEPC treated 
distilled water. All glassware, newly opened microfuge tubes and pipette tips were 
autoclaved. 
DNA was extracted from five livers. Once dissected the livers were placed on ice in a 
sterile 50 ml Falcon tube in 10 x volume of lysis buffer (0.6% SOS; 20 mM Tris-HCL, 
pH 7.5; 100 mM NaCl; 50 mM EDTA, pH 8.0). The tissue was homogenised using a 
Polytron homogeniser and incubated at 37°C for 30 minutes. Proteinase K was 
added to a final concentration of 0.4 mg/ml, and the tissue incubated for a further five 
hours at 37°C. The DNA was extracted with an equal volume of equilibrated phenol 
(pH 8.0) , phenol :chloroform:iso-amylalcohol (50:49:1 , vlv) and chloroform:iso-
amylalcohol (49: 1, vlv), by mixing for 15 minutes, followed by centrifugation at 4000 g 
for 10 minutes to separate the phases. DNA was precipitated with two volumes of 
100% ethanol and 0.3 M sodium acetate (pH 5.2) and collected by spooling with a 
glass rod. Once collected the DNA was dipped into 70% ethanol and air dried. DNA 
was resuspended overnight at 4°C in Tris-EDTA buffer (10 mM Tris-HCI, pH 7.5; 1 
mM EDTA, pH 8.0). The absorbance at 260 nm was determined and the DNA diluted 
to a final concentration of 1 mg/ml. DNA was checked for degradation on a 1 % TBE 
(0.09 M Tris-borate; 0.002 M EDTA, pH 8.0) agarose gel containing ethidium bromide 
(50ng/ml) and visualised with UV light. 
2.3.3 Degenerate Primer PCR 
Degenerate primers were designed to regions conserved in the cloned mammalian 
GnRH receptors [personal communications with Dr Janet Hapgood]. The location of 
the primers with regard to the mouse GnRH receptor gene can be seen in figure 2.1. 
The degenerate primers were as follows (N = g, a, t, or c; r = g or a; y =tor c; x = c 
or a, h = a, c, or t; d = a, g, or t): 









J H6a2 5' acactcgagccrtadatntrnggrtc. 
PCR reactions were set up in a dedicated fume hood using aerosol resistant filter tips 
(Quality Scientific Plastics), to prevent contamination. 1 µg of X. laevis genomic DNA 
was amplified in a Perkin-Elmer-Cetus thermal cycler in 50 µI containing 20 mM Tris-
HCI (pH 8.4), 50 mM KCI , 1.5 mM MgC'2, 200 mM dNTP's, 250 ng of the degenerate 
primers and 2.5U Taq DNA polymerase (Gibco BRL). PCR amplifications were 
performed as follows: denaturation at 93°C for 2.5 minutes, followed by 35 cycles of 
93°C for 1 minute, 55°C for 2 minutes and 72°C for 3 minutes, and ending with an 
extension step at 72°C for 5 minutes. 1 O µI of the reaction products were 
electrophoresed through a 2% MetaPhor (FMC) TBE agarose gel containing ethidium 
bromide (50 ng/ml). 
Gene Exon I Exon 2 Exon3 Figure 2.1. Schematic 
diagram of the location of 
the degenerate primers 
relative to the mouse GnRH 
receptor gene and cDNA. 
c::> c::> ~ c:> ~ Diagram is not to scale. 




JH2a ~ JH 6a, 
• Transmembrane domain 
JH Sa 
c::> Sense primer 
~ A.ntisense primer 
2.3.4 Southern Blot Analysis 
PCR products were electrophoresed through a 1 % agarose TBE gel. The DNA in the 
gel was denatured for 30 minutes in denaturing solution (1.5 M sodium chloride; 0.5 
M sodium hydroxide), and then neutralised by washing twice in neutralising solution 
(1 .5 M sodium chloride; 0.5 M Tris-HCI, pH7.2; 1 mM EDTA) for 15 minutes. DNA 
was transferred to nitrocellulose membrane (Hybond N\ Amersham) overnight in 20 
x SSC (3M NaCl; 0.3 M sodium citrate, pH?.2) by capillary blot. The membrane was 
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washed in 2 x SSC, and fixed for 20 minutes in 0.4 M sodium hydroxide. Probes 
were labelled to a specific activity of approximately 7 x 108 cpm/µg using [a32P]dCTP 
(3000Ci/mmol) and the Megaprime labelling kit (both Amersham). Labelled probes 
were purified from unincorporated deoxynucleotides using a Sephadex G-50 spin 
column, equilibrated with 100 µI of STE (10 mM tris-HCI , pH 8; 1 mM EDTA; 100 mM 
NaCl). Probes used are specified in results. Blots were prehybridised, for 1 h prior to 
an overnight hybridisation in hybridisation solution containing the denatured [32P]-
labelled probe, 50% deionised formamide, 100 µg/ml denatured herring sperm DNA, 
2 x Pipes (0.02 M piperazine-N,N'-bis[2-ethanesulphonic acid, 0.8 M NaCl) and 0.5% 
SOS. Membranes were washed for 15 minutes at room temp in 1 x SSC, 0.1 % SOS 
followed by a 20 minutes wash at 50°C in 0.5 x SSC, 0.1 % SOS, and a second 20 
minutes wash at 50°C in 0.2 x SSC; 0.1 % SOS. Membranes were subjected to 
autoradiography and in most cases a 3 to 5 h exposure at -70°C was sufficient to see 
results. 
2. 3. 5 PCR product subcloning and analysis 
PCR products of interest were excised from low melting point agarose gels (FMC 
BioProducts) and subcloned using Amersham pMOSb/ue T-vector kit (see appendix 
7.1 for map), according to manufacturer's specifications. Recombinant colonies were 
screened for inserts using either colony hybridisation to a probe of interest or colony 
PCR. For colony hybridisation colonies were grided onto agar plates containing 
ampicillin (100 µg/ml) in duplicate. Colonies were lifted onto Hybond N+ 
nitrocellulose (Amersham) 72 mm disc membranes in duplicate, denatured in 
denaturing solution (1.5 M sodium chloride; 0.5 M sodium hydroxide) for 7 minutes, 
neutralised twice in neutralising solution (1 .5 M sodium chloride; 0.5 M tris-HCL, 
pH7.2; 1 mM EDTA) for 3 minutes, fixed for 20 minutes in 0.4 M NaOH and probed 
as for Southern blots. For the purposes of colony PCR, colonies of interest were 
picked in 20 µI of sterile water. 15 µI was used to inoculate an overnight culture, 
while the other 5 µI was used for PCR amplification in 20 µI with 1.5 mM MgC'2, 200 
mM dNTPs, 20 mM Tris-HCL (pH8.4 ), 50 mM KCL, 10 pmoles of vector specific ' 
primers (see appendix, for vector maps), 1 U of Taq DNA polymerase (Gibco BRL). · 
PCR cycle conditions were set up as for the degenerate primer PCR (2.3.3). PCR 
products were analysed by agarose gel electrophoresis followed by Southern blotting 
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or direct SOS-alkaline lysis mini-preparation of DNA from positive colonies. DNA of 
interest was sequenced (T7 Sequenase version 2.0, Amersham). 
2. 3. 6 Screening and analysis of the Genomic DNA library 
AX. laevis Lambda EMBL4 (see appendix 7.2 for map) genomic library was kindly 
supplied by Dr T. Sargent (NIH). The library was made from DNA extracted form red 
blood cells of a female homozygous diploid frog line (HD-1) of X. laevis, prepared by 
gynogenesis by Dr Robert Tomkins. The DNA was subjected to a partial digestion 
with Sau3A and the 15-20 kbp fraction was recovered from a sucrose gradient. The 
DNA was ligated to the EMBL4 BamH1-Sal1 cut vector, packaged in vitro and plated. 
The titer of the library was established as 1.6 x 109 pfu/ml, by plating on Escherichia 
coli LE392 [Leder et al., 1977]. A million plaques were screened by filter 
hybridisation with Hybond N+ (Amersham), as described by Benton and Davis (1977). 
PCR generated subclone pXla.1 (see appendix 7.3) was used as a probe, and was 
labelled as described above, using the Amersham Megaprime labelling kit. Primers 
JH5s and JH6a2 were substituted for the random hexamers, due to the low specific 
actvity generated with the random primers. Phage DNA from positive plaques, which 
were subjected to secondary and tertiary screenings, was prepared using the small 
scale liquid lysate method [Benson and Taylor, 1984]. DNA was analysed by 
appropriate restriction endonuclease digestion, followed by Southern blotting. The 
genomic clone EcoR 1 restriction endonuclease fragment of approximately 3 kbp was 
subcloned into the dephosphorylated EcoR1 site of pBSK(+/-) (Stratagene, see 
appendices 7.4 and 7.5 for maps), and sequenced with the T7 Sequenase system 
(Amersham), using gene specific primers. 
2.3. 7 Amplification of cDNA 
Several approaches were used for attempted PCR amplification of full-length cDNA, 
using gene specific primers designed from the subclones obtained after PCR on 
genomic DNA (pXla.1) and sequencing of the genomic clone (pXla.2). See 
appendices 7.3 and 7.5b for the primer design and location. These approaches were 
mainly adapted from the initial RACE (rapid amplification of cDNA ends) method 
described by Frohman et al. (1988). This method was used, but no conclusive 
results were obtained. An adaptation of this method, described by Chenchik et 
a/.(1995) was finally used to successfully clone the full-length cDNA of the pituitary 
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GnRH receptor. This method made use of a Marathon cDNA kit (Clonetech), which 
requires the ligation of adapter primers at the 5' ends of double stranded cDNA which 
is more efficient than homopolymeric tailing described by Frohman et al. (1988). 5 
µg of total RNA was digested with 5 U of RNase free DNase I for 30 minutes at 37°C, 
followed by extraction with phenol to remove the enzyme, and precipitation with 
100% ethanol. cDNA synthesis from 1 µg of total RNA, was performed according to 
kit specifications with [a-32P]dCTP (1 µCi/µI , Amersham), in order to facilitate 
quantification of cDNA synthesis. Double stranded cDNA was analysed by agarose 
gel electrophoresis followed by autoradiography. Adaptor primers were ligated onto 
the 5' ends of the double stranded cDNA. The cDNA was then amplified in a thermal 
cycler (Perkin-Elmer) in 50 µI containing 200 mM dNTPs, adaptor primers and gene 
specific primers (X/1a.1a and X/1a.2a, see appendix 7.5b) at 10 µM and 1x 
Advantage KlenTaq polymerase mix (Clonetech) with its reaction buffer. PCR 
amplifications were performed as follows: denaturation at 94°C for 1 minutes, 
followed by 35 cycles of denaturation at 94°C for 30 sec. and either annealing at 
64°C for 30 sec. and extension for 3 minutes at 68°C or annealing and extension for 
3 minutes at 68°C. Negative controls for the PCR were as follows: no cDNA, and an 
adaptor only control. This control is used to determine if any of the products 
generated are as a result of amplification with only the adaptor primer. In some of 
the amplifications a negative control where only gene specific primers were added, 
was included, in order to determine if any products were a result of non-specific 
amplification. A positive control cDNA, with gene specific primers was included in the 
kit. After two rounds of PCR, using nested gene specific and adaptor primers, 
products of all the reactions were loaded onto a 1 % agarose gel and subjected to 
Southern blotting. 100 pmoles of oligonucleotide probe (X/1a.4s, see appendix 7.5b) 
was labelled with [y32P]dATP at 5000 Ci/mmol and 10 U of T 4 polynucleotide kinase 
(both Amersham) for 1 h at 37°C. Following the labelling reaction , the probe was 
purified on a Sephadex G-10 spin column equilibrated with 100µ1 of 1 x STE (10 mM 
tris-HCI, pH 8; 1 mM EDTA; 100 mM NaCl). The membrane was prehybridised for 2 
h prior to an overnight hybridisation in hybridisation solution consisting of; the 
labelled oligonucleotide probe in 5 x Denhardts reagent (0.1 % (w/v) of Ficoll, 
polyvinylpyrrolidone, and BSA); 6 x SSC (0.9 M NaCl. 0.09 M sodium citrate, pH 7.2)) 
and 0.5% (w/v) sodium dodecyl sulphate (SOS). The hybridisation temperature was 
5°C lower than the melting temperature of the oligonucleotide, which was calculated 
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from the nucleotide sequence as, 2(A+ T)+4(G+C). After hybridisation, the 
membrane was subjected to low stringency washing for 5 minutes at room 
temperature in 5 x SSC, and 0.1 % SOS, followed by autoradiography. Any positive 
products were analysed as in section 2.3.5 (PCR product subcloning and analysis). 
2. 3. 8 Isolation of a full-length cDNA clone 
The 1.2 kbp cDNA encoding the full-length receptor was amplified from Marathon 
pituitary cDNA using Pfu DNA polymerase (Stratagene) and primers designed to the 
5' and 3' untranslated regions. The 5' sense primer was designed to the untranslated 
region of the sequence of the marathon clones and the 3' antisense primer was 
designed to the untranslated region of pXla.2 (see appendix 7.5 and fig. 2.6, primer 
Xl1 a. 1 a). Five individual cDNA clones were sequenced in both the forward and 
reverse directions (T7 sequenase version 2.0, Amersham). Where sequences varied 
(see section 2.4.3) the relevant region of the genomic clone, amplified by PCR was 
sequenced for verification. 
2. 3. 9 Cell Culture 
COS-1 cells were grown in 25 ml cell culture flasks (Corning) in Dulbecco's modified 
Eagle's medium (DMEM) containing 10% heat inactivated foetal calf serum in a 5% 
CO2 incubator. Cells were subcultured when 70% confluent using 0.25% trypsin, 
0.04% EDTA in PBS (137 mM NaCl, 2.68 mM KCI, 0.43 mM NaH2P04, 1.47 mM 
KH2P04, pH 7.4). Cells were maintained in antibiotic-free medium. 
2.3.10 Transient transfection of COS-1 cells 
The X. laevis GnRH receptor cloned from pituitary cDNA was subcloned into the 
BamHI and Xhol sites of pcDNA 1/Amp (lnvitrogen) (see appendix 7.6), expression 
vector containing the SV40 early promoter. DNA for transfection was prepared from 
a 500 ml overnight culture of 2 x YT Broth (10 g/L NaCl, 10 g/L Yeast extract, 16 g/L 
Bactotryptone) containing Ampicillin (100 µg/ml). Plasmid DNA was extracted using 
the Wizard DNA purification system (Promega). 24 h prior to transfection, cells were 
plated at appropriate density on poly-0-lysine coated dishes, in DMEM containing 
10% foetal calf serum, penicillin (0.2 U/ml) and streptomycin sulphate (100 µg/ml) 
(Gibco BRL). DNA was transfected in serum-free DMEM for 4 h using an adapted 
DEAE-Dextran method [Keown et al., 1990], with a 50 minute chloroquine (200 µM) 
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treatment and a 2 minute 10% dimethylsulfoxide shock [Luthman and Magnusson, 
1983; Lopata et al. , 1984]. For studies on membrane receptor binding 3 x 106 
cells/10 cm dish (Corning) were transfected with 15 µg of DNA For assays of 
inositol phosphate production and whole cell binding assays, 2 x 105 cells/well (12 
well plates, Corning) were transfected with 2µg of DNA Cells were grown for 48 h 
after transfection, before each experiment. 
2.3.11 Receptor Binding Assay 
Both cell membrane assays and whole cell binding assays were tested. For 
membrane binding, cell membranes were prepared from transfected cells, as 
described in Millar et al. (1989). The receptor binding assay was performed using 
80000 cpm of 1251-[D-Ala6, N-Me-Leu7,Pro9-NHEt]GnRH, 1251-[Ant26]GnRH 
(Antagonist 26) and 1251-[His5, D-Arg6, Trp7, Tyr8]GnRH, which were radioiodinated 
according to an adapted chloramine-T method [Millar et al., 1995]. For whole cell 
binding, cells were washed twice for 5 minutes at 4°C in buffer I (140 mM NaCl; 4 
mM KCI; 20 mM HEPES; 8.6 mM glucose; 1 mM CaCl2; 1 mM MgClz; 0.1 % BSA, 
fatty acid free; pH7.4), followed by incubation for 3 h at 4°C with 100 000 cpm of 
labelled GnRH agonist and an appropriate amount of unlabelled GnRH agonist. The 
binding at 10-6 mGnRH agonist was considered to represent the non-specific binding 
(NSB). After incubation the cells were washed three times in buffer I to remove 
unlabelled peptides, removed from the plates with 0.5 M NaOH and bound 
radioactivity counted. 
2.3.12 Inositol Phosphate Assay 
Transfected COS-1 cells were labelled overnight in 0.5 ml of Medium 199 (Gibco 
BRL), containing 2% foetal calf serum and 2 µCi/ml myo[2-3H]inositol (Amersham) as 
described in Millar et al., (1995). Cells were washed twice for 5 minutes at 37°C in 
buffer I, followed by stimulation with GnRH, as required, in buffer I and 10 mM LiCI 
for 1 h at 37°C, with gentle agitation. Inositol phosphates were extracted with 10 mM 
formic acid for a minimum of 30 minutes at 4°C, as described in Berg et al., (1994). 
Total inositol phosphates (IP1, IP2 and IP3) were separated on a Dowex ion 
exchange column, eluted with 3 ml of 1 M ammonium formate/0.1 M formic acid and 
radioactivity determined. Data points were determined in duplicate, and data 
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reduction was determined using GRAPHPAD PRISM. EDso values are the mean of 
three separate experiments. 
2.4 Results 
2.4. 1 A putative GnRH receptor amplified from genomic DNA 
After amplification of genomic DNA using the degenerate primers, products were 
blotted onto nitrocellulose and probed with mouse GnRH receptor cDNA. A positive 
band of approximately 120 bp was obtained with the primer pair, JH5s and JH6a2 
(fig. 2.1 ). The other primer pairs, gave products of the correct size on ethidium 
bromide stained agarose gels, but these products did not hybridise to the mouse 
cDNA probe (fig. 2.2). The positive 120 bp band was subcloned and sequenced. Of 
the ten clones analysed, two different subtypes were identified (clone Xla .1 and clone 
X/b.1 ), which showed homology to the mammalian GnRH receptors (see appendix 
7.3 and 7.7 for sequences). Clone X/b.1 will be discussed in greater detail in chapter 
3. 
2.4.2 Genomic clone for pXla.1 receptor subtype isolated 
Clone pXla.1 was used to screen a Xenopus laevis genomic DNA library. DNA from 
eight positive plaques was extracted, after secondary and tertiary screening. 
Restriction endonuclease digestion and Southern blot analysis showed that the 
genomic clones are approximately 14-16 kbp (fig. 2.3). Digestion with EcoRI and 
Sall restriction endonucleases followed by Southern blotting revealed a 3 kbp 
fragment which hybridised to pXla.1. Subcloning this 3 kbp EcoR1 fragment (fig. 2.3, 
see appendices 7.5a and b) of the genomic clone yielded the sequence of this entire 
exon, consisting of transmembrane domains 6 and 7, as well as an intracellular 
carboxy-terminal tail. 
2.4.3 Full-length cDNA of pXla isolated from pituitary RNA 
In order to amplify the GnRH receptor from the pituitary, cDNA with adaptors ligated 
onto the 5' ends, was synthesised using the Marathon cDNA synthesis kit 
(Clonetech). The quality of the pituitary cDNA constructed using the Marathon cDNA 
kit (Clonetech) was assessed in comparison to control cDNA (supplied by kit) by 
agarose gel electrophoresis followed by autoradiography (fig. 2.4). The pituitary 
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cDNA was then amplified in two rounds of nested PCR, using gene specific primers 
designed to pX/1 a.2 (see appendix 7.5a and b), followed by Southern blot analysis, 
three specific products of 10 kbp, 1.2 kbp and 0.8 kbp were amplified by PCR with an 
annealing temperature of 64°C (fig. 2.5). Only the 800 bp band was amplified with an 
annealing temperature of 68°C (fig . 2.5). The cDNA encoding the full-length receptor 
was amplified using primers designed to the 5' and 3' untranslated regions. The 1.2 
kbp band was subcloned into the pMOSB/ue-T vector and sequenced using gene 
specific primers. Figure 2.6 shows the nucleotide and deduced amino acid sequence 
of the cDNA and the location of primers used for nested PCR and sequencing. Five 
different cDNA clones were sequenced and despite the use of the high fidelity 
polymerase, Klentaq, (Clonetech) and Pfu DNA Polymerase (Stratagene) [Barnes, 
1994] differences between the five clones were present. Three amino acid mutations 
were present: G to an A in transmembrane domain (TM) I, resulting in Ala
55 to Thr 
change was present in two of the clones, in TM V an A to a T mutation resulting in 
Tyr211 becoming a Phe in one of the clones and a T to G mutation causing a stop 
codon at Tyr238 in TM IV was also present in only one of the clones. Because none 
the five clones contained all three nucleotide changes, the consensus sequence was 
deduced to be the correct sequence, and was confirmed by sequencing of the 
relevant area of the genomic clones. 
MC 12 3 4 56 7 8M 
300bp-
100bp-
Figure 2.2. Southern blot of the products after PCR on X. laevis genomic DNA with 
the degenerate primers, probed with the mouse GnRH receptor cDNA. M represents 
the MW marker, C, mouse cDNA as the positive control and 1-8, the combinations of 
degenerate primers used. 1: JH1s/JH2a; 2: JH4s/JH6a2; 3: JH5s/JH5a2; 4: 
JH5s/JH6a1; 5: JH4s/JH6a1; 6: Primer blank. A 120 bp product which hybridises to 
the mouse receptor cDNA could be seen with the primer pair; JH5s and JH6a2. 
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Figure2.3. Southern blot probed with labelled pX/a.1, of the 8 genomic clones ( 1-8) 
isolated after the tertiary screening of the X. /aevis genomic DNA library with X/1 a. 
The clones are digested with Sal1 and Sal1 plus EcoR1. Sal1 will excise the insert 
from EMBL4. The 3 kbp band, which hybridised to the probe was subcloned into 
pBluescript (Stratagene, see appendix 7.4), and recombinant clones sequenced (se 
appendices 7.5a and b). M represents the.MW marker. 
M C Pit 
600bp -
Figure2.4. Autoradiograph showing the X. laevis pituitary cDNA after the first strand 
synthesis (Pit). A positive control was provided with the Marathon cDNA 
amplification kit (Clonetech) (C). Most of the cDNA was approximately 600 bp. M 











Figure 2.5. Southern blot after two rounds of nested Marathon PCR on X. laevis 
pituitary cDNA. The first (1st) and second (2nd) nested PCR products were probed 
with a labelled nested primer. A 0.8 kbp product could be seen after amplification 
with an annealing temperature of 64°C (A), while 1 O kbp, 1.2 kbp and 0.8 kbp 
products could be seen after PCR with an annealing temperature of 68°C (B). The 
1.2 kbp product was subcloned and sequenced revealing the 5' sequence of the X 
laevis GnRH receptor. 1: X laevis pituitary (Pit.) cDNA amplified with adaptor primers 
(AP) and frog gene specific primers; 2: positive control cDNA; 3: Pit. cDNA with only 
gene specific primers; 4: Pit. cDNA with only adaptor primers; 5: positive control 
cDNA with only gene specific primers, 6: positive control cDNA with only adaptor 
primers; 7: no DNA negative control. 
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Theoretical translation of the sequence revealed a 368 amino acid protein with the 
seven hydrophobic transmembrane domains (TMs), characteristic of a G-protein 
coupled receptor. [Probst et al., 1992] (fig. 2.6). This receptor has 46% and 55% 
amino acid identity with the human and catfish GnRH receptors, respectively [Kakar 
et al., 1992; Chi et al., 1993; Tensen et al., 1997]. 
2.4.4 The pituitary receptor couples to phospholipase C and distinguishes GnRH 
natural ligands and analogues 
The recombinant X. laevis GnRH receptor transfected into COS-1 cells coupled to 
phospholipase C, as revealed by the inositol phosphate production after stimulation 
with GnRH and various other GnRH agonists (fig. 2.7). This stimulation could be 
completely inhibited by the addition of antagonist 26 ([Ac-D-p-CIPhe 1·2, D-Trp3, D-
Lys6, D-Ala10NH2] GnRH) and partially inhibited by the addition of antagonist 135-18 
([Ac-D-Nal1, D-4-CIPhe2 , D-Pal3, lle5, D-lsopropyllys6·8, D-Ala 10NH2]GnRH) (fig. 2.8). 
Of the naturally occurring isoforms of GnRH tested, cGnRH II showed the highest 
potency for the amphibian receptor (ED50 0.23 nM), followed by sGnRH (EDso 18 
nM), mGnRH (EDso 420 nM) and cGnRH I (ED50 >10000 nM). cGnRH II also 
showed the highest potency for the receptor than any of the other GnRH agonists 
tested (fig.2.7 A, table 2.1). His5, Trp7 and Tyr8 are all required for the high activity of 
cGnRH II, as suggested by the decreased potencies of [His5]GnRH and 
[Trp7,Tyr8]GnRH (fig.2.7 8, table 2.1). D-amino acid substitutions in position 6 of 
cGnRH II do not increase its potency, but a constrained amino acid in position 6 of 
mGnRH does increase its potency for stimulating inositol phosphate production (fig. 
2.7 8 and C). 
Figure 2.6. Sequence of the full-length GnRH receptor cloned from pituitary cDNA 
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Figure 2.7. Inositol phosphate production in COS-1 cells transfected with the X. 
laevis pituitary GnRH receptor and stimulated with A: Chicken GnRH II (•), Salmon 
GnRH (' ... ) mammalian GnRH ( + ), and chicken GnRH I ( ... ); B: Chicken GnRH II 
(a), [Trp7, Tyr8]GnRH ( ... ), [His5, D-Arg6, Trp7, Tyr8]GnRH ( + ), [His~GnRH ( .... ), 
[His5, D-Tyr6]GnRH ( • ); and C: Chicken GnRH II (•), Buserelin ( .... ), [Hiss, D-Trp6, 
Trp7, Tyr8]GnRH ( ... ), and [Hiss, D-Lys6, Trp7, Tyr8]GnRH ( + ). · Data represent 
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Figure2.8: Inhibition of inositol phosphate production by GnRH antagonists. 
Partial inhibition of stimulation with mammalian GnRH (10-6 M) (A) and chicken 
GnRH II (3x10-10 M) (8) by antagonist 135-18 ([Ac-D-Na11, D-4-CIPhe2, D-Pal3, lle5, 
D-lsopropyllys6•8, D-Ala 10NH2]GnRH). Inhibition of stimulation with mammalian 
GnRH (10-6 M) (C), and chicken GnRH II (3x10-10 M) (D) by antagonist 26 ([Ac-D-p-
CIPhe 1•2, D-Trp3, D-Lys6, D-Ala 10NH2] GnRH). The mammalian receptor antagonist 
135-18 is a partial agonist to the Xia receptor, while antagonist 26 in an antagonist in 
both the mammalian and the frog receptors. 
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Table 2.2. ED50s of GnRH agonists for inositol phosphate production in COS-1 cells 
transfected with the X. laevis pituitary GnRH receptor. EDso values are the mean of 
three separate experiments. Mean = SEM, data reduction was performed using 
Graphpad Prism 
EDso(nM) 
420 ± 100 
0.23 ± 0.1 
18 ± 10 
>10000 
6.6 ± 0.1 
1095 ± 300 
5±3 
400 ± 15 
0.2 ± 0.1 
0.47 ± 0.2 
0.3 ± 0.14 
Peptide 
mammalian GnRH 
[Hiss, Trp7, Tyr8] GnRH (chicken GnRH II) 
[Trp7, Leu8] GnRH (salmon GnRH) 
[Gln8] GnRH (chicken GnRH I) 




[Hiss, D-Arg6 , Trp7 Tyr8] GnRH 
[Hiss,D-Trp6 , Trp7,Tyr8]GnRH 
Hiss,D-L s6 , Tr 7,T r8 GnRH 
2.4.5 Binding of GnRH analogues to the pituitary receptor could not be detected 
Both whole cell and membrane binding assays were performed, but no specific 
binding with 1251 labelled [D-Ala6,NMe-Leu7,Pro9-NHEt]GnRH, [D-Arg6]cGnRH 11 and 
antagonist 26 could be detected. This might indicate that the X. laevis receptor has a 
low expression in the transiently transfected COS-1 cells or has a relatively low 
affinity for the ligands tested. 
2.4. 6 The X. laevis pituitary GnRH receptor gene consists of three exons. 
Gene specific primers were used to amplify regions of the gene in order to determine 
the location of the introns within the gene (fig. 2.9). It contains two introns within the 
coding region, intron II and Ill. lntron II is approximately 4.5 kbp, while intron Ill is 
approximately 6.8 kbp. There is a third intron (intron I) three nucleotides, prior to the 
start codon, in the 5' untranslated region, of approximately 1.3 kbp. 
2.5 Discussion 
PCR amplification of genomic DNA revealed a short fragment of a putative receptor 
with homology to the mammalian GnRH receptors. This was used to identify a 
genomic clone from a X. laevis genomic DNA library. The full-length cDNA of this 
receptor was cloned from the pituitary and revealed a 368 amino acid receptor. This 
receptor has a 46% amino acid identity with the human GnRH receptor [Kakar et al. , 
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Gene Structure 
I ntron I I ntron 11 I ntron 111 
__.(-1 .3 kbp)__. (-4.5 kbp) (-5.8 kbp) • 
5•-0TI-i ~ - Exo_n_ll ~ ~ H }--_Ex_ on_lV--+j__._l D-3' 
Exon I ' + \ I + \ / + + 1+ 
/ l,__J ' \ ~ \ ,' : 
: 100 bp '\ i \ / : 
,' \ I 
\ / I 
' \ ! \ ,' : 
I , I 
\ / I 
I \ I 
\ / I 
/ ' \~ \ ,' : 
+ Antisense primer 
~ Sense primer 
- lntron 
D 5'/3' untranslated region 
D Coding 
region 
Figure 2.9. Schematic representation of the X. laevis GnRH receptor gene showin
g 
the three exons and two introns. The entire gene is between 12 and 13 kbp
. The 
location of the primers used for gene analysis and sequencing are shown. 
1992; Chi et al. , 1993], and a 55% amino acid identity with the cloned catfish Gn
RH 
receptor [Tensen et al. , 1997]. 
The amino terminus is very poorly conserved with the human GnRH recept
or (fig. 
2.10) and the catfish GnRH receptor. The glycosylation site Asn 
18 in the human 
receptor is not conserved , but there is an N-linked glycosylation consensus 
site at 
Asn 16. The cysteines, Cys 
14 in the amino-terminus of the human GnRH receptor and 
Cys200 in extracellular loop 11 , which have been suggested to form a disulphide
 bridge 
[Davidson et al., 1997] are not conserved. Cook and Eidne [1997] , however, ha
ve 
found that this disulphide bridge is not important for mammalian GnRH activity
 in the 
rat receptor. The two cysteines in extracellular loops I and 11, which have
 been 
shown for the mammalian GnRH receptors [Davidson et al. , 1997; Cook and Eid
ne, 
1997], as well as other GPCRs [for review, see Strader et al. , 1994], to form
 a 
54 
disulphide bridge, Cys107 and Cys184 (Cys114 and Cys196 in the human GnRH 
receptor) , are, however, conserved in the X. laevis pituitary receptor. 
Figure 2.10. Diagram of the Xenopus laevis pituitary GnRH receptor, showing amino 
acid residues, which are conserved with the human GnRH receptor (blue) and 
conservative substitutions (green). 
The transmembrane domains (TM) of the X. laevis receptor are highly conserved with 
the human GnRH receptor (fig. 2.10). TM VI and Ill are the most conserved, at 69 
and 62% identity respectively, followed by TMs VII , IV, II , V, and I. The high 
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conservation seen in the TM helices, is required for the formation of the hydrophobic 
a-helices, which anchor the receptor in the membrane and for helix/helix interactions 
through specific amino ·acid side chains. In general , the TM domains are highly 
conserved among GPCRs [for review, see Strader et al. , 1994]. The high 
conservation within receptor types, in these domains, may also reflect amino acid 
residues, which are important for ligand binding. All the amino acid residues in the 
TMs of the mammalian GnRH receptors, which have been shown to be important for 
ligand interactions are conserved in the amphibian receptor [for review, see Sealfon 
et al. , 1997]. Asp91 in the frog GnRH receptor, which aligns to Asp00 in TM II of 
human receptor and proposed to interact with His2 of GnRH, and Lys114 of the frog 
receptor which aligns to Lys 121 in TM Ill of the human GnRH receptor, which may 
interact with His2 or pGlu 1 of GnRH [Zhou et al., 1995; Rodie et al. , 1996; for review, 
see Sealfon et al., 1997]. Asn 102 in TM II , which interacts with the glycine amide at 
the carboxy-terminus of GnRH is also conserved (Asng;, in the X. laevis receptor) 
[Davidson et al. , 1996(b)]. 
Asn87 in the human GnRH receptor has been shown by mutagenesis, to interact with 
Asp318 in TM VII [Zhou et al. , 1994]. Mutagenesis of Asn87 to an Asp in the human 
receptor was inactive, unless a second mutation of Asp318 to a Asn was also 
incorporated [Zhou et al. , 1994]. Two aspartic acid residues in these positions in 
TMs II and VII of the human GnRH receptor, therefore, affected the receptor in such 
a way as to render it inactive. Interestingly Asn87 in TM II of the human GnRH 
receptor is an Asp in the X. laevis receptor (Asp80) . The X. laevis receptor, therefore, 
has an aspartic acid in both TMs II and VII (Asp80 and Aspn;). This arrangement is 
presumably functional in the X. laevis receptor due to other co-ordinated amino acid 
changes, which have yet to be identified. Mutations of the catfish GnRH receptor 
have revealed that the aspartic acid residue in TM II (Asp00) is important for the 
functioning of the receptor, while a mutation of Asp321 in TM VII can only be 
accommodated if there is a Asp at position 90 [Blomenrohr et al. , 1997]. 
Extracellular loop (EL) I is the most conserved of the extracellular loops, followed by 
EL II and EL Ill. The carboxy-terminal end of EL II is highly conserved, while the 
amino-terminal end is completely unconserved (fig. 2.10). Glu~n of the mouse GnRH 
receptor (or the equivalent Asp-:m. of the human GnRH receptor) in EL Ill is important 
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for selectivity for Arg8 of GnRH, seen in the mammalian GnRH receptors [Flanagan 
et al., 1994]. As previous studies suggested that the amphibian pituitary was not 
selective for different GnRH agonists [Licht et al., 1984; 1987], it was surprising to 
note that the Glu in the corresponding position of the X. laevis receptor, was 
conserved (Glu288 , fig. 2.10). Pharmacological characterisation of the X. laevis GnRH 
receptor reveals that it does apparently have some discrimination for the Arg in 
position 8 since [Gln8]GnRH (cGnRH I) was at least 20-fold less potent than 
[Arg8]GnRH (mGnRH). Nevertheless it is clear that the Glu288 of the X. laevis GnRH 
receptor is not as powerful a determinant of ligand selectivity as in the mammalian 
receptor, because unlike in the mammalian receptors , cGnRH II and sGnRH, which 
lack the Arg in position 8, are far more potent than mGnRH (table 2.2). Interestingly, 
a praline residue (Pro303) in the human GnRH receptor follows the crucial acidic 
residue, whilst a praline precedes the acidic Glu288 in the amphibian receptor. As 
praline residues are known to disrupt the secondary structure of proteins [Chou and 
Fasman, 1978] particularly a-helices, this change may drastically alter the 
conformation of the loop, and thus change the orientation of the acidic residue side 
chain and consequently the ligand selectivity. The crucial determinants of high ligand 
potency in the X. laevis receptor, in distinct contrast to mammalian receptors, is a Trp 
in position 7, as all analogues with this residue had high potency (table 2.2). 
Presumably there is a cognate interacting residue (or residues) in the X. laevis 
receptor. 
Intracellular loop (IL) I of the X. laevis receptor is much shorter than that of the 
human receptor (5 amino acids in the frog, versus 12 amino acids in the human). 
The mammalian GnRH receptors have a longer IL I when compared to all other 
GPCRs characterised to date [Probst et al. , 1992]. This long IL I in mammals may 
have evolved to compensate for the lack of carboxy-terminal tail, which is absent in 
the mammalian receptors. The short IL I of the X. laevis receptor is in keeping with 
other GPCRs with intracellular carboxy-terminal tails. IL II is poorly conserved. The 
DRS motif at the border of TM Ill and IL II of the mammalian GnRH receptors, is a 
DRH in the amphibian receptor. The Asp and Arg residues, which are conserved in 
the amphibian receptor, have been shown to be important for receptor conformation, 
expression, agonist-induced activation and internalisation [Arora et al. , 1997]. The 
Arg residue (Arg 139) is thought to interact with the Asp in position 138 and the lie at 
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position 143, which occurs one turn down in the a-helix of TM Ill, extending into IL Ill 
[Ballesteros et al., 1998]. This interaction may position the Arg appropriately for the 
active and inactive receptor conformations [Ballesteros et al., 1998]. The carboxy-
terminus of IL Ill is highly conserved. This region is thought to be important for G-
protein coupling and signal transduction. Ala
261 of the human receptor, which aligns 
to Ala247 of the X. laevis receptor, is conserved. This residue has been shown to be 
crucial for G-protein coupling and receptor internalisation [Myburgh et al. , 1998]. 
The X. laevis GnRH receptor, like the catfish [Tensen et al., 1997], goldfish (see 
chapter 4) and chicken [Y-M Sun et al., in preparation] GnRH receptors has an 
intracellular carboxy-terminal tail. The carboxy-terminal tail of GPCRs has been 
implicated in receptor phosphorylation leading to desensitisation and possibly 
internalisation [for review, see Benovic et al., 1988]. The mouse GnRH receptor 
shows no short-term homologous desensitisation [Davidson et al., 1994(b )]. This 
phenomenon may have evolved to facilitate the LH-surge required for ovulation. The 
frog pituitary GnRH receptor, in spite of having a intracellular carboxy-terminal tail 
responds to continuous high dose administration of GnRH and does not exhibit 
desensitisation [for review, see Licht, 1990]. The carboxy-terminal tail has several 
serine and threonine residues, which are putative protein kinase C and protein kinase 
A phosphorylation consensus sites required for homologous desensitisation. The 
presence of the carboxy-terminal tail and lack of desensitisation in the amphibian is, 
therefore, enigmatic. 
Several GnRH receptor agonists were tested for their ability to stimulate inositol 
phosphate production in COS-1 cells transiently transfected with the X. laevis GnRH 
receptor. mGnRH, sGnRH and cGnRH I have previously been shown to be 
equipotent in stimulating LH release from the amphibian pituitary [Licht et al., 1987]. 
These results are not reflected in the inositol phosphate assays on the X. laevis 
GnRH receptor, in which sGnRH is approximately 20-fold more potent than mGnRH, 
while cGnRH I shows very low activity (fig. 2. 7 A; table 2.2). The discrepancy 
between the bioassay results in the amphibian pituitary and the GnRH stimulated 
inositol phosphate response in the transfected COS-1 cells is unknown, but may be 
as a result of the sensitivity of the different assays used. cGnRH II showed an 
approximately 2000-fold higher ability to stimulate inositol phosphate production than 
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mGnRH (fig. 2.7; table 2.2). cGnRH II has previously been shown to bind amphibian 
pituitary homogenates with a higher affinity than buserelin, a mGnRH agonist 
[Fasano et al., 1990] (fig. 2.7 C, table 2.2). [Trp7, Tyr8]GnRH, which is 2-fold more 
potent than cGnRH 11 , in stimulating LH release in the chicken pituitary [Millar et al. , 
1989], had a lower potency than cGnRH II for the amphibian receptor (table 2.2). 
[His5]GnRH also had a lower potency in stimulating inositol phosphate production, 
thus, indicating that the combination of the His5, Trp7, and Tyr8, in cGnRH II is 
required for its high activity in the amphibian receptor. D-amino acid substitutions in 
position 6 of GnRH are thought to enhance the activity of naturally occurring GnRHs 
by constraining them in the active conformation (for review, see Sealfon et al., 1997). 
These substitutions have no effect on the potency of cGnRH 11 but constraining 
mGnRH enhances its potency by almost 100-fold, as seen for 8userelin (fig. 2. 7 8, C; 
table 2.2). 
Antagonist 26 ([Ac-0-p-CIPhe 1·2, O-Trp3, O-Lys6, 0-Ala 10NH2]GnRH) behaved like a 
true antagonist, and completely inhibited both mammalian- and chicken GnRH II 
stimulated inositol phosphate production, but were less potent than in the mammalian 
receptor [] (fig. 2.8 C, D). The mammalian GnRH receptor antagonist 135-18 ([Ac-O-
Nal1, 0-4-CIPhe2, O-Pal3, lle5, O-lsopropyllys6•8 , 0-Ala 10NH2]GnRH), however, was a 
partial agonist for the amphibian GnRH receptor, as it could not completely inhibit the 
mGnRH and cGnRH II stimulated inositol phosphate production, and weakly 
stimulated inositol phosphate production at high concentrations (fig. 2.8 A, 8). This 
suggests that the amphibian GnRH receptor binding site for 135-18 must be different 
from that of the mammalian receptor and that interactions occur, which can stabilise 
the X. laevis GnRH receptor in the active conformation. 
Despite the use of several different labelled GnRH analogues (1 251-[D-Ala6, N-ME-
Leu7, Pro9-NHEt]GnRH; 1251-[His5, D-Arg6, Trp7, Tyr8]GnRH; and 1251-[Ac-O-p-
CIPhe 1·2, O-Trp3, O-Lys6, O-Ala10NH2]GnRH), no specific binding to the amphibian 
receptor could be shown in transfected COS-1 cells. Specific displacement of 1251-
labelled cGnRH II by cGnRH II and buserelin, has previously been shown in the 
pituitary of the green frog, Rana esculenta [Fasano et al., 1990]. The lack of labelled 
ligand binding in the COS-1 cells expressing the X. laevis receptor, is either a result 
of poor expression of the receptor or due to a low affinity of the receptor for the 
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labelled ligands tested. Less than 1 % specific binding of 
1251-labelled mammalian- or 
cGnRH II agonists (1 251-[D-Ala6 , N-ME-Leu7 , Pro9-NHEt]GnRH; 
1251-[His5, D-Arg6 , 
Trp7, Tyr8]GnRH) could be detected in X. /aevis pituitary membranes (for results, see 
chapter 3). The lack of detectable receptor binding may, therefore, be as a result of 
the low expression of this receptor in the transfected cells or due to a low affinity 
binding. 
The sequence variations seen in the receptor cDNA clones may be as a result of 
either the duplicate genes, which result from the tetraploid genome of this species or 
the result of mutations which were incorporated by the polymerase during 
amplification of the cDNA. The sequence was therefore confirmed by sequencing of 
the genomic clone. The gene structure of this receptor is highly conserved with that 
of the mammalian GnRH receptor genes [Zhou and Sealfon 1994; Fan et al. , 1994], 
and consists of three exons, divided by two introns. The amphibian has a third intron 
at -3, which is approximately 1.3 kbp. The size of the exon encoding the 5' 
untranslated region of this receptor is unknown. The adaptor primer ligated at 
position -216 of the start codon. Although this may indicate the transcription start site 
it cannot be confirmed without proper characterisation of the promoter region 5' to 
this, and may be an artifact of cDNA synthesis. 
The cloning and characterisation of the amphibian pituitary GnRH receptor, has thus, 
provided some useful insights into the structure/function activity of GnRH receptors. 
This vertebrate receptor is substantially different from the mammalian receptors with 
regard to both structure and pharmacology. The amino acid sequence is 53% 
different from the human GnRH receptor with major changes in the amino-terminus, 
and both intracellular and extracellular loops, while the transmembrane domains 
have a higher conservation. The amphibian receptor has a different ligand selectivity 
for the naturally occurring GnRHs, possibly due to a change in the presentation of 
extracellular loop Ill. The mammalian GnRH receptor antagonist 135-18 is a partial 
agonist for this receptor, indicating that the low amino acid conservation possibly 
dictates changes in ligand recognition and receptor activation. The presence of an 
intracellular carboxy-terminal tail may indicate a different mechanism of receptor 
regulation, internalisation and desensitisation, which may be important for the 
amphibian pituitary response. In depth analysis of several of these changes has 
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already been initiated for the X. /aevis GnRH receptor as well as the chicken GnRH 
receptor which has recently been cloned (Y-M Sun et al. , in preparation; Ott et al. , 
1998)) . The use of chimeric receptors as well as site-directed mutagenesis, where 
several changes are incorporated at once, may help to delineate co-ordinated amino 
acid changes and how they relate to receptor specificity, activation and regulation. 
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Chapter 3 
Chicken GnRH II-like peptides and a receptor selective for chicken GnRH II in 
amphibian sympathetic ganglia 
3.1 Summary 
GnRH has been demonstrated to be a neurotransmitter in amphibian sympathetic 
ganglia, where its release from the presynaptic nerve terminals reversibly inhibits M-
current, a time- and voltage-dependent potassium current [Jan and Jan, 1980]. The 
occurrence of GnRH and GnRH receptors in sympathetic ganglia extracts was 
investigated. A peptide was detected in extracts of bullfrog (Rana catesbeiana) and 
African clawed frog (Xenopus laevis) sympathetic ganglia, which had identical 
immunoreactivity and retention times on high performance liquid chromatography as 
cGnRH 11. Under the chromatographic conditions used, a second unknown peptide with 
cGnRH II immunoreactivity co-eluted with synthetic mammalian GnRH, but showed no 
cross-reactivity with the specific mGnRH antisera. The second unknown peptide was 
not hydroxy-praline cGnRH II or oxidised cGnRH II. To test the possibility of the 
presence of a receptor specific for cGnRH II in sympathetic ganglion neurons, 
competition binding of membranes extracted from the sympathetic ganglia of the two 
amphibian species was investigated with 1251-labelled GnRH agonists. The binding of 
1251-[His5,D-Arg6,Trp7,Tyr8JGnRH (a cGnRH II agonist) to membranes from the 
sympathetic ganglia of both amphibian species was specific and had a higher affinity 
than cGnRH 11, mGnRH and a mGnRH agonist, [D-Ala6,NMe-Leu
7,Pro9-NHEtJGnRH. 
These findings suggest that endogenous cGnRH 11 may play a role in synaptic 
transmission in the sympathetic ganglia via a receptor specific for cGnRH II. In an 
attempt to clone a GnRH receptor from these neurons RNA was extracted from 
sympathetic ganglia and several different techniques were utilised. A novel second 
GnRH receptor subtype was detected after PCR on genomic DNA, but a full-length 
cDNA for this isoform could not be found in the sympathetic ganglia cDNA. Despite the 
specific binding seen in membranes from sympathetic ganglia it is, therefore, not clear 
whether a second GnRH receptor subtype is expressed in these ganglia. 
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3.2 Introduction 
The functional significance of the presence of more than one form of GnRH in any one 
species is unknown, but suggests a widespread function (see chapter 1 ). The best 
characterised role of GnRH is the regulation of the synthesis and release of 
gonadotropins from the anterior pituitary [for reviews, see Schally et al. , 1971; Kiesel , 
1993]. GnRH does, however, have several other neuroendocrine roles, including a 
paracrine role in the gonads [for review, see Hsueh and Schaeffer, 1985], an autocrine 
role in certain tumours [Harris et al., 1991 ], and synaptic transmission [ Jan and Jan, 
1980]. As described in chapter 2 the distribution and abundance of the two forms of 
GnRH found in amphibia has been well characterised [Rivier et al. , 1981 ; King and 
Millar, 1986; SheMOod et al. , 1986; Di Meglio et al., 1991; Fasano et al. , 1993; Muske 
et al. , 1994; Licht et al., 1994; King et al. , 1994( a); Collin et al. , 1995; Di Matteo et al. , 
1996; Pinelli et al., 1997]. These studies suggest that in amphibians, mGnRH, which is 
found predominantly in the hypothalamus, is the prime regulator of gonadotropin 
release, while cGnRH II, which predominates in the midbrain and hindbrain may have 
an additional role, possibly in neurotransmission. 
GnRH has been demonstrated to be a co-neurotransmitter at the synapses in bullfrog 
sympathetic ganglia. Its release from the preganglionic nerve terminals generates a 
late, slow, excitatory postsynaptic potential [Jan and Jan, 1980]. The depolarisation is 
due to the inhibition of M-current, which is a time-and voltage-dependent potassium 
current [Adams and Brown, 1980; Brown and Adams, 1980; Jan and Jan, 1982; Adams 
et al., 1983], named from its inhibition by muscarinic acetylcholine receptor agonists. M-
current was initially described in bullfrog sympathetic ganglia but has since been shown 
in many central and peripheral neurons [Brown, 1988] and rat sympathetic ganglia 
[O'Nen et al., 1990]. M-current has a potential clamping effect on the neurons of the 
sympathetic ganglia and may be part of a negative feedback mechanism that regulates 
neuron excitability [Adams et al., 1982; Jones, 1985; KirkVvOod and Lisman, 1992]. 
Inhibition of this current may, therefore, allow the neurons to be more responsive to 
sympathetic inputs. M-current inhibition has been shown to have long term effects on 
neuron excitability [Kirk'M>od and Lisman, 1992]. The depolarisation results from a 
blockade of the M-current, via the interaction of a pertussis toxin insensitive G-protein 
with the M-channel [Pfaffinger, 1988; Lopez and Adams, 1989; Lopez, 1992; Stansfeld 
et al. , 1993]. Several second messenger systems have been investigated and although 
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some effects on M-current were observed, none have been directly implicated [Bosma 
and Hille, 1989; for review, see Adams and Brown, 1980]. It has, therefore, been 
proposed that the G-protein may interact directly with the M-channel, like the inwardly 
rectifying potassium channels of the heart [Breitwieser et al. , 1985]. GnRH has been 
shown to be a neurotransmitter in bullfrog sympathetic ganglia, although the 
endogenous isoform is unknown, cGnRH II is a candidate for several reasons [for 
review, see Adams and Brown, 1980]. Synthetic cGnRH II is a 100-fold more potent 
than [Trp7, Leu8]GnRH (sGnRH), and a 1000-fold more potent · than mGnRH, 
[Gln8]GnRH (cGnRH I) and [Tyr3,Leu5,Glu6,Trp7,Lys8]GnRH (lamprey GnRH I), in its 
ability to inhibit M-current [Jones, 1987]. The agonist-dependent inhibition also 
desensitises to cGnRH II , but not to salmon GnRH [Jones 1987, for review, see Adams 
and Brown, 1980]. In order to investigate this, HPLC and RIA were used to determine 
whether cGnRH II is present in extracts of sympathetic ganglia. The possibility of the 
presence of a receptor specific for cGnRH II was also tested, using various analogues 
of GnRH in receptor binding assays on membranes from these neurons. The presence 
of a second GnRH receptor subtype in sympathetic ganglia was also investigated using 
PCR-based technologies. 
3.3 Materials and Methods 
3.3.1 Tissue Dissection 
Tissue from the bullfrogs was supplied by Dr Y. Peng (University of Chicago, USA), and 
was prepared as follows: Adult bullfrogs were decapitated and the viscera removed. 
For the HPLC study, ganglia 7 through 1 O along with spinal nerves 7 and 8 from 12 
bullfrogs were removed (fig. 3.1 ). The tissue was bathed in O Ca2\ 1 mM EGTA Ringer 
solution. The O Ca2+ Ringer was used to minimise the release of GnRH during the 
dissection. Connective tissue was removed from the ganglia and the spinal nerves in 
order to obtain the most highly concentrated nervous tissue possible. Tissues were 
pooled and lyophilised for HPLC. For the receptor binding assay, ganglia 7 through 10 
from 12 bullfrogs were removed while the tissue was bathed in O Ca2\ 1 mM EGTA 
Ringer solution. Again, connective tissue was removed from the ganglia. The ganglia 
were then placed in phosphate-buffered saline (PBS ) on ice. Whole bullfrog brains 
without the pituitary, were removed from the telencephalon to the tectum. The brains 
were placed immediately in PBS, while the connective tissue enveloping the frog brain 
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was removed. The samples were then frozen on dry ice, lyophilised, and extracted as 
described below. Tissue from X laevis was prepared as follows: adult X laevis were 
pithed and the viscera removed, exposing the vertebral column. Ganglia 7 through 10 
were excised and placed directly in PBS on ice. The cranial bone was then cut away to 
expose the brain (fig. 3.2) and the pituitary was removed and placed in PBS on ice. For 
the HPLC, the ganglia from 10 X. laevis were collected. 
3.3.2 Tissue Extraction 
Lyophilised tissue was extracted with 2N acetic acid containing 10-3 M 
phenylmethanesulfonylfluoride at 4°C using a Thomas homogeniser. The 
homogenates were centrifuged at 18,000 g for 1 h at 4°C, and the supernatants were 
lyophilised. Tissue extracts were reconstituted in water and sonicated prior to HPLC. 
3.3.3 High-Performance Liquid Chromatography (HPLC) 
HPLC analysis was performed using a Beckman model 421 equipped with a model 112 
solvent delivery module and a model 153 UV detector. Samples were injected via a 2 
ml loop onto a Vydac C-18 reverse-phase column (0.46 x 25 cm; 5 µm particle size). 
The mobile phase was 0.1 % heptafluorobutyric acid (solvent A) and 60% acetonitrile in 
0.1% heptafluorobutyric acid (solvent 8). Elution conditions were: 32% B for 10 
minutes, a linear gradient from 32% to 60% B over 30 minutes, followed by a linear 
gradient from 60 to 99% B over 5 minutes, and finally 99% B for 5 minutes. The flow 
rate was 1.5 ml/min. One-minute fractions were collected. Aliquots of tissue extracts 
and 20 ng of each of eight known GnRHs were chromatographed as standards. 
Following runs of synthetic peptides, the entire HPLC system was cleaned with several 
gradients of solvents A and B, as described above, and finally with acetonitrile, to 
ensure against contamination. Furthermore, prior to runs of biological material, blank 
column runs were monitored by radioimmunoassay to ensure that the HPLC system 
was not contaminated and that the peaks observed in biological runs were authentic. 
Column fractions were lyophilised, reconstituted in phosphate-buffered saline, and 
assayed in duplicate for immunoreactive GnRH using antisera 678, 1076, and 675. 
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Figure 3. 1. Diagram of the nervous system 
of Rana esculenta from the ventral surface 
[Marshall, 1932] 
The sympathetic nervous system consists 
of a longitudinal nervous band on each 
side of the body, connected by branches 
with spinal nerves. Ganglia 7-10 (57-510) 
were removed from bullfrog and X laevis 
for binding and HPLC studies. 
F, facial nerve; He, cerebral hemisphere; Le, optic 
tract; Lop, optic lobe; M, boundary between medulla 
oblongata and spinal cord; M1-10, spinal nerves; N, 
nasal sac; Ni, sciatic nerve; No, crural nerve; o, 
eyeball; S, trunk of sympathetic; S1-10, the 
sympathetic ganglia; Sp, continuation of 
sympathetic into head; I, olfactory nerve; II, optic 
nerve; Ill, motor oculi; IV, fourth nerve; V, trigeminal 
and facial nerves; Va, ophthalmic branch of 
trigeminal; Ve, maxillary branch of trigeminal; Vd, 
mandibular branch of trigeminal; Ve, hyomandibular 
branch of facial; Vg, Gasserian ganglion; Vs, upper 
end of sympathetic trunk; VI, abducens nerve; VII, 
facial nerve; VIII, auditory nerve; X, 
glossopharyngeal and pneumogastric nerves; X1, 
ramus anterior of glossopharyngeal; X2, ramus 
posterior of glossopharyngeal; X3-4, branches of 
pneumogastic. 
Figure 3.2. Diagram of a frog brain from the 
ventral surface [Marshall, 1932] 
The cranial bone was cut away to expose the 
brain and the pituitary, P, which was then 
removed. 
CH, cerebral hemisphere; IN, tuber cinereum; M, 
medulla oblongata; 0, olfactory lobe; OC, optic 
chiasma; P, pituitary body, I, olfactory nerve; II, optic 
nerve; Ill, motor oculi nerve; IV, fourth nerve; V, 
trigeminal nerve; VI, sixth nerve; VII and VIII, combined 
root of facial and auditory nerves; IX and X, combined 
root of glossopharyngeal and pneomogastric nerves. 
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3.3.4 Oxidation of Chicken GnRH II 
1 µg of cGnRH II at 0.2µg/µI was oxidised in the presence of 50% hydrogen peroxide 
(H202, Sigma) for 1 h at room temperature. 
3.3.5 Radioimmunoassay of GnRHs 
Radioimmunoassays for GnRH were as previously described for cGnRH II [King and 
Millar, 1986]. Antiserum characteristics, in terms of antigen used, titre, sensitivity, and 
cross-reactivity with known GnRHs, are given in Table 3.1 . cGnRH II antiserum 678 (in 
a heterologous radioimmunoassay using mGnRH tracer and standards) requires the 
NH:z- and COCH-termini for binding and cross-reacts with all known GnRHs. mGnRH 
antiserum 1076 is specific for mGnRH, and binds the middle of the molecule. Specific 
cGnRH II antiserum 675 recognises residues five to eight of the molecule. The amount 
of peptide present in the sympathetic ganglia was determined from the amount of 
immunoreactive GnRH present in the pooled extracts, divided by the total number of 
frogs used in the study. 
Table 3. 1 Antisera Characteristics 
mGnRH 1076 
cGnRH II 678 
675 
1:50 000 17 
1:40 000 25 
1:5 000 18 
100 59 0.4 0.3 <0.1 11 
100 416 81 473 3.1 23 
<0.1 <0.1 100 <0.1 <0.1 
The Radioimmunoassays were homologous ·except for the radioimmunoassay where 
chicken GnRH II antiserum 678 was used with mammalian GnRH tracer. M, 
mammalian GnRH; Cl, chicken GnRH I; CII, chicken GnRH II; S, Salmon GnRH; LI, 
lamprey GnRH I; Mh, hydroxyproline mammalian GnRH. 
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3.3. 6 Radioiodination of GnRH analogues 
[His
5,D-Arg6,Trp7,Tyr~GnRH and [D-Ala6,NMe-Leu7,Pro9-NHEt]GnRH were iodinated 
according to an adapted chloramine-T method [Millar et al., 1995]. Iodinated peptide 
was purified on a Vydac C18 reverse phase column (0.46 x 25 cm; 5 µm particle size) 
using a linear gradient of 0.01 M ammonium acetate (NHAc), pH 4.6 to 60% 
CH3CN/40% 0.01 M NHAc pH4.6. A profile of the elution of 1251[His5,D-
Arg6,Trp7,Tyr~GnRH can be seen in figure 3.3. The specific activity for both iodinated 
peptides was approximately 1000 µCi/µg as determined by the self-displacement 






































Figure 3.3. Elution profile of 125l[His5, D-Arg6, Trp7, Tyr8JGnRH. 
Radiolabelled C GnRH II agonist was eluted from a Vydac C-18 column with a linear 
gradient of acetonitrile in ammonium acetate (0.01 M, pH 4.6) 
3.3. 7 Receptor Binding Assay 
1251-[D-Ala6,NMe-Leu7,Pro9-NHEt]GnRH (superactive mGnRH agonist) and 
125HHis5,D-
Arg6,Trp7,Tyr~GnRH (superactive cGnRH II agonist), which are putative superactive 
analogues of two of the naturally-occurring GnRH peptides known to be present in 
amphibians, were used to study binding of GnRH to receptors in sympathetic ganglia of 
both amphibian species [Millar et al., 1986(b); Millar et al., 1989]. The freshly dissected 
sympathetic ganglia tissue was homogenised using a Dounce homogeniser (Wheaton) 
in ice-cold binding buffer (10 mM HEPES, 1 mM EDTA and 0.1% fatty acid free BSA). 
The homogenate was centrifuged for 30 minutes at 10,000 g at 4°C. The binding assay 
was performed as previously described [Millar et al., 1986(b)]. The membrane pellet 
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was weighed and resuspended in binding buffer such that each experimental tube 
contained one third sympathetic ganglion or pituitary equivalent, for the X. laevis and for 
the bullfrog one sixth sympathetic ganglion equivalent. Data points were determined in 
triplicate. The mouse a T3 pituitary gonadotrope cell line, which expresses mammalian 
GnRH receptors [Windle et al., 1990], was used as a positive control, and sciatic nerve 
was used as a putative negative control. Non specific binding was determined by 
displacement with either 10-5 M mGnRH agonist or cGnRH II (see figure legends). Non 
specific binding was subtracted from total binding to give specific binding. The total 
radioactivity of the labelled peptide added to each tube was approximately 80,000 cpm. 
3.3.8 Cloning of a second GnRH receptor subtype 
The degenerate primers JH5s and JH6a2 were used to amplify the second subtype of 
receptor from genomic DNA (see Chapter 2, Materials and Methods). This clone was 
labelled and used as a probe to screen a X. laevis genomic DNA library, for detailed 
methods, see section 2.3.6. 
3. 3. 9 Cloning of a partial cDNA 
Total RNA was prepared from X. laevis hindbrain, pituitaries and sympathetic ganglia 
by extraction with guanidium thiocynate [Chomczynski and Sacchi, 1987], as 
described in section 2.3.2. Gene specific primers were designed to the PCR product 
amplified using JH5s and JH6a2, pX/b.1 (see appendix 7.7). These primers were 
used to amplify cDNA synthesised from 1 µg of DNase I digested sympathetic 
ganglia total RNA, using the Marathon cDNA synthesis kit (Clonetech). cDNA 
synthesis was monitored by the incorporation of [a-32P]dCTP (1 µCi/µI, Amersham). 
cDNA was amplified using the Marathon system (Clonetech) and products were 
probed with the nested primer X/1 b.4s. These methods are described in detail in 
Chapter 2 (see section 2.3.7). Positive products were subcloned into the pMOSBlue 
T-vector (Amersham) and recombinant colonies analysed by colony PCR or colony 
hybridisation to a suitable probe (see section 2.3.5). 
3.3. 10 Cloning of cDNA from the gene 
The exon trapping method developed by Buckler et al. (1991) was utilised in an 
attempt to isolate transcribed sequences from the genomic clone of X/b. The 
genomic clone in EMBL 4 was digested with BamH1 endonuclease to yield three 
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products of approximately 8 kbp, 6 kbp and 3 kbp. The latter two endonuclease 
fragments were cloned into the dephosphorylated BamH1 site of the pSPL3 vector 
(see appendix 7.8a)(Exon Tapping System; Gibco BRL). Two clones of each type, 
designated pSPL3.2a and pSPL3.2b for the 6 kbp clones and pSPL3.3a and 
pSPL3.3b for the 3 kbp clones, were prepared and co-transfected in combinations 
into COS-1 cells. The combinations are described in table 3.2. Plasmid DNA for 
transfection was prepared using the Wizard DNA purification system (Promega). 24 
h prior to transfection, cells were plated at a density of 3 x 10
6 cells on 1 O cm poly-D-
lysine coated dishes (Corning), in DMEM containing 10% foetal calf serum, penicillin 
(0.2 U/ml) and streptomycin (100 µg/ml). Cells were transfected with a total of 15 µg 
of plasmid DNA (7.5 µg of each clone) in serum-free DMEM for 4 h using an adapted 
DEAE-dextran method [Keown et al., 1990], with a 50 minute chloroquine (200 µM) 
treatment and a 2 minute 10% dimethylsulphoxide shock [Luthman and Magnusson, 
1983; Lopata et al., 1984]. Cells were grown for 48 h after transfection in DMEM 
containing 10% foetal calf serum and penicillin/streptomycin, prior to extraction of 
total RNA Cells were removed from plates using 0.04% EDTA in 10 ml of PBS, 
collected by centrifugation for 10 minutes at 1000 rpm and resuspended in 500 µI of 
denaturing solution (see section 2.3.2). Total RNA was extracted as described 
above and resuspended at a concentration of approximately 1 µg/µI in DEPC water. 
cDNA synthesis and two rounds of nested PCR were performed as described in the 
kit protocol. The products of the PCR reactions were analysed by agarose gel 
electrophoresis and Southern blotting with 32P labelled pXJb.1. Clone pXJb.1 was 
labelled to a specific activity of approximately 7 x 10
8 cpm/µg using [a-32P]dCTP 
(3000 Ci/mmol) and the Megaprime labelling kit (both Amersham). Any positive PCR 
reactions were then subjected to an additional round of PCR using gene specific 
primers designed to pXJb.1 (see appendix 7.7). Products were analysed once again 
by agarose gel electrophoresis and Southern blotting. Any positive products were 
excised from a low melting point agarose gel (FMC BioProducts) and subcloned into 
the pMOSBlue T-vector (Amersham). Recombinant colonies were sequenced (T7 
Sequenase version 2.0, Amersham). 
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Table 3.2. Combinations of plasmids, co-transfected for exon trapping analysis 





5 Untransfected COS-1 cells 
3.3.11 Sympathetic ganglia cDNA library construction and screening 
Sympathetic ganglia poly A+ RNA was purified from 100 µg of total RNA by 
adsorption to oligo(dT) cellulose (Sigma) according to a modified method first 
described by Aviv and Leder (1972). A Stratagene (La Jolla, California) ZAP-cDNA 
synthesis kit was used to make the cDNA libraries from 1 µg of mRNA. The 
sympathetic ganglion library was amplified to a titre of 1.4 x 105 pfu/µI of phage 
lysate. 106 plaques of the amplified library were screened as described in the ZAP-
cDNA kit protocol, with 32P-labelled mouse GnRH receptor cDNA. The cDNA was 
labelled to a specific activity of approximately 7 x 108 cprn/µg using [a32P]dCTP 
(3000 Ci/mmol) and the Megaprime labelling kit (both Amersham). Labelled probes 
were purified from unincorporated deoxynucleotides using a Sephadex G-50 spin 
column, equilibrated with 100 µI of STE (10 mM tris-HCI, pH 8; 1 mM EDTA; 100 mM 
NaCl). The hybridisation conditions were as described in section 2.3.4. The library 
was also screened with labelled ~-actin cDNA to determine the quality of the library. 
~-Actin was labelled using the Megaprime labelling kit (Amersham). 
3.4 Results 
3.4. 1 Chicken GnRH II is a GnRH isoform present in sympathetic ganglia 
Detection of the amount of GnRH by radioimmunoassay (NH~and COOH-terminus-
directed antiserum 678) in the sympathetic ganglia was as follows: bullfrog (266 pg per 
animal) and X. laevis (43 pg per animal) (Dr J. King). In HPLC of the bullfrog 
sympathetic ganglion extract, two peaks were revealed by the NH~ and 
COCH-terminus-directed antiserum 678, and these co-eluted with synthetic mGnRH 
and cGnRH II (fig. 3.4.A). Specific mGnRH antiserum 1076 showed no cross-reactivity, 
thus mGnRH is not present in the sympathetic ganglion (fig. 3.4.C). cGnRH II 
antiserum 675 cross-reacted with both peaks, and quantification of each of the peaks 
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was approximately equal to that quantified with antiserum 678 (fig. 3.4.B). Peak II is 
likely to be cGnRH II, while the identity of peak I is unknown. The possibility of this 
peak being one of two less hydrophobic chemically modified forms of cGnRH II; namely 
oxidised cGnRH II and hydroxyproline cGnRH II, was tested. Under standard HPLC 
conditions; hydroxyproline cGnRH II (Zymogenetics) co-eluted with synthetic mGnRH, 
while oxidised cGnRH II, co-eluted with synthetic cGnRH II. In heterologous RIAs, 
however, antisera 678 and 675, showed similar cross-reactivity (38% and 31 %) to 
oxidised cGnRH II (fig.3.5 A and B). Under the same conditions antiserum 675 showed 
a higher cross-reactivity with hydroxyproline cGnRH II (37.5%) than antiserum 678 
(2%). Neither hydroxyproline cGnRH II or oxidised cGnRH II, thus, exhibited 
characteristics of the peptide in peak I. The X. laevis sympathetic ganglion extract 
showed similar findings (data not shown). 
3.4.2 GnRH receptors in the sympathetic ganglia showed a specificity for a chicken 
GnRH II agonist 
In order to determine the receptor specificity in the sympathetic ganglia, binding of 1251-
mGnRH agonist and 1251 cGnRH II agonist (see materials and methods for peptide 
definitions), to membranes from bullfrog sympathetic ganglia and X laevis sympathetic 
ganglia and pituitary were tested in comparison to a.T3 cells (figs. 3.6 and 3.7, 
respectively). The specific binding of 1251-cGnRH II agonist was lower than the specific 
binding of 1251-mGnRH agonist, for the a T3 cells, in both experiments, with a ratio of 
0.52 and 0.3 (figs. 3.6 and 3.7, respectively). In contrast, the specific binding of 
1251-
cGnRH II agonist was higher than the specific binding of 1251-mGnRH agonist for the 
bullfrog sympathetic ganglia (fig. 3.6), with a ratio of 2.67. The differential binding of the 
X /aevis sympathetic ganglia to labelled cGnRH II and mGnRH agonists is consistent 
with the results obtained with the bullfrog sympathetic ganglia. The binding ratio of the 
two agonists was 3.9 respectively. The X laevis pituitary membranes show no 
selectivity for the two different labelled agonists. The concentrations of various GnRH 
agonists to inhibit 50 percent of the binding of 1251-cGnRH II agonist (the ICso) in bullfrog 
and X /aevis, are compared in table 3.3. The cGnRH II agonist had an ICso of 
approximately 10-s M in the sympathetic ganglia of both amphibian species (fig. 3.8, 
table 3.3). The affinity of cGnRH II was slightly lower with ICsos for the two species 
between 10-1 Mand 10-6 M. The binding of the mGnRH agonist and mGnRH was much 
lower, with the relative affinities differing in the two species. 
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Figure 3.4. Reverse-phase HPLC of an aliquot of bullfrog sympathetic ganglion 
extract and radioimmunoassay with (A) NHz-and COOH-terminus-directed cGnRH II 
antiserum 678, (B) cGnRH II antiserum 675, and (C) mGnRH antiserum 1076. 
lmmunoreactive GnRH was eluted from a Vydac C-18 column with a stepwise 
gradient of acetonitrile in 0.1 % heptafluorobutyric acid. Elution positions of synthetic 
mGnRH (M) and cGnRH II (CII) are indicated. Retention times of other known 
GnRHs under these conditions are: chicken I (11 min), catfish (11 min), mammalian 
hydroxyproline (16 min), lamprey I (23 min), dogfish (29 min), and salmon (30 min) 
(This was done by Dr J. King). 
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Figure 3.5. Heterologous radioimmunoassays of (A) antiserum 678 with 
1251 labelled 
mammalian GnRH and (B) antiserum 675 with 
1251 labelled chicken GnRH II. Percent 
binding was calculated as a percent of the maximum possible binding. Mammalian 
GnRH (T), Chicken GnRH II (•), oxidised chicken GnRH II (0) and hydroxyproline 
chicken GnRH II ( + ). Values are mean ± SE. 
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12 c:::J 1251-[D-Ala6,NMe-Leu7,Pro9- fll-lEt]GnRH 
Q -1251-[His5,D-Arg6,Trp7 ,TyrB] GnRH 












Sympathetic ganglion Alpha T3 
Figure 3.6. Binding of (D) 1251-mammalian GnRH agonist and <•> 1251-chicken GnRH 
II agonist to membranes from bullfrog sympathetic ganglion and a T3 cells. Triplicate 
aliquots containing 1/6 tissue equivalents were incubated with labelled peptide for 1 h 
at 4°C. Data are expressed as percentage binding, which was calculated as 
percentage specific binding (cpm)/tissue (mg)/total cpm added. Nonspecific binding 
was the binding (cpm) at 10-5 M [D-Ala6,NMe-Leu7,Pro9-NHEt]GnRH (D) and [His5,D-

























Figure 3. 7. Binding of (D) 1251-mammalian GnRH agonist and <•> 1251-chicken GnRH 
II agonist to membranes extracted from X. /aevis pituitary, sympathetic ganglion and 
sciatic nerve, and aT3 cells. Triplicate aliquots containing 1/3 tissue equivalents 
were incubated with labelled peptide for 1 h at 4°C. Data are expressed as 
percentage binding which was calculated as specific binding (cpm)/tissue (m~)/total 
cpm. Nonspecific bindin~ was the bindin~ (cpm) at 10-5 M [D-Ala6,NMe-Leu ,Pro9-
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Figure 3.8. Competition binding curves of the chicken GnRH II agonist (1251-[His5,D-
Arg6,Trp7,Tyr8]GnRH), on membranes from sympathetic ganglia of (A) bullfrog and 
(B) X laevis , in the presence of increasing concentrations of unlabelled [His
5,D-
Arg6,Trp7,Tyr8]GnRH (0), cGnRH II (•). mGnRH (e), [D-Ala
6,NMe-Leu7,Pro9-
NHEt]GnRH (0). Percentage binding was calculated as percentage binding (cpm)/ 
specific binding (cpm), where binding is determined as nonspecific bindin~ 
subtracted from the binding. Nonspecific binding (NSB) was the binding (cpm) at 10-
M [His5,D-Arg6,Trp7,Tyr8]GnRH. Maximum binding (Bo) was deter.mined in the 
absence of unlabelled peptide. Values are mean ± S.D. Data reduction was 
performed using GRAPHPAD PRISM™. 
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Table 3.3. lnhibtion constants 
Peptide /C50 of binding in 
bullfrog sympathetic 
an lia membranes 
ICso of binding in )i. 
/aevis sympathetic 
an lia membranes 
[His ,D-Arg ,Trp ,Ty GnRH 











Inhibition constants for the competitive binding of [His5,D-Arg6,Trp7,Tyrl}GnRH, chicken 
GnRH II , mammalian GnRH, [D-Ala6,NMe-Leu7,Pro9-NHEt]GnRH, and hydroxyproline 
chicken GnRH II with 1251-[His5,D-Arg6,Trp7,Tyr~GnRH to membranes from sympathetic 
ganglia of X laevis and bullfrog. Data reduction was performed using GRAPHPAD 
PRISM™. 
3.4.3 Amplification of genomic DNA yielded a second GnRH receptor isoform 
PCR using the degenerate primers JH5s and JH6a2, resulted in the amplification of 
two putative receptor subtypes, which showed homology to the cloned mammalian 
GnRH receptors (see section 2.4.1). These clones, pXla.1 and pX/b.1 both showed a 
35% identity at the amino acid level, to the human GnRH receptor (see appendices 
7.3 and 7.7). Clone pX/b.1, however, had a two amino acid insertion in the region of 
extracellular loop 3 (fig . 3.9). The full-length cDNA for pXla.1 was cloned from the 
pituitary and is described in chapter 2. Clone Xlb.1 was used to screen a X laevis 
genomic DNA library. Five positive plaques were isolated after secondary and 
tertiary screening. Restriction enzyme and Southern blot analysis showed that the 
genomic clones are approximately 16 kbp. 
1 39 
JH5s JH6a2 
Human giwyw£ DPEMLN .. RL SDPVNHFFFL FAFLNPCF dp.liy 
X.la gi wyw£ QPEMI N . . QT PEYLNHSLFL FGLLHTCT dp.liy 
X.lb giwyw£ PPEMLTEEKV PPVLSHI LFL FGLLNTCL dp.Iiy 
Figure 3.9. Alignment of the PCR products, Xia and Xlb obtained with the 
degenerate primers, JH5s and JH6a2 to the amino acid sequence of the 
corresponding region of the human GnRH receptor. Xia and Xlb have a 35% amino 
acid identity to the human GnRH receptor, extracellular loop Ill. Xlb has a two amino 
acid insertion. Primer sequences are shown in italics, conserved residues are shown 
in red and conservative changes are in blue. 
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3.4.4 Amplification of sympathetic ganglion cDNA 
Sympathetic ganglion cDNA was synthesised as described in materials and methods 
and the quality was assessed by agarose gel electrophoresis. (fig. 3.10). No 
products could be seen in the same size range as the control cDNA. Low molecular 
weight smears could, however, be seen. Despite the low molecular weight of the first 
strand cDNA products, they were, nevertheless, used in nested PCR with primers 
designed to pX/b.1 (see appendix 7.7). After a second, nested PCR, the products 
were probed with an internally nested primer (fig. 3.11 ). Products from PCR 
amplifications with annealing temperatures of 64°C and 68°C hybridised to the 
primer. The products amplified with an annealing temperature of 64°C were slightly 
larger, with a faint product at approximately 900 bp, than those amplified at 68°C, 
where the largest product was approximately 600 bp (fig. 3.11). The 900 bp product 
was subcloned and 136 recombinant colonies screened by colony PCR followed by 
Southern blotting or colony hybridisation, both using the labelled nested gene specific 
primer (Xl1b.4s, see appendix 7.7). DNA was prepared from 22 recombinant 
colonies, which hybridised to the primer. Only 11 of these clones contained inserts in 
the expected size range. Figure 3.12 shows a summary of the sequencing results. 
Analysis of the clones, MSG.1 - MSG.6 showed homology to the X. laevis pituitary 
GnRH receptor and the human GnRH receptor (fig. 3.12). One of the clones MSG.7, 
which had a different sequence after the valine (fig. 3.12, see arrow) may have a 
retained intron, as no open reading frame could be found. This valine, therefore, 
appears to be the exon/intron boundary. This boundary would align identically to the 
boundary of intron II in the human GnRH receptor gene [Fan et al., 1994] and the 
intron II boundary of the X. laevis pituitary GnRH receptor (see chapter 2). The 
sequence with the longest open reading frame (MSG. 4) with homology to the human 
GnRH receptors as well as the X. laevis pituitary GnRH receptor, possibly ends at the 
border of transmembrane domain V and extracellular loop Ill, which does not align to 
the exon/intron boundaries of any of the characterised GnRH receptor genes [Zhou 
and Sealfon, 1994; Fan et al., 1994; and chapter 2]. This truncation, probably 
represents an incomplete cDNA transcript. As none of the cDNA clones contained a 
full-length receptor, cDNA synthesis was repeated to increase the specificity, using a 
gene specific primer designed to pX/b.1 (X/b.1a, see appendix 7.7) instead of the 
oligo dT cDNA synthesis primer supplied by the Marathon kit. The double stranded 
cDNA was run on an agarose gel following second strand synthesis, but no cDNA 
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could be seen after a one week exposure of the autoradiograph. This may be due to 
the low incorporation of [32P]dCTP as a result of only the one species of RNA being 
synthesised into cDNA. PCR amplification was, therefore, continued. Following two 
rounds of nested PCR amplification, and Southern blotting, no products containing 
the nested primer X/b.4s sequence could be seen. 
1kb· 
0.6_ 
M C SG 
Figure 3.10. Autoradiograph showing the X /aevis sympathetic ganglia cDNA after 
the first strand synthesis (SG). A positive control was provided with the Marathon 
cDNA amplification kit (Clonetech) (C). M represents the MW marker. Only very low 
molecular weight products could be seen (see arrow). 
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Ta 64°c Ta 68°c 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
1Kbp-
340bp-
Figure 3. 11. Autoradiograph of the Southern blot after two rounds of nested 
Marathon PCR on the X. laevis sympathetic ganglia cDNA, using the gene specific 
primers designed to Xlb (see appendix 7.7, primers X/1b.1a and X/1b.2a for 5' 
amplification and X/1 b.4s and X/1 b.3s for 3' amplification). The blot was probed with 
[y32P]dATP end-labelled X/1b.4s. Lanes 1 - 3 and 10 - 12 represent 5' amplification, 
lanes 5 - 7 represent 3' amplification , lanes 4, 7 - 9, 13 - 15 are negative controls, 
where no DNA was added. Ta: annealing temperature; M: MW marker; 1: 
sympathetic ganglia cDNA amplified with adaptor- and antisense gene specific 
primers (ie. 5' RACE); 2: sympathetic ganglia cDNA amplified with adaptor primers 
only; 3: sympathetic ganglia cDNA amplified with gene specific primers only; 4: no 
cDNA control; 5: sympathetic ganglia cDNA amplified with adaptor- and sense gene 
specific primers (ie. 3' RACE); 6: sympathetic ganglia cDNA amplified with gene 
specific primers only; 7 - 9: no cDNA controls with different primer combinations; 10 -
13: sympathetic ganglia cDNA as for lanes 1 -3; 13 - 15: no cDNA controls, with 
different primer combinations. A 900 bp product was seen after PCR with an 
annealing temperature of 64°C (see arrow), while after amplification at 68°C, the 
largest product was approximately 600 bp. 
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3.4.5 3' Amplification of sympathetic ganglia cDNA reveals that the Xlb receptor has 
an intracellular carboxy-terminal tail. 
Three sense gene specific primers were designed to pX/b.1, for amplification of 
sequences 3' to pX/b.1. The membrane used in figure 3.11 was stripped by the 
addition of boiling 0.5 % SOS and probed with the primer X/1 b.1 a, which is an 
internally nested primer for the 3' amplification reaction (see appendix 7.7). Two high 
molecular weight products of 3 kbp and > 10 kbp hybridised to the primer (fig. 3.13). 
The 3 kbp product was subcloned, and 30 recombinant colonies screened by colony 
PCR, followed by Southern blotting. Six positive clones were obtained. The smallest 
of these, pSG3'1, of approximately 500 bp was sequenced. The sequence of this 
clone revealed the partial sequence of the intracellular carboxy-terminal tail (see 
appendix 7.9). 
3.4.6 PCR amplification of pituitary, hindbrain and sympathetic ganglion cDNA using 
primers to pXlb. 1. 
The expression of the alternative subtype of the GnRH receptor, (pX/b.1) may occur 
in tissues other than the sympathetic ganglia and it is possible that both the subtypes 
of receptor are expressed in the pituitary. Alternatively, the expression of this 
receptor, may co-localise with the expression of cGnRH II in the amphibian brain 
[King et al., 1994(a)]. Pituitary cDNA was, therefore, subjected to amplification (fig. 
2.4) using the primers designed to the pX/b.1 GnRH receptor subtype, as well as 
cDNA synthesised from total RNA extracted from the hindbrains of several adult male 
X. laevis. Sympathetic ganglion cDNA was also used as a reference. Following 
three rounds of nested PCR amplification at an annealing temperature of 64°C, the 
PCR products were subjected to Southern blotting with the labelled internally nested 
primer, Xl1b.3a. The results can be seen in figure 3.14. Only the pituitary gave clear 
low molecular weight products of approximately 200 - 500 bp, which hybridised to the 
labelled primer. Slight smears can be seen in the products amplified from 
sympathetic ganglion and hindbrain cDNA. The PCR on the pituitary cDNA was 
repeated, but with variable annealing temperatures, ranging from 62°C to 68°C, and 
variable concentrations of cDNA, in order to optimise the conditions so as to obtain 
higher molecular weight products, possibly containing the full length cDNA. Although 
higher molecular weight products were obtained, no discreet bands could be seen on 
the blot. The products appeared to be smears ranging from approximately 2 kbp to 
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16 kbp. The lower part of the smear was excised from an agarose gel the DNA 
extracted from the agarose and subcloned. 66 recombinant colonies were screened 
by colony hybridisation, of which 20% were positive. DNA was extracted from 
positive colonies, and colonies with inserts in the correct size range were sequenced 
with X/1 b.2a primer. Five of the clones, gave completely unrelated sequences, while 
a sixth clone gave the correct sequence, but with the same intron sequence which 
was obtained in the sympathetic ganglion clones (MSG.7) (fig. 3.12). 
3.4. 7 Exon trapping 
Products obtained after the initial PCR on the cDNA, extracted from COS-1 cells 
transfected with the various combinations of pSPL3 subclones (table 3.2) were 
subjected to agarose gel electrophoresis followed by Southern blotting (fig. 3.15). 
Products were digested with and without BstX 1 restriction enzyme in order to 
eliminate products resulting from vector splicing (see appendix 7.8b). All the 
products gave slight smears. These products were then amplified in two nested PCR 
reactions using the gene specific primers, X/1b.1a and X/1b.2a (see appendix 7.7), 
with the vector specific primer dUSDs (see appendix 7.8a and b). The products were 
then blotted onto nitrocellulose and probed with the third nested primer X/1 b.4s (fig. 
3.16). Only cDNA from combination number 3 (table 3.2) hybridised to the labelled 
primer. The products were approximately 200 bp -1 kbp in size, but no discreet 
bands could be seen after the Southern blot. These products were subcloned. DNA 
was prepared from 34 recombinant clones and analysed by Eco R1 and Pst 1 
restriction enzyme digestions, followed by Southern blotting. Several of the clones 
gave identical digestions, so only seven of the clones were sequenced. Although the 
exon Ill and exon II appear to be spliced together, like the marathon sympathetic 
ganglia clones (fig. 3.12), analysis of regions more 5' to this gave unidentified 
sequence with no open reading frames and no sequence homology to the 
mammalian receptor. The one clone, which did have an open reading frame gave a 
sequence with a 96.4% nucleotide sequence identity in a 140 bp region, with the X 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4.8 cDNA library screening yielded no positive clones 
The sympathetic ganglion cDNA library was screened, using mouse GnRH receptor 
cDNA. No positive plaques were obtained after screening 10
6 plaques. The quality 
of the library was tested by probing with p-actin cDNA. One positive plaque was 
obtained per 1000 pfu. The cDNA library was also screened with the genomic 
fragments, pXla.1 and pX/b.1, but no positive plaques were obtained. 
10Kbp-
2.8Kbp -
Ta 64°c Ta 68°c 
M 1 2 3 4 5 6 7 8 9 10 11 1213 14 15 
.. .. 
Figure 3.13. See figure 3.11 for gel loading. The membrane from figure 3.11 was 
stripped and probed with [y32P]dATP end-labelled Xl1 b.1 a, in order to see if any 3' 
amplification products were obtained. Two clear products of approximately 2.8 and 
10 Kbp are seen in lane 5, (see arrows) which is sympathetic ganglia cDNA amplified 
with adaptor- and sense gene specific primers. High background bands are seen in 
lanes 1, 2 and 6 - 10 due to the overlap of primers used for PCR amplification and 
probing. 
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cDNA1 Pit SG B ---~~r-, 
1 234587 M 
A I •condarr PCR 
B• Tertiary PCR 
M 
Figure 3.14. Autoradiograph of the Southern blot showing the X. /aevis pituitary (Pit, 
1, 1/10 dilution of cDNA; 2, 1/100 dilution of cDNA), sympathetic ganglia (SG 3, !/10 
dilution of cDNA; 4, 1/100 dilution of cDNA) and hindbrain (B, 5. 1/10 dilution of 
cDNA; 6, 1/100 dilution of cDNA) after secondary and tertiary PCR amplifications 
with primers to pXlb.1. (appendix 7.7). The blot was probed with [y32P]dATP end-





1 2 3 4 5 
...----, ..----, ....-----, r------, 
B - 8-8-8-B-M 
B: Bst X1 digestion 
- · no digestion 
Figure 3.15. Autoradiograph of the Southern blot after amplification of exon trapped 
cDNA with the vector specific primers, SDs and SA2 (appendix 7.8a and b), showing 
the 5 combinations of transfection (table 3.2) with and without BstX1 digestion. 






1 2 3 4 5- M 
Figure 3.16. Autoradiograph of the Southern blot after secondary amplification of 
BstX1 digested, exon trapped cDNA with the gene specific primer to pX/b.1, X/1b.1a 
in combination with the vector primer dUSD2 (appendix 7.7 and 7.8a and b), showing 
the 5 combinations of transfection (table 3.2). Membrane was probed with 
[y32P]dATP end-labelled X/1 b.4s. M, represents the MW marker. 
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3.5 Discussion 
The electrical consequence of the release of GnRH in the bullfrog sympathetic ganglia 
is the inhibition of the M-current, which makes the ganglionic neuron highly excitable 
due to the increased membrane impedance. Unlike the short effect of acetylcholine 
release (lasting milliseconds) from the same set of nerve terminals, release of GnRH 
affects the membrane excitability for many minutes. Thus, during these minutes, the 
ganglia cells change from linear input-output relays to highly non-linearly amplifying 
synapses. The long-lasting effects of release of a neuropeptide as a transmitter in 
modulating a neuron's subsequent responses make this form of neuropeptide 
transmission an important candidate for a role in learning and memory in the nervous 
systems. 
In this study we have detected the presence of immunoreactive cGnRH II in 
sympathetic ganglia of two amphibian species, R. catesbeiana and X. laevis, which has 
identical properties to synthetic cGnRH II. As GnRH has been shown to be a 
neurotransmitter in the bullfrog [Jan and Jan, 1980], it is very likely that the endogenous 
isoform of GnRH, used as a neurotransmitter in this system was cGnRH II. This is 
consistent with the electrophysiological studies where exogenous cGnRH II was found 
to be the most potent inhibitor of M-current [Jones, 1987). The fact that less cGnRH II 
(43pg per animal) was detected in the ganglia of X. laevis than in R. catesbeiana can 
be accounted for by the difference in the sizes of the two species. Although 
electrophysiological data on M-current inhibition in X. laevis, is required, to conclusively 
prove the involvement of cGnRH II in this form of neurotransmission, it is likely that the 
effect on M-current by this peptide is similar to that in the bullfrog. 
A second, unidentified, immunoreactive form of GnRH was also found in the 
sympathetic ganglia of both amphibian species. This peptide is not mGnRH as it 
showed no cross-reactivity with the specific mGnRH antiserum. It is also not a 
degradation product of cGnRH II, as it cross-reacted with the NH:z- and COCH-terminus 
directed antibody. It is possible that this peptide could be a chemically modified form of 
cGnRH II, because of their similar reactivity with the two cGnRH II antibodies or a novel 
form with sufficient common epitopes to result in considerable cross-reaction. Two 
possible forms of modified cGnRH II were tested, namely hydroxyproline cGnRH II and 
oxidised cGnRH II. Hydroxylation of cGnRH II, like the hydroxylation of mammalian 
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GnRH, may be a post-translational enzymatic modification for regulation of the cGnRH 
II response [Gautron et al. , 1992]. The oxidation of cGnRH II may be an artefact of the 
extraction procedure. Both of these peptides would be less hydrophobic than cGnRH II 
and thus should elute earlier in the HPLC gradient. Neither of them proved to be 
candidates, due to the HPLC retention times and relative cross-reactivity with the 
different specific antisera. An unidentified form of GnRH has previously been detected 
in the X laevis, but this form was very hydrophobic and, therefore, could not account for 
the earlier-eluting isoform [Licht et al. , 1994(a)]. The identity of the peptide in peak I is, 
therefore, unknown, and may be a novel form of GnRH, or a chemical modification of 
cGnRH II. Chemical modifications of GnRH arising during extraction, lyophilisation and 
chromatography in acetonitrile have previously been shown to occur as a result of 
artefacts of the HPLC procedure [King et al. , 1988). 
The binding of the cGnRH II analogue to the sympathetic ganglia membranes of both 
amphibian species is specific as it can be displaced with unlabelled peptide. The 
inhibition coefficient (IC!:O) of this binding was 1 O nM, which is approximately 10-fold 
higher than that obtained for the suppression of M-current [Jones, 1987]. This 
difference is consistent with the amplification seen in signal transduction [Strickland and 
Loeb, 1981]. The differences in binding of the a T3 gonadotrope cell line with the two 
different ligands is anticipated as the mammalian GnRH pituitary receptors (fig. 3.6 and 
3. 7), are known to show a high fidelity for mGnRH when compared to other GnRH 
isoforms [Millar et al. , 1986(b), for review, see King and Millar, 1995]. The molecular 
structure of the sympathetic ganglion receptor to which cGnRH II binds is not known, 
but this study provides strong evidence for it to be significantly different from the cloned 
mammalian pituitary GnRH receptors [for review, see Stojikovic et al., 1994]. The 
binding of both the mammalian and chicken II GnRH agonists in the pituitary of the X 
laevis was low (fig. 3. 7). A low binding of this peptide in the pituitary of the green frog 
has been previously reported [Fasano et al. , 1990], but no binding with the GnRH 
receptor from X laevis pituitary could be detected in COS-1 cells ( chapter 2). The 
amphibian pituitary GnRH receptor also shows a high selectivity for cGnRH II , 
compared to mGnRH analogues ( chapter 2), but this receptor was not expressed in the 
sympathetic ganglia, as no specific products were obtained after reverse transcriptase 
PCR on sympathetic ganglia cDNA with primers to the Xia receptor subtype. 
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We attempted to clone a receptor, which may correspond to the receptor which binds to 
cGnRH II in the sympathetic ganglia. Although a second subtype of receptor with 
homology to the X. laevis pituitary receptor as well as the cloned mammalian GnRH 
receptors was cloned from genomic DNA, no full length cDNA could be isolated from 
sympathetic ganglia cDNA using several PCR-based techniques. TVvO types of clones 
were, however, identified, with differences in the sequence after the putative exon/intron 
boundary. One had no open reading frame and may have been intron sequence, while 
the other had an open reading frame, with homology to the GnRH receptors, but was 
not a full-length receptor. 
This putative receptor subtype does not represent a duplicate gene of the GnRH 
receptor isolated from X. laevis pituitary cDNA, which may result from the tetraploid 
genome of X. laevis, as the amino acid identity of this clone to the GnRH receptor 
isolated from pituitary cDNA is low (51 %). There is, however, a possibility that clone 
Xfo may be a pseudogene, which arose from a duplication of the receptor thereby 
explaining the lack of a full length receptor and inconclusive splicing results from the 
exon trapping analysis of the genomic clone. This receptor may have been active in an 
ancient amphibian predecessor, but became redundant later in evolution. There are, 
however, several arguments against this possibility. All the sequences of the subclones 
except one which align to exon Ill and exon II of the X. laevis pituitary GnRH receptor, 
are open reading frames, with significant amino acid identity to both the human GnRH 
receptor and the X. laevis pituitary GnRH receptor. Only one clone contained 
sequence, which after the putative exon/intron boundary was not an open reading 
frame. At this region of sequence divergence, there is a typical intron donor site [Mount, 
1982], therefore, adding evidence that this sequence is intronic. Further evidence for 
the existence of this second receptor comes from PCR analysis of extracellular loop Ill 
of lizard (Agama atra) genomic DNA by Dr E. Rumbak. Using identical conditions to 
those used to amplify the tVvO genomic clones from X. laevis DNA, two clones were 
isolated from lizard DNA One clone, Liz.1 had a high amino acid sequence identity to 
the X. /aevis pituitary clone (76% ), while the other, Liz.2 had a high amino acid identity 
to the X. laevis Xfo clone (78%). This clone also had the tVvO amino acid insertion in the 
sequence of extracellular loop Ill when aligned to the mammalian, catfish and X. laevis 
pituitary GnRH receptors (fig. 3.9). The lizard clone, Liz.2, also had the two adjacent 
pralines, which were not present in the other pituitary GnRH receptors (fig. 3.9). A 
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human clone with homology to this lizard clone, Liz.2 and the X. laevis clone, X/b was 
identified in the human genome data base (Millar et al. , submitted). The human clone 
had a high amino acid identity at 81 % and 73% with the lizard and X. laevis clone XID 
respectively, and had the t'MJ adjacent praline residues, despite lacking the two amino 
acid insertion. These three receptors (XID, Liz.2 and the human clone), therefore, 
appear to be related. It is thus very unlikely that a receptor gene, which arose prior to 
the evolutionary divergence of reptiles, amphibians and mammals and which has been 
highly conserved in the region of extracellular loop Ill , is an inactive pseudogene. 
The expression of XID receptor is, however, unknown. Sympathetic ganglion cDNA 
was extensively analysed using library screening as well as the sensitive Marathon 
(Clonetech) reverse transcriptase PCR. The sympathetic ganglion library gave 
reasonable expression with the ubiquitously expressed j3-actin cDNA probe, despite the 
low titre, even after amplification (1.4 x 10
5 pfu/µI). The library was initially screened 
with the mouse GnRH receptor cDNA clone. This was, ho'Never, prior to the isolation of 
the two PCR clones generated from genomic DNA, Xia and XID. Subsequent analysis 
of the homology of these clones to the mammalian GnRH receptor clones revealed a 
low homology (<45%), a probe with such a low homology would not hybridise under the 
conditions used to screen the library. The library was, therefore, screened with the 
genomic clones Xia and XID. No positive clones were identified. The expression of 
these receptors may, thus, be too low to be represented in the one million plaques 
screened. The fact that no positive plaques \.Vere identified in the sympathetic ganglion 
library may, therefore, be as a result of the low initial titre of the library, or the low 
expression of this receptor in these neurons. The Marathon (Clonetech) PCR with 
primers designed to XID on sympathetic ganglia revealed a receptor, which did not 
contain the full length cDNA, but did appear to be processed in these neurons. Two 
splice variants \.Vere, however, obtained, one with an open reading frame with sequence 
homology to the cloned GnRH receptors, while the other had no open reading frame 
and no sequence homology, and may, therefore, be intron sequence. This 
unprocessed cDNA may have been due to a small amount of contaminating genomic 
DNA, or incompletely spliced RNA The full length clone of Xia was isolated from 
pituitary cDNA (Chapter 2), and was not expressed in the sympathetic ganglia, as 
determined by reverse transcriptase PCR. No full length, processed clones were 
isolated after Marathon PCR (Clonetech), this may have been due to the low average 
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molecular weight of the sympathetic ganglia cDNA (fig. 3.10. ). cDNA synthesis was, 
therefore, repeated, but a gene specific primer was substituted for the oligo dT primer 
supplied with the synthesis kit. After nested PCR, the products were analysed. No 
specific products were obtained. Pituitary and hindbrain cDNA were also analysed for 
expression of this receptor. Again unprocessed cDNAs were identified, possibly 
indicating a lack of expression in these tissues. PCR products may have been as a 
result of a small amount of contaminating genomic DNA, but no direct conclusions on 
the expression of this second receptor subtype can be made. The genomic clone of Xfo 
was, therefore, used in an attempt to clone the full-length processed cDNA of this 
receptor. X laevis genomic library, which was supplied by Dr T. Sargent (NIH, USA) 
was screened and five genomic clones isolated. The genomic clone was digested into 
smaller fragments, cloned into a splicing vector and transiently transfected into COS-1 
cells. The cells were allowed to grow for three days, prior to the extraction of total RNA 
cDNA was synthesised and amplified using PCR with primers designed to the splicing 
vector in combination with gene specific primers designed to Xfo. Although preliminary 
results seemed hopeful, a detailed analysis of several clones did not reveal any further 
sequence information. Because gene specific primers to the known regions of 
sequence were used in combination with a nested probe, clones corresponding to this 
region of the receptor were automatically enriched, while others, possibly corresponding 
to the unknown 5' sequences, which may have been present, would be un-identified. 
Due to the many variables in this Exon Trapping (Gibco BRL) method, such as 
orientation of the original clones and the possible lack of other 5' exons I decided to 
work with the regions of the receptor, with known sequences. It would, therefore, be 
easy to monitor the success of the method, by Southern blotting with a nested probe, 
for example, and if successful, it would be possible to return to the original cDNA for 
amplification and sequence analysis, but due to the presence of unprocessed cDNA no 
further sequence analysis was done. The one subclone generated by PCR 
amplification with a combination of gene specific primers to Xfo and the splicing vector 
showed a high nucleotide sequence homology (96.4%) for a significant length (140 bp) 
to X Jaevis 28 S, 18 S and 5.8 S RNA (see appendix 7.10). This may be a result of a 
splicing artifact, generated by the splicing to an adjacent gene encoding the ribosomal 
RNAs. No direct conclusions could, therefore, be made from the exon trapping results. 
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Several approaches were, therefore, used in an attempt to clone the full-length cDNA of 
this receptor. The results seem to provide evidence that the full-length transcript for this 
receptor may not be expressed in the sympathetic ganglia, despite the occurrence of 
partially processed transcripts in these neurons. The possibility, therefore, exists, that 
this gene may be a pseudogene and is not expressed. As discussed above, there are 
several arguments against this, such as the occurrence of a highly homologous 
receptor in the lizard, Agama atra, and the human. A completely unprejudiced 
approach may, therefore, be required to clone this receptor. While it is tempting to 
assume that this receptor is the receptor responsible for the cGnRH II-induced inhibition 
of M-current in the sympathetic ganglia, seen in physiological studies, this assumption 
may be unfounded and the receptor may have a different function and may, therefore, 
be expressed in alternative, discreet brain areas. Although M-current has been 
described in rat [Owen et al., 1990] it is not known whether it is a conserved mechanism 
for controlling neuron excitability in all vertebrates, and one can only speculate that this 
receptor is present in other vertebrate species. The fact that homologous receptor 
subtypes are also present in reptiles and mammals does not illuminate the situation, as 
this amphibian receptor has an unknown function and expression. A systematic 
approach using a diverse range of tissues may, therefore, be required. Studies using in 
situ hybridisation have been initiated with collaborators, but no results are available yet. 
While no conclusions on the structure of this receptor can be made with the limited 
sequence information available, a few interesting observations can be addressed. 
From the sequence which is available, this cDNA appears to encode a G-protein 
coupled receptor with a 47%, 51 % and 53% amino acid identity to the human, catfish 
and X laevis pituitary GnRH receptors, respectively [Kakar et al., 1992; Chi et al. , 1993; 
Tensen et al. , 1997; and chapter 2]. The sequence includes regions, which align from 
transmembrane domain (TM) V, to the intracellular carboxy-terminal tail , including 
intracellular and extracellular loops II I as well as TMs VI and VII . Like the X laevis 
pituitary receptor, the regions aligning to the putative hydrophobic transmembrane 
domains are highly conserved with the human GnRH receptor, with TM VI being the 
most conserved. The carboxy-terminal region of IL Ill is highly conserved including the 
alanine, which aligns to Ala261 of the human GnRH receptor, stressing the importance of 
this region in G-protein coupling [Myburgh et al. , 1998]. EL Ill of this receptor subtype is 
poorly conserved, with the highest amino acid identity (50%) to the X laevis pituitary 
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receptor and a slightly lower identity to the corresponding region of the mammalian 
GnRH receptors (42-43%). The acidic amino acid, shown to be important for ligand 
selectivity (Glu~n in the mouse or Asp3J2 in the human GnRH receptor) in the 
mammalian GnRH receptors [Flanagan et al. , 1994] is not present. There is in fact, a 
praline residue in the corresponding position. The X. laevis pituitary receptor which 
does have a limited ligand selectivity (chapter 2), does have an acidic residue (Glu288) in 
the corresponding position, but the preceding praline may alter the conformation of the 
loop so as to decrease the ligand selectivity (chapter 2). One could speculate, 
therefore, that the XID receptor subtype, which has two adjacent pralines in this position 
may have a reduced ligand specificity. This low specificity may be reflected by the 
relatively high ICso for mGnRH and mGnRH analogues (table 3.3). The intracellular 
carboxy-terminal tail of this receptor has several putative phosphorylation sites, which 
may be important for desensitisation, which has been shown to be an integral part of 
cGnRH II stimulated M-current inhibition [Jones, 1987; for review, see Adams and 
Brown 1980]. 
Although I have shown by membrane binding assays, that a protein receptor is present 
in the sympathetic ganglia that binds cGnRH II with high affinity, I have been unable to 
clone the full-length receptor. In summary, however, one would expect this receptor to 
be a GPCR as G-protein coupling is required for M-current inhibition. The coupling 
mechanism is unknown, but does not seem to involve the Gq/G11 system typical of the 
other GnRH receptors. This receptor binds cGnRH II with a greater affinity than 
mGnRH and shows a rapid desensitisation upon stimulation with cGnRH II [Jones, 
1987]. The endogenous ligand is unknown, but cGnRH II is a likely candidate as it 
reversibly inhibits M-current [Jones, 1987; for review, see Adams and Brown, 1980], 
was found in extracts of the sympathetic ganglia and shows specific binding to 
membranes from the ganglia. 
From a molecular evolution perspective, as cGnRH II is highly conserved throughout 
evolution, occurring in all the major vertebrate groups, including cartilaginous fish, bony 
fish, amphibians, reptiles, birds, and several metatherian and early-evolved eutherian 
mammals [King et al. , 1989; King et al. , 1990; Oellovade et al. , 1993; King et al. , 
1994b], as well as more recently, primates [Lescheid et al. , 1997] and humans [White et 
a/. , 1998], it would be interesting to determine if this isoform of GnRH is used as a 
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neurotransmitter in these vertebrate species. The present study provides strong 
evidence for the involvement of endogenous cGnRH II in M-current suppression in the 




Gonadotropin-releasing hormone receptor subtypes in the goldfish 
( Carassius auratus) 
4.1 Summary 
In the goldfish (Carassius auratus) the two endogenous forms of gonadotropin-
releasing hormone, namely chicken GnRH II ([His
5,Trp7,Tyr8]GnRH) and salmon 
GnRH ([Trp7,Leu8]GnRH), stimulate the release of gonadotropins (GtHs) and 
growth hormone (GH) from the pituitary. This is thought to occur via the 
stimulation of two distinct receptors on the surface of gonadotropes and 
somatotropes. These receptors can be distinguished on the basis of differential 
GtH and GH releasing activities of endogenous GnRHs with variant amino acids 
in position 8 [Habibi et al., 1992) as well as various analogues, which differentially 
stimulate or inhibit GnRH stimulated GH or GtH release [Murthy et al., 1993; 
1994; Murthy and Peter, 1994). The cDNAs for two distinct GnRH receptor 
subtypes have been cloned from goldfish brain and pituitaries, designated GfA 
and GfB. These receptors have a 67% nucleotide homology and a 71 % amino 
acid identity to each other. Both receptors have approximately 43% amino acid 
identity with the human GnRH receptor, while the GfB receptor subtype shows a 
distinctly higher homology to the catfish GnRH receptor (82%) than the GfA 
receptor (71%). Although neither receptor subtype shows identical 
pharmacological characteristics of either the GtH- or the GH-releasing receptors, 
they have a very distinct ligand specificity. Like the X laevis pituitary GnRH 
receptor (chapter 2) and the catfish GnRH receptor [Tensen et al., 1997), both 
receptor subtypes show a high specificity for cGnRH II in comparison to mGnRH 
and sGnRH. In situ hybridisation revealed that both receptor subtypes are 
expressed in the brain and pituitary. The GfA receptor is also expressed in the 
interstitial cells of the ovary and hepatocytes in the liver (Dr RE. Peter, University 
of Alberta, Edmonton, Canada). Thus both the GfA and GfB receptor subtypes 
may have important roles in pituitary regulation and both GH and GtH secretion, 
the GfA receptor may have an additional role due to its expression in non-
regulatory tissues such as the liver. 
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4.2 Introduction 
cGnRH II and sGnRH have been identified in the brains of the goldfish, Carassius 
auratus [Yu et al., 1988; Kobayshi et al., 1992; Kim et al., 1995). All teleosts 
examined to date have cGnRH II in combination with either the mammalian, 
salmon (Trp7,Leu~GnRH), catfish ([His5,Asn~GnRH) or seabream GnRH 
([Ser~GnRH) subtypes [for reviews, see Sherwood et al., 1993, 1997; King and 
Millar 1997). The distribution of the two endogenous forms of GnRH found in 
goldfish, has been studied using radioimmunoassays in combination with HPLC 
[Yu et al., 1988; Kobayashi et al., 1992) and immunocytochemistry [Kim et al., 
1995). sGnRH predominated in the rostral brain areas including the olfactory 
bulb, telencephalon, hypothalamus and pituitary. cGnRH II, however, had a more 
widespread distribution; overlapping with that of sGnRH, but predominated in the 
posterior brain regions [Yu et al., 1988; Kobayashi et al., 1992; Kim et al., 1995; 
for review, see Kim et al., 1997). Both sGnRH and cGnRH II may, therefore, be 
involved in regulating pituitary hormone secretion in goldfish. 
Both the endogenous subtypes of GnRH in goldfish can stimulate the release of 
the gonadotropins (GtH II) and growth hormone (GH) [Marchant et al., 1989; for 
review, see Trudeau, 1997). GnRH has also been shown to stimulate GH 
secretion in the carp, Cyprinus carpio [Lin et al., 1993), Tilapia hybrids [Melamed 
et al., 1995) but not in catfish, Clarias gariepinus [Bosma et al., 1997). Most fish 
species have two forms of gonadotropins (GtHs) [Kawauchi et al., 1989), referred 
to as GtH I and GtH II, but due to the similarities of these GtHs with mammalian 
FSH and LH, they are often referred to as fish FSH and LH [Prat et al., 1996). 
GnRH receptors have been detected on the surface of gonadotropes and 
somatotropes in the goldfish pituitary, using electron microscopy [Cook et al., 
1991). Binding studies on goldfish pituitaries have suggested the presence of two 
binding sites, distinguished by their binding dynamics, as a high affinity, low 
capacity site and a low affinity, high capacity site [Habibi et al., 1987). The 
potency of both GtH and GH release is, however, consistent with the high affinity 
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binding sites of the pituitary [Habibi et al., 1989). Both sGnRH and cGnRH II can 
displace a 1251-labelled sGnRH analogue from goldfish pituitary membrane 
preparations [Habibi et al., 1987). Furthermore, both the endogenous peptides 
can displace biotinylated sGnRH analogue from the surfaces of both 
somatotropes and gonadotropes in the pituitary [Cook et al., 1991). It was 
originally suggested that the two endogenous peptides bind the same receptor on 
the surface of somatotropes and gonadotropes, but they could activate two 
different intracellular signalling systems in the different cells, stimulating the 
release of GH from somatotropes and GtHs from gonadotropes [Chang et al., 
1991(a); 1991(b)J. Despite these binding results, the receptors on the two cell 
types are likely to be different as the GtH II- and GH-releasing activity of different 
GnRH analogues differ substantially [Habibi et al., 1992; Murthy et al., 1994; 
Murthy and Peter, 1994). For GtH II-releasing activity cGnRH II is more potent 
than sGnRH and mGnRH. For GH-releasing activity, however, sGnRH is more 
potent than mGnRH and cGnRH II, which are approximately equipotent [Habibi et 
al., 1992). The GH-releasing activity also appears to be more selective for GnRH 
analogues with variations in position 8, such as [His8]GnRH, [Leu8]GnRH and 
[Tyr~GnRH, while the GtH II-releasing activity shows a lower response to these 
analogues [Habibi et al., 1992). The two receptors can also be distinguished by 
their response to the GnRH antagonists. Analogue E ([Ac-Pro1,D-Fpa2,D-
Trp3·6]GnRH) is pure antagonist for both salmon and cGnRH II stimulated GtH II 
and GH release, while analogue C ([Ac-Pro1, D-Fpa2, D-Trp3•6,Trp7,Leu8)GnRH) 
inhibits sGnRH and cGnRH II stimulated GtH-11 release, but stimulates GH 
release. A third analogue, analogue L ([Ac-D-Nal1, D-Cpa2, D-Pal3,Arg5,D-Pal6,D-
Ala 1~GnRH) weakly stimulates GtH II release but inhibits GH release [Murthy and 
Peter, 1994; Murthy et al., 1993; 1994]. 
The possibility of two GnRH receptor subtypes in the goldfish pituitary was, 
therefore, investigated. Two receptor subtypes were identified from goldfish 
pituitary and brain. These receptor subtypes show a low homology with the 
mammalian GnRH receptors and one receptor shows a high homology with the 
catfish GnRH receptor [Tensen et al., 1997). Pharmacological studies of the two 
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receptors, transiently transfected into COS-1 cells revealed distinct functional 
characteristics between the receptors, which may correspond to the functional 
activity of the receptors. 
4.3 Materials and methods 
4.3.1 Peptides 
The following peptides were used in this study, the agonists: GnRH; 
[His5,Trp7,Tyr6]GnRH (Chicken GnRH II, cGnRH II); [Gln6]GnRH (Chicken GnRH I, 
cGnRH I); [Tyr6]GnRH; [D-Arg6,Trp7,Tyr6]GnRH; and [D-Arg6,Trp7,Leu8)GnRH 
were prepared by solid-phase synthesis and purified by C-18 reverse-phase 
chromatography. [Ser8]GnRH (seabream GnRH, sbGnRH); [Trp7,Leu6]GnRH 
(salmon GnRH, sGnRH); [His5,D-Arg6,Leu6]GnRH; [His6]GnRH was from R.W. 
Roeske and the antagonists: [Ac-Pro1,D-Fpa2,D-Trp3·6]GnRH (analogue E); [Ac-
Pro1, D-Fpa2, D-Trp3•6,Trp7,Leu8)GnRH (analogue C); and [Ac-D-Na11, D-Cpa2, D-
Pal3,Arg5,D-Pal6,D-Ala 1~GnRH (analogue L) were gifts from J. Rivier. 
4.3.2 Experimental animals and tissue preparation 
Goldfish material was supplied by Dr R.E. Peter (University of Alberta, Edmonton, 
Canada). Female and male goldfish (30-40 g body weight) were purchased from 
Grassyfork Fisheries (Martinsville Indiana). The fish were maintained in a 300-
litre flow through aquarium at 15°C under 16 h light and 8 h dark photoperiod and 
were fed daily, ad libitum, with commercially prepared fish pellets. Goldfish were 
anaesthetised and livers, whole brain and pituitaries were dissected. Dissected 
material was immediately frozen on dry ice and stored at -70°C until needed. 
Genomic DNA was purified from five livers as described in section 2.3.1. Total 
RNA was purified from whole brain and pituitaries by extraction with guanidium 
thiocynate [Chomczynski and Sacchi, 1987]. 
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4.3.3 Cloning of goldfish GnRH receptors 
Degenerate PCR primers, JH5s and JH6a2, (see section, 2.3.3 for primer 
sequence) designed to conserved regions of the mammalian GnRH receptors, 
were used to amplify two putative GnRH receptor subtypes from goldfish genomic 
DNA (GfA and GfB) (see section, 2.3.3 - 2.3.5 for a detailed description of 
methods). The nucleotide sequence of these clones was used to design gene-
specific primers to amplify up the remainder of these GnRH receptor sequences 
from cDNA (see appendices, 7.11 and 7.12 for primer nomenclature, sequence 
and location). 
4.3.4 cDNA synthesis and amplification 
This work was conducted in collaboration with Prof. N. filing (University of Cape 
Town, Biochemistry Department), but all the methods used are described here, for 
completeness. The work on pituitary cDNA synthesis, amplification, analysis, 
cloning and sequencing of both receptor subtypes was conducted by Prof. llling. I 
synthesised the whole brain cDNA, but PCR amplification was done by Prof. llling. 
I did all subsequent product analysis, cloning ·and characterisation. 
cDNA was synthesised from total RNA purified from goldfish whole brains and 
pituitaries, using the Marathon cDNA synthesis kit (Clonetech). [a-32P]dCTP (1 
µCi/µI, Amersham) was added to the cDNA synthesis reaction in order to enable 
the quantification of cDNA synthesis. Double stranded cDNA was analysed by 
agarose gel electrophoresis, followed by autoradiography. Adaptor primers, were 
ligated onto the 5' ends of the double stranded cDNA. 
The 5' end of GfA cDNA was amplified using nested PCR with GfA.1 as and 
GfA.3as (see appendix 7.11 for location and sequence) in combination with the 
adaptor primers AP1 and AP2 (Clonetech). PCR products were then analysed by 
Southern blot using the nested primer GfA.2s end-labelled with fluorescene-11-
dUTP using the 3' Oligonucleotide labelling and detection system (ECL, 
Amersham). A single product of 2800 bp was detected, which was cloned into the 
pGEM-T vector (Promega, see appendix 7.13 for map). Nucleotide sequence 
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analysis of this PCR product, showed that it contained the start codon for the 
GnRH receptor. The 3' end of the GnRH receptor, extending from extracellular 
loop 3 to the C-terminal tail, was similarly cloned, by nested PCR amplification of 
goldfish pituitary cDNA with GfA.2s and GfA.4s (see appendix 7.11), in 
combination with AP1 and AP2. Several PCR products were identified on a 
Southern blot, which was probed using the ECL system (Amersham) and 
fluorescene labelled GfA.1 as primer. One of these products contained the 
nucleotide sequence of the GfA receptor extending to a stop codon in the C-
terminal tail. This nucleotide sequence information was used to design nested 
gene-specific primers to the non-coding 5' and 3' regions of the GfA receptor. 
The primers were as follows: 




5' atctggataatcaggaatttcttg 3' 
5' tagttcgaaccatcgcttcatcgt 3' 
5' ctcagagtctggttcattatggag 3' 
The nested primers, GfA.5s and GfA.6s to the 5' untranslated region were used in 
combination with the nested 3' primers, GfA.7as and GfA.8as to amplify up the 
full-length receptor from goldfish pituitary cDNA. The nucleotide sequence of 
several clones, amplified using both Klentaq (Clonetech) and Pfu DNA 
polymerases (Stratagene) was determined using both manual (T7 sequenase, 
Amersham) and automated sequencing. 
The 5' end of the GfB receptor was cloned by PCR amplification on Marathon 
pituitary cDNA with primers GfB.1 as and GfB.3as in combination with the AP1 and 
AP2 primers (see appendix 7.12 for primer sequence and location). Multiple 
products were identified in Southern blot using the ECL system (Amersham) on 
the PCR reaction with the nested fluorescene end-labelled GfB.2s primer. These 
products were cloned into the pGEM-T vector. No clones with a full-length 5' 
open reading frame were identified. Whole brain cDNA was therefore, 
synthesised using the Marathon cDNA synthesis kit (Clonetech) and was 
amplified as above. Sequence analysis of the PCR products subcloned into the 
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pGEM-T vector showed that one of the clones contained the full-length 5' coding 
region of the GfB receptor. This nucleotide sequence information was used to 
design two primers to the 5' untranslated region. The primers were as follows: 
Gf8.4s 5' cgagtggagcatgtctagatgctaata 3' 
Gf8.5s 5' actgtccgcatattagtggaaatgagg 3' 
The nested primers, Gf8.4s and GfB.5s were used in combination with the AP1 
and AP2 primers, to amplify up the full-length type B receptor from Marathon 
goldfish brain cDNA. The PCR product was subcloned and the nucleotide 
sequence of 4 clones, determined. 
4.3.5 Transient transfection of COS-1 cells 
The full-length Type A and Type B goldfish GnRH receptors were subcloned into 
pcDNA I/Amp (lnvitrogen), a mammalian expression vector containing the SV40 
early promoter. DNA for transfection was prepared from a 500 ml overnight 
culture of 2 x YT broth (10 g/L NaCL, 10 g/L Yeast extract, 16 g/L Bactotryptone) 
containing ampicillin (100 µg/ml). See section 2.3.10 (chapter 2) for a detailed 
description of transfection methods. 
4.3.6 Inositol Phosphate Assay 
Inositol phosphate assays were as described in chapter 2, section 2.3.12. 
4.4 Results 
4.4. 1 The primary structure 
Two full-length putative goldfish GnRH receptor cDNA subtypes, GfA and GfB, 
were identified after PCR (fig. 4.1A and B). Start codons were assigned on the 
basis of homology to the cloned GnRH receptors [for review, see Sealfon et al., 
1997]. Both cDNA clones encoded putative GnRH receptors with seven 
hydrophobic transmembrane domains and like the Xenopus laevis pituitary GnRH 
receptor (chapter 2) and the catfish GnRH receptor, [Tensen et al., 1997], 
intracellular carboxy-terminal tails. Eight full-length clones of GfA were 
sequenced. Two differences in the amino acid sequence occurred of which the 
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consensus sequence of the eight clones was taken to be wildtype. A C to T 
transition in transmembrane helix Ill (TM Ill) resulting in Ala 125 being changed to a 
Val, and a C to T transition in extracellular loop II resulting in His 195 being 
changed to a Tyr. All clones, however, gave a similar inositol phosphate 
response. Both Klentaq (Clonetech) and Pfu (Stratagene) DNA polymerases 
were used to amplify these clones, and both polymerases have a high fidelity 
resulting from the 3'/5' exonuclease activity [Barnes, 1994). The differences in 
nucleotide sequence may, therefore, have been due to · either gene 
polymorphisms or as a result of the tetraploidy that exists in goldfish. Four full-
length clones of GfB were sequenced. The coding regions of these all resulted in 
identical amino acid receptors, although, differences in the nucleotide sequences 
occurred in both the coding and non-coding regions. 
GfB and GfA have a 67% nucleotide sequence homology and a 71% amino acid 
identity, with highest homology in the transmembrane domains (fig. 4.2, table 4.1). 
GfB, however, has a higher homology to the catfish GnRH receptor than does the 
GfA receptor, with percent amino acid identities of 82% and 71% respectively (fig. 
4.3, table 4.1). The identities of the GfA and GfB receptors, to the primary 
sequence of the human GnRH receptor, were both approximately 43% (table 4.1 ). 
Hydrophobicity plots of the amino acid sequences of these receptors, clearly show 
the seven putative hydrophobic transmembrane domains (fig. 4.3) . They also 
show a hydrophobic region towards the carboxy terminal end of the cytoplasmic 
tail. 
4.4.2 Pharmacological characterisation of goldfish GnRH receptors. 
Both the GfA and GfB GnRH receptor subtypes coupled to phospholipase C when 
transiently transfected into COS-1 cells as revealed by the stimulation of inositol 
phosphates (IPs) by GnRH agonists (fig. 4.4, table 4.2). Both the GfA and GfB 
receptors showed the same order of potencies for natural GnRH with cGnRH II > 
sGnRH > mGnRH > sbGnRH (fig . 4.4). However, the ED50s, of the endogenous 
GnRH agonists for the two receptor subtypes, however, differed substantially 
(table 4.2). GfB seems to have a lower potency than the GfA receptor with all the 
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GnRH agonists tested. This may be due to a lower affinity or a lower expression 
of the GfB receptor in the transfected cells. The relative increase in ED50s are, 
however, not proportional and thus indicates a different ligand selectivity of the 
two receptors (table 4.2). The relative potency for mGnRH for the GfA and GfB 
receptors compared to sGnRH, was equal (0.02), while cGnRH II was much more 
potent in stimulating IP production in GfA than GfB, with relative potencies to 
sGnRH, of 153 and 16.5 respectively. The GfB receptor is also much more 
selective to GnRH agonists with variant amino acids in position 8, as while having 
a similar potency to mGnRH as the GfA receptor, it has a much lower potency for 
[His~GnRH, sbGnRH, and [Tyr8]GnRH than the GfA receptor (table 4.2). 
The analogues of GnRH containing a D-Arg in position 6 had variable effects on 
the potencies. The D-Arg6 sGnRH showed a 10-fold higher potency in the GfA 
receptor, but only a 2-fold higher potency in the GfB receptor (table 4.2). [His5,D-
Arg6,Leu8]GnRH had an approximately equal potency to sGnRH in the GfA 
receptor, while it had a greater than 10-fold decrease in the GfB receptor 
compared to sGnRH. [D-Arg6,Trp7,Tyr~GnRH had an equal potency to cGnRH II 
in the GfA receptor and an approximately 4-fold higher potency than cGnRH II in 
the Gf E receptor. 
The analogues E, C and L, which have different stimulatory and inhibitory 
properties on GtH II and GH secretion, were also tested. All three analogues 
appeared to behave as antagonists, for both sGnRH (fig. 4.5) and cGnRH II (data 
not shown) stimulated inositol phosphate production. 
Figure 4.1. Nucleotide and deduced amino acid sequences of the GfA (A) and 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.2. Sequence alignment of the goldfish GnRH receptor subtypes A and B to the human and catfish GnRH receptors. Alignments were done using the Gap program of GCG. The putative transmembrane domains are indicated (Donnelly et al., 1994). cf, catfish; GfB, goldfish B; GfA, goldfish A; h, human. The two goldfish receptor subtypes A and B have a 71 % amino acid identity, while GfB has a 81 % amino acid identity to the cfGnRH receptor, and the GfA subtype shows a lower homology of 71 % to this receptor. All the fish receptors have amino acid identities of between 42 and 43% to the human GnRH receptor. Upper numbering refers to GfB, while lower numbering refers to GfA. 
1 1----------- 49 hGnRHR -----MANSA SPEQNQNHCS AINNSI .. PL MQGNLPTLTL SGKIRVTVTF cfGnRHR MSGNTTLLLS NPTNVLDNSS VLNVSVSPPV LKWETPTFTT AARFRVAATL GfB MSGKMPLLSV NPTSIWENSS VLNATPHFP. SDWETPTFTV AAHFRVVATL GfA ---------- -MSDNTSLPS VSNASLLPPL TDWRAPSFTP AAQARVAATM 
1 ~ 
50------TM I---------------1 1----------TM II--95 hGnRHR FLFLLSATFN ASFLLKLQKW TQKKEKGKKL SRMKLLLKHL TLANLLETLI cfGnRHR VLFVFRAASN LSVLLSVTRG RGR .... RLA SHLRPLIASL ASADLVMTFV GfB VLFVFAAISN LSVLISVTRG RGR .... HLA SHLRPLIGSL ASADLVMTFV GfA VLFLFAAVSN LALLISVSRG RGR .... RLA SHLRPLIISL VSADLMMTFI 40 
85 
96-------------1 1------------TM III------------1145 hGnRHR VMPLDGMWNI TVQWYAGELL CKVLSYLKLF SMYAPAFMMV VISLDRSLAI cfGnRHR VMPLDAVWNV TVQWYAGDAM CKLMCFLKLF AMHSAAFILV VVSLDRHHAI GfB VMPLDAIWNI TVQWYAGNAM CKNLCFLKLF AMHSAAFILV VVSLDRHHAI GfA VMPLDMVWNV TVQWYAGDGL CKLLCFLKLF AMQTSAFILV VISLDRHHAI 86 
135 
146 1-----------TM IV------------1 190 hGnRHR TRPLALKSNS KVGQSMVGLA WILSSVFAGP QLYIFRMIHL ADSSGQTKVF cfGnRHR LHPLDTLDAG RRNRRMLLTA .ILSLLLASP QLFIFRAIKA KGVD ..... F GfB LHPLEALDAG RRNRRMLLAA WILSILLASP QLFIFRAIKA EGVD ..... F GfA LHPLDSLNAH QRNRRMLLLA WSLSALIASP QLFIFRTVKV KSVD ..... F 136 
180 





hGnRHR SQCVTHCSFS QWWHQAFYNF FTFSCLFIIP LFIMLICNAK cfGnRHR VQCATHGSFQ QHWQETAYNM FHFVTLYVFP LL.MSLCYTR GfB VQCVTHGSFR QRWQETAYNM FHFVTLYVFP LLVMSFCYTH 
GfA TQCVTHGSFH ERWYETAYNM FHFVTLYVIP LLVMSCCYTC 
181 230 
241 
hGnRHR QDPH ... ELQ 
cfGnRHR RSKDKAGEPC 
GfB RGKGKGGEPC 
GfA KSTE .. GE.S 
231 
1----------------TM VI-------290 
LNQSKNN.IP RARLKTLKMT VAFATSFTVC WTPYYVLGIW 
LRRSGTDMIP KARMKTLKMT IIIVASFVIC WTPYYLLGIW 
LRRSGTNMIP KARMKTLKMT IIIVASFVVC WTPYYLLGIW 
LRRSGTDMIP KARMKTLKMT IIIVLSFVVC WTPYYLLGIW 
277 
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Figure 4.3. Hydrophobicity plots of the GfA (A) and GfB (B) receptor subtypes, 
showing the characteristic seven hydrophobic transmembrane domains. 
Hydrophobicity plots were done using the Wisconsin Package Version 9.0, 
Genetics Computer Group (GCG) Madison, Wisconsin {Pepstructure). 
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Table 4.2. EDso5 of GnRH agonists for inositol phosphate production in COS-1 
cells transiently transfected with the Goldfish A and B GnRH receptor subtypes. 
Data are calculated as the mean of three separate experiments . 
. -.Jt -·. 
4.6±0.3 1 1 
0.03±0.01 153 3.4±2 16.5 
210±69 0.02 2850±21 0.02 
684±100 0.007 >10 000 >0.006 
11±3 0.42 >20 000 >0.003 
4.65±1 1 640±100 0.08 
0.03±0.01 153 0.8±0.5 70 
3.3±2 1.4 630±100 0.08 
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Figure 4.4. Inositol phosphate production in COS-1 cells transiently transfected 
with the GFA (A) and GF E (B) GnRH receptor subtypes, after stumulation for 1 h 
with various GnRH agonists. (T) mammalian GnRH; (A) [Trp
7,Leu8]GnRH 
(salmon GnRH); (•) [His5,Trp7,Tyr8]GnRH (chicken GnRH II) and(+) [Ser8]GnRH 
(seabream GnRH). For both receptor subtypes, chicken GnRH II has the highest 
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Figure 4.5. Inhibition of inositol phosphate production in COS-1 cells transfected 
with the GfA (A-C), and the GfB (D-F) GnRH receptor subtypes stimulated with 
salmon GnRH at 10-8 M in the presence of increasing concentrations of analogues 
C, E and L. A:(•) salmon GnRH with [Ac-Pro 1, Df pa2, D-Trp3·6,Trp7,Leu~GnRH 
(analogue C), and (0) analogue C alone; B: <•) salmon GnRH with [Ac-Pro1,D-
Fpa2,D-Ttp3·6]GnRH (analogue E), and (0) analogue E alone; C: (A) salmon 
GnRH with [Ac-D-Na11, D-Cpa2, D-Pal3,Arg5,D-Pal6,D-Ala 1~GnRH (analogue L), 






4. 5 Discussion 
The dual effect of GnRHs in the goldfish ( Carassius auratus) on gonadotropes 
and somatotropes described by Marchant and co-workers (1989] has initiated the 
investigation of the receptor subtypes by a detailed analysis of the 
pharmacological response of the two cell types to different GnRH agonists and 
a·ntagonists [Habibi et al., 1992; Murthy and Peter, 1994; Murthy et al., 1994; 
1993]. On the basis of in vivo studies, there is evidence for two distinct receptor 
subtypes in the goldfish, which mediate the synthesis and release of GtH II and 
GH from gonadotropes and somatotropes, respectively. In this chapter the 
occurrence of two receptor subtypes in goldfish, was investigated using sequence 
information from the cloned mammalian GnRH receptors. The pharmacology of 
these two receptor subtypes was analysed with regard to previous information on 
the two putative receptors in the goldfish pituitary. 
Amplification of genomic DNA with degenerate oligonucleotide primers designed 
to conserved regions in the cloned mammalian GnRH receptors revealed two 
putative GnRH receptor subtypes in the goldfish, designated Gf A and GfB. The 
complete cDNAs encoding these receptors were cloned from pituitary and brain, 
respectively. These receptors, like the other cloned non-mammalian receptors 
showed a low amino acid identity to the mammalian GnRH receptors 
(approximately 43%). The two· goldfish receptor subtypes had a relatively high 
amino acid identity to each .other (71%), but the GfB receptor was more similar to 
the catfish GnRH receptor (Tensen et al., 1997] (82% identity) compared to the 
GfA receptor (71 %). These receptor subtypes are not duplicate genes, which 
result from tetraploidisation, as the homology in the coding region of duplicate 
genes would be greater than 90% [Lin and Peter, 1997]. The sequence variations 
seen in the analysis of the individual cDNA clones may, however, be a result of 
tetraploidisation as they would be in the expected homology range. Alternatively, 
these changes may have either been a result of gene polymorphisms, as RNA 
was extracted frorry several goldfish, or as a result of mutations that arose during 
the PCR reaction. The latter is, however, unlikely as high fidelity polymerases 
were used to amplify these receptor subtypes [Barnes, 1994). 
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Like all the cloned GnRH receptors [for review, see Sealfon et al., 1997;], the 
goldfish receptors are typical G-protein coupled receptors with seven hydrophobic 
transmembrane domains, as revealed by the amino acid sequence alignment, as 
well as hydrophobicity plots of the amino acids (figs. 4.2 and 4.3). The goldfish 
GnRH receptors share a number of features with the cloned mammalian GnRH 
receptors. 
Like the X laevis GnRH receptor (chapter 2) and the catfish GnRH receptor 
[Tensen et al., 1997] the goldfish GnRH receptors have a low homology to the 
mammalian receptors in the amino-terminal region. Interestingly the goldfish 
receptors, as well as the catfish GnRH receptor, have a glycosylation consensus 
site, which aligns to the human GnRH receptor glycosylation site (Asn 18) (fig. 4.2). 
The GfB receptor subtype as well as the catfish GnRH receptor, however, have 
two additional glycosylation consensus sites, one at Asn 11 and one at Asn 18. 
Receptor glycosylation has been shown to be important in receptor expression or 
stability [Davidson et al., 1995]. It is likely, therefore, that the asparagines at 
position 23 in the GfB and catfish receptors and position 12 in the GfA receptor 
are glycosylated as these align to the known glycosylation site of the human 
GnRH receptor (Asn 18) . The other two sites in the GfB and catfish GnRH 
receptors may, however, not necessarily be glycosylated, but it is interesting to 
note their conservation between the two species. There are three glycosylation 
consensus sites in the rodent GnRH receptors, but only the two in the amino 
terminus are glycosylated [Davidson et al., 1995; Arora et al., 1997]. 
The two cysteines which have been shown to form a disulphide bridge between 
the amino terminus and EC II in the human GnRH receptor (Cys 14 and Cys200) 
[Davidson et al. , 1997] are not conserved in the goldfish GnRH receptors. The 
two cysteines which have been shown to form a disulphide bridge between EC I 
and EC II, which is conserved in all GPCRs are, however, both conserved in the 
goldfish GnRH receptors. 
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The transmembrane domains of both the goldfish GnRH receptor subtypes show 
a high conservation, both to each other and the mammalian GnRH receptors, 
showing the importance of these regions to the conformation of the receptor. Like 
the X laevis pituitary GnRH receptor ( chapter 2) and the other cloned non-
mammalian GnRH receptors [Tensen et al., 1997; Sun et al., in preparation], the 
goldfish GnRH receptors have an aspartic acid in the corresponding position of 
TM II to the asparagine (Asn87) in the human GnRH receptor (fig. 4.2). The 
asparagine has been shown to interact with an aspartic acid residue in TM VII 
(Asp318) [Zhou et al., 1993). Blomenrohr and co-workers [1997) have shown that 
the aspartic acid in TM II (Asp00) is important for the functioning of the catfish 
GnRH receptor. The presence of aspartic acid residues in both TMs II and VII in 
the human GnRH receptor have been shown by mutagenesis to affect the 
conformation of the receptor, such that it is inactive [Zhou et al., 1994). The 
goldfish, and the other non-mammalian GnRH receptors, which have aspartic 
acids in both TMs II and VII must, therefore, be accommodated by other co-
ordinated changes in the transmembrane helices. This will be discussed in 
greater detail in chapter 5. 
All the intracellular loops are highly conserved between the two goldfish receptor 
subtypes, as well as the catfish GnRH receptor (fig. 4.2), but have a much lower 
homology with the human GnRH receptor. The IL I of the teleost receptors are is 
four amino acids shorter than that of the human GnRH receptor. The only residue 
in IL 1, which is conserved between the human GnRH receptor and the fish 
receptors, is a serine. This residue could be phosphorylated in all the receptors, 
as there is a phosphorylation consensus site in this area (basic/basic/X/X/serine). 
This serine may, thus, be important in receptor desensitisation or internalisation of 
both the mammalian and non-mammalian receptors. IL Ill shows a higher 
conservation to the mammalian GnRH receptors, particularly at the carboxy-
terminal end. This region is thought to be important in coupling to G-proteins. 
The GfA receptor is three amino acids shorter than the GfB receptor in this region. 
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Extracellular loop I is the most highly conserved of the extracellular loops between 
the teleost receptors as well as the human GnRH receptor (fig. 4.2). EC II of the 
teleost receptors is much shorter than that of the mammalian receptors. EC Ill 
has a slightly lower homology, but the acidic amino acid residue which was shown 
to be important in binding to the Arg8 of mGnRH, is conserved in the teleost 
receptors. Like the X. laevis pituitary GnRH receptor, the position of the adjacent 
praline is different and this might contribute to the decreased specificity for 
mGnRH (chapter 2). The GfA receptor has an acidic amino acid residue at 
position 285 in EC Ill (Glu285), the catfish GnRH receptor also has an acidic in this 
position (Gln298), while the GfB receptor has a basic amino acid in this position 
(Arg298) . Three amino acids 3' to this residue, the situation is reversed, where the 
GfB receptor has an acidic amino acid (Gln301), while the catfish and GfA 
receptors have the basic amino acids histidine and lysine respectively. These 
sequence differences may thus be cancelled out, and thus not have any effect on 
the receptor, or alternatively they may contribute to differences in the ligand 
selectivity of the GfA and GfB receptor subtypes. If these differences are 
important it would be interesting to determine the selectivity of the catfish GnRH 
receptor to different GnRH analogues particularly with variations in position 8, 
such as [His8]GnRH and [Tyr8]GnRH. 
Both the goldfish receptor subtypes, like all the non-mammalian GnRH receptors 
cloned to date [chapter 2, Tensen et al., 1997; Sun et al., in preparation] have an 
intracellular carboxy-terminal tail. The carboxy-terminal tails of GPCRs have 
been shown to be important in homologous desensitisation [for review, see 
Benovic et al., 1988]. The carboxy terminal tail of the GfA receptor subtype is 
slightly shorter than that of the GfB receptor subtype, but both have several 
phosphorylation consensus sites. The carboxy terminal tails are only 37% 
conserved between the two goldfish receptor subtypes, which is very low in 
comparison to the overall amino acid identity of 71 %. The tail of the GfB receptor 
subtype does, however still have a high homology with that of the catfish GnRH 
receptor subtype (68%). 
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The effect of different GnRH analogues on the two goldfish receptors transiently 
expressed in COS-1 cells was investigated by measuring the inositol phosphate 
production after stimulation. Both receptors coupled to phospholipase C, as both 
showed a dose dependent increase in inositol phosphate production after GnRH 
stimulation. The goldfish receptors seemed to show a similar selectivity for the 
naturally occurring GnRH agonists tested, as cGnRH II was the most potent in 
stimulating inositol phosphate production, followed by sGnRH and mGnRH. All 
the GnRHs tested had a lower potency in the GfB receptor compared to the GfA 
receptor. This may reflect a decreased binding affinity for the GnRH analogues in 
the GfB receptor, or may be as a result of a lower expression of this receptor in 
the COS-1 cells. 
Several different analogues of GnRH were investigated in order assess if the 
goldfish receptor subtypes correspond to previous studies on the pharmacology of 
the receptors on somatotropes and gonadotropes in the goldfish pituitary. The 
different selectivity for GnRH agonists with variations in position 8 was the most 
marked. The GfB showed a large decrease in potency for [His6]GnRH, and 
[Tyr8]GnRH when compared to mGnRH ([Arg6]GnRH), which had a proportionally 
similar potency for the GfA receptor (table 4.2). This decreased selectivity of GfB 
for [His6]GnRH and [Tyr6]GnRH is similar to that seen in the GtH releasing activity 
of the gonadotropes [Habibi et al., 1992). 
Studies on the inhibition of both sGnRH and cGnRH II stimulated inositol 
phosphate production with the analogues E, C and L, did not correlate with 
previous studies [Murthy and Peter, 1994; Murthy et al., 1994; 1993). These 
studies showed that analogue E ([Ac-Pro1.D-Fpa2,D-Trp3·6]GnRH) is a pure 
antagonist for both salmon and cGnRH II stimulated GtH II and GH release, while 
analogue C ([Ac-Pro1, D-Fpa2, D-Trp3•6,Trp7,Leu8)GnRH) inhibits salmon and 
cGnRH II stimulated GtH release, but stimulates GH release and analogue L ([Ac-
D-Na11, D-Cpa2, D-Pal3,Arg5,D-Pal6,D-Ala 1°]GnRH) weakly stimulates GtH release 
but inhibits GH release. Based on the selectivity for GnRHs with variations in 
position 8, GfB may be the GtH-releasing receptor, while the GfA receptor 
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subtype, may be the GH-releasing receptor. One would, therefore, expect 
analogue E to be a true antagonist for both the A and B receptor subtypes, 
analogue C to be an antagonist for the GfB receptor and an agonist for the GfA 
receptor, and analogue L to be an antagonist for the GfA receptor and an agonist 
for the GfB receptor. The three analogues were, however, pure antagonists for 
both the receptor subtypes as they all inhibited both cGnRH II (data not shown) 
and sGnRH stimulated inositol phosphate production (fig. 4.5). Despite the 
difference in selectivity of [His8]GnRH and [Tyr~GnRH corresponding to the 
studies on GtH II and GH release, these antagonists do not appear to distinguish 
the two receptor subtypes. 
The two goldfish receptor subtypes also have a different selectivity for the [D-
Arg6]GnRH analogues. The GfA receptor, unlike the GfB receptor, seems to have 
no increased potency for the cGnRH II-like analogue [D-Arg
6,Trp7,Tyr8]GnRH, 
while the opposite is true for the sGnRH-like analogue, [D-Arg6,Trp
7,Leu8]. These 
analogues, thus, distinguish between the GfA and GfB subtypes, but there is no 
published data on the effect of these analogues on GtH II and GH release. 
In situ hybridisation studies on goldfish brain, ovaries and liver have been 
conducted by Dr R.E. Peter (University of Alberta, Edmonton, Canada), using 
anti-sense probes designed to the A and 8 receptor subtypes [llling et al., in 
preparation]. These studies have shown that both the GfA and GfB receptor 
subtypes are both expressed in the pituitary, with overlapping expression in 
gonadotropes and a limited overlap in somatotropes. There were no significant 
differences between the expression of the two receptors in the pituitary. Both 
receptors showed extensive expression in the brain but the GfA receptor showed 
unique additional hybridisation to several brain areas, including the nucleus 
anterior tuberis, the optic tectum and the area ventralis telecephali, as well as 
interstitial and theca cells of the ovary and hepatocytes in the liver. 
In conclusion therefore, the two receptors, which have been cloned and 
characterised, are both expressed in the goldfish brain and pituitary. Although 
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there is some evidence, based on the amino acid sequence homology with the 
GtH-releasing receptor in catfish and pharmacological data with position 8 
substituted analogues, that these receptors represent the two receptors for GH-
and GtH- release in the goldfish. These results were, however, not confirmed with 
the pharmacological studies using analogues E, C and L, which have previously 
.been shown to distinguish the two receptors [Murthy and Peter, 1994; Murthy et 
a/., 1994; 1993]. The two receptors may, however, correspond to the GH and GtH 
releasing receptors and that the differences in the in vitro bioassays and the 
inositol phosphate studies in transfected COS-1 cells may be due to a complex 
interplay between agonist, receptor, G-proteins and second messenger systems 
in the goldfish pituitary gonadotropes and somatotropes which cannot be 
mimicked in the transfected system. In situ hybridisations with probes designed to 
the two receptor subtypes, however, did show the localisation of both the 
receptors to gonadotropes but not significantly to somatotropes, but rather 
showed a distinct distribution in the brain, ovaries and liver. Thus either a third 
GnRH receptor with GH-releasing activity may exist in the goldfish pituitary, or 
alternatively GnRH has a paracrine effect in stimulating GH-release. The two 
receptor subtypes described here, may play an important role in the regulation of 





The field of comparative endocrinology has provided useful insights in the study of 
both non-mammalian and mammalian systems, at several levels. The present study 
on gonadotropin-releasing hormone receptors, has made use of two model systems, 
which are comparable to the mammalian system, but have unique characteristics 
which should provide useful insights into the structure and function of GnRH 
receptors. 
Structural determinants of agonist and antagonist binding are vital for the design of 
therapeutic agents. A detailed analysis of the cloned mammalian GnRH receptors 
has been useful in determining amino acid residues important for receptor 
conformation, ligand binding and specificity, and motifs or residues required for G-
protein coupling [for review, see Sealfon et al., 1997]. These studies were done 
using receptor site-directed mutagenesis whereby the effect of changing key amino 
acids which were identified by either alignments with other related G-protein coupled 
receptors, or intuitive insights based on receptor/ligand specificity. An alternative 
approach to identify important amino acid residues is to observe co-ordinated 
structural/functional changes in evolutionarily distinct GnRH receptors. Amino acid 
residues or motifs, which are conserved, may either be important for the overall 
conformation of the receptor, ligand binding or G-protein interactions. Residues, 
which are not conserved may be unimportant, may contribute to unique receptor 
features, such as ligand specificity or may represent co-ordinated changes at several 
sites. Residues, which are conserved amongst the non-mammalian GnRH receptors 
but not the mammalian receptors may also provide useful insights into the 
structural/functional relations of GnRH receptors. A comparison of the primary 
sequence of the GnRH receptors from X. laevis, goldfish (this thesis) and catfish 
[Tensen et al., 1997] to the mammalian GnRH receptors has provided many insights 
into the structure and function of GnRH receptors. 
There are several interesting features, which are _revealed by the conservations 
between the non-mammalian GnRH receptors described in this work, the catfish 
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GnRH receptor [Tensen et al., 1997) and the mammalian GnRH receptors (fig. 5.1). 
In this discussion the numbering system is based on the human GnRH receptor. 
The asparagine (Asn 18) in the amino-terminus, which has been shown to be 
glycosylated in the mammalian receptors [Davidson et al., 1995; 1996(a); Arora et 
al., 1997], is conserved. Glycosylation of the receptor has been shown to improve 
expression, but does not seem to affect ligand binding or signal transduction 
[Davidson et al., 1995; Arora et al., 1997). The glycosylation of the non-mammalian 
receptors may, therefore, also be important for optimal receptor expression. 
The transmembrane domains (TM) show the highest conservation, with TM VI being 
the most conserved. This high conservation is expected as the transmembrane 
domains amongst different GPCRs usually show a high level of conservation [Probst 
et al., 1992; for review, see Strader et al., 1994). Amongst the conserved residues in 
the transmembrane domains are the highly conserved praline residues in TM II, TM 
IV, TM V, TM VI and TM VII [Baldwin, 1993]. Other highly conserved residues 
among GPCRs, which are conserved between the non-mammalian and mammalian 
GnRH receptors include the asparagine (Asp53) in TM I, the tryptophan (Trp 164) and 
serine (Ser167) in TM IV and the tyrosine (Tyr323) in TM VII. Asp 138 and Arg 139 at the 
border of TM Ill and IL II which are important for agonist induced activation 
[Ballesteros et al., 1998] and internalisation [Davidson et al., 1994(a); Arora et al., 
1997] are also conserved. The two isoleucines located one turn up or down in the a.-
helix from Arg 139, (lie 135 and lie 143) are thought to 'cage' the arginine limiting the 
movement of the receptor in adopting the active or inactive conformations 
[Ballesteros et al., 1998], are also conserved in the non-mammalian GnRH receptors. 
lie 143 is conserved, while lie 135 is conserved in the X laevis pituitary and goldfish A . 
GnRH receptors and a valine in the catfish and goldfish B GnRH receptors. Valine is 
also a B-branched amino acid, and this is thus a conservative change. 
In all the GnRH receptors the residues shown to be important in ligand binding, are 
conserved. These residues include Asn 102 at the top of TM II, which has been shown 
to interact with the glycine amide of GnRH [Davidson et al., 1996(b)] and Asp98 in TM 
II and Lys 121 in TM Ill, which have been shown to interact with the histidine in position 
two of GnRH [Rodie et al., 1996; Zhou et al., 1995). 
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The intracellular loops (IL) are poorly conserved. IL I of all the receptors, however, 
consists of predominantly basic amino acid residues. The conservation of Ser74 , is 
interesting as this is a consensus phosphorylation site for protein kinase C in all the 
receptors (basic/XIX/Ser/XIX/basic). The relatively high conservation of the carboxy-
terminal portion of IL Ill, may be as a result of the importance of this region in G-
protein coupling. Ala261, which has been directly implicated in G-protein coupling, is 
also conserved [Myburgh et al., 1998]. 
Of the extracellular loops, EL I is almost 100% conserved, while the central portion of 
EL II is highly conserved the amino- and carboxy-termini of this loop are poorly 
conserved, and EL Ill shows almost no conservation. Several of the residues of EL I 
such as Trp107, Gly110, Leu112, Cys114 are conserved amongst many GPCRs (Probst 
et al., 1992). The high conservation in this loop may, therefore, be as a result of its 
importance to the general conformation of the receptors. The cysteines, which form 
the highly conserved disulphide bridge between Cys 114 of EL I and Cys 196 of EL II [for 
review, see Strader et al., 1994) are also conserved. 
There are also several features of the non-mammalian GnRH receptors, which are 
distinct from the mammalian receptors (fig. 5.2). The most noticeable of these is the 
presence of an intracellular carboxy-terminal tail in all the non-mammalian receptors. 
Studies on the chicken [Sun et al., in preparation] and catfish [Tensen et al., 1997) 
GnRH receptor carboxy-terminal tails have shown them to be important for ligand 
induced rapid desensitisation [Heding et al., 1998) and internalisation [Heding et al., 
1998; Pawson et al., 1998). Addition of the catfish GnRH receptor carboxy-terminal 
tail to the rat GnRH-receptor increased expression of the rat receptor [Lin et al., 
1998). Truncation of the catfish GnRH receptor tail, however, reduced agonist 
binding [Blomenrohr et al., 1997]. The carboxy-terminal tails of the non-mammalian 
GnRH receptors may, thus, be important for rapid ligand-induced receptor 
desensitisation and internalisation and may have direct or indirect affects on receptor 
expression and ligand binding. The mammalian GnRH receptors, which lack a 
carboxy-terminal tail do not show a rapid desensitisation after agonist stimulation like 
other GPCRs [Davidson et al., 1994], but do show a long-term agonist induced down 







Figure 5.1. Diagram of the human GnRH receptor, showing amino acid residues, 
which are conserved with the X laevis pituitary GnRH receptor (chapter 2), the partial 
clone of the second X laevis GnRH receptor (chapter 3) , the goldfish A and B GnRH 
receptor subtypes and the catfish GnRH receptor [Tensen et al. , 1997] (blue) and 
conservative changes (green). 
the absence of a carboxy-terminal tail [Heding et al. , 1998; Lin et al. , 1998; Pawson 
et al., 1998] to prevent receptor desensitisation and down regulation may be 
important in allowing the protracted LH-surge required for ovulation. This lack of 
receptor desensitisation is, however, not responsible for the LH surge, which is 
initiated by an increased secretion of estradiol-17p, and appears to be due to a 
complex interplay of increased GnRH secretion coupled to an increased pituitary 
response, possibly by an increased expression of the GnRH receptor. Estrogen has 
previously been shown to increase GnRH receptor mRNA levels [Sealfon et al., 
1990; Quinones-Jenab et al., 1996]. The carboxy-terminal tails have several 
phosphorylation consensus sites, which may be involved in receptor desensitisation 
via phosphorylation by serine/threonine kinases. The carboxy-terminal tails may also 
be important in the stabilisation of receptor structure by providing an additional 
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scaffold possibly by the palmitoylation of Cys residues or the insertion of hydrophobic 
residues of the tail into the membrane [for review, see Strader et al., 1994]. It is 
interesting to note that all the non-mammalian GnRH receptors lack the second 
disulphide bridge thought to occur in the human GnRH receptor between Cys 
residues in the NH2-terminus and EL Ill [Davidson et al., 1997]. This second 
disulphide bridge may have, therefore, evolved to compensate for the lack of 
carboxy-terminal tail. The mammalian GnRH receptors are unique in that the IL I is 
much longer than that of the non-mammalian GnRH receptors and other GPCRs 
[Probst et al., 1992; Tsutsumi et al., 1992]. This may also have evolved in the 
mammalian GnRH receptors to accommodate the lack of carboxy-terminal tail. 
Related to this is the lack of conservation of the second protein kinase C 
phosphorylation consensus site in IL I of the mammalian receptors at Thr64, with any 
of the non-mammalian receptors. 
A second different feature is the presence of an Asp residue in TM II of all the non-
mammalian receptors in accordance with most GPCRs and, which is an Asn in the 
mammalian GnRH receptors (Asn87). The mammalian GnRH receptors appear to 
have undergone a reciprocal change between Asn87 and Asp318 in TM VII when 
compared to other GPCRs. This exchange suggests an interaction of the side chains 
of these residues in TM II and TM VII [Zhou et al., 1994]. Mutagenesis of Asn87 to an 
Asp requires the simultaneous mutation of Asp318 to and Asn to maintain ligand 
binding [Zhou et al., 1994]. It is, thus, interesting to note that the non-mammalian 
receptors have Asp residues on both the corresponding positions of TMs II and VII. 
Mutations of the Asp in TM VII of the catfish GnRH receptor to an Asn could still bind 
GnRH [Blomenrohr et al., 1997]. Mutations of the Asp in TM II (Asp90) to an Asn, 
however, showed almost no binding [Blomenrohr et al., 1997]. The Asp in position 
90 of TM II in the catfish GnRH receptor, thus, seems to be critical for receptor 
functioning, and this is likely to be true for all the non-mammalian GnRH receptors. It 
is possible that there are other co-ordinated changes in the non-mammalian 
receptors, which support the Asp residues in both TMs II and VII. Most noticeable 
differences between the non-mammalian and mammalian GnRH receptors is that the 
mammalian receptors have a basic Lys at position 81, which is approximately two 
turns above the Asn87, while the non-mammalian receptors all have hydrophobic 
residues in the corresponding position (Ala in the catfish; Gly in GfB; lie in GfA and 
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Leu in XI.A). Adjacent to the Lys residue is a His. The non-mammalian receptors all 
have a Ser in the corresponding position. Also one turn up in the a-helix from Asn87, 
the mammalian receptors have an acidic glutamic acid (Glu90), while the non-
mammalian GnRH receptors have either a Met (teleost GnRH-Rs) or a Val (X laevis 
pituitary GnRH-R), which are both hydrophobic non-polar residues. The presence of 
these three extra hydrophobic amino acids in TM II of the non-mammalian GnRH 
receptors may act individually or in concert, to alter the conformation of the a-helix in 
such away that it is able to support Asp interactions between TMs II and VII. 
The acidic residue in EL Ill, Glu301 of the mouse GnRH receptor (or Asp302 of the 
human GnRH receptor), is crucial for selectivity of Arg8 in mammalian GnRH 
[Flanagan et al., 1994]. It was initially thought that the non-mammalian receptors 
which were shown not to have a high specificity for mGnRH [for review, see King and 
Millar, 1997], would not have an acidic residue in the corresponding position to the 
Glu301 of the mouse GnRH receptor. Surprisingly an acidic residue is consistently 
conserved in this position of the non-mammalian GnRH receptors, except in the X 
laevis B receptor subtype. An in depth pharmacological characterisation of the 
amphibian and teleost GnRH receptors, however, revealed that contrary to previous 
studies [for review, see King and Millar 1997] the receptors do have a limited 
selectivity for Arg8. This is revealed by the increased potency of the non-mammalian 
receptors for mGnRH, in comparison to that of cGnRH I ([Gln~GnRH). This 
selectivity for mGnRH in the non-mammalian GnRH receptors is, however, reduced 
in comparison to that of the mammalian GnRH receptors, therefore ·Suggesting other 
changes, possibly affecting the interaction between the basic Arg in position 8 and 
the acidic residue in EL Ill of the receptor. Interestingly a praline residue precedes 
the acidic residue in the non-mammalian GnRH receptors, while a praline follows the 
acidic residue in the mammalian GnRH receptors. Because pralines are known to 
affect the secondary structure of proteins by inducing ~-turns or disrupting a-helices 
[Chou and Fasman, 1978], this difference may drastically alter the conformation of 
EL Ill and effect the orientation of the side chain of the acidic residue, and hence 
ligand selectivity. The X laevis B GnRH receptor subtype, which has two adjacent 
praline residues in the corresponding position, and lacks the acidic residues (fig. 5.2), 
may therefore, have a drastically different ligand selectivity to both the other non-
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1 1------- --50 
Hgnrhr -----MANSA SPEQNQNHCS AINNSIPL . . MQGNLPTLTL SGKIRVTVTF 
Catf i sh MSGNTTLLLS NPTNVLDNSS VLNVSVSPPV LKWETPTFTT AARFRVAATL 
GfB MSGKMPLLSV NPTSIWENSS VLNATPHFP . SDWETPTFTV AAHFRVVATL 
GfA ---------- -MSDNTSLPS VSNASLLPPL TDWRAPSFTP AAQARVAATM 
Xl a -------MAV NQTQRSLVIS DNNASATGNA DPWTEPTFTL AAKVRVGVTC 
Xlb ---------- ---------- ---------- ---------- ----------
51 ----TM I ---------------1 1------ TM II --100 
Hgnrhr FLFLLSAT FN ASFLLKLQKW TQKKEKGKKL SRMKLLLKHL TLANLLETLI 
Catfish VLFVFRAASN LSVLLSVTRG RGRRLA .... SHLRPLIASL ASADLVMT FV 
GfB VLFVFAAISN LSVLISVTRG RGRHLA .. .. SHLRPLIGSL ASADLVMTFV 
GfA VLFLFAAVSN LALLISVSRG RGRRLA . ... SHLRPLIISL VSADLMMTFI 
Xl a CFFLIASCSN VAVLCSIS . . . GKRCK .... SHLRVLILSL SVADLLVT FL 
Xl b ---------- ---------- ---------- ---------- ----------
101 ----------1 1-------- ------TM III ------150 1 
Hgnrhr VMPLDGMWNI TVQWYAGELL CKVLSYLKLF SMYAPAFMMV VI SLDRSLAI 
Catfish VMPLDAVWNV TVQWYAGDAM CKLMCFLKLF AMHSAAFILV VVSLDRHHAI 
GfB VMPLDAIWNI TVQWYAGNAM CKNLCFLKLF AMHSAAFILV VVSLDRHHAI 
GfA VMPLDMVWNV TVQWYAGDGL CKLLCFLKLF AMQT SAFILV VI SLDRHHAI 
Xl a VMPLDALWNV MVQWYAGELS CKVLNFGKLF AMYSAALVLV VI SLDRHWAI 
Xl b ---------- ---------- ---------- ---------- ----------
151 1----------TM VI ------------1 200 
Hgnrhr TRPLALKSNS KVGQSHVGLA WILSSVFAGP QLYI FRMIHL ADSSGQTKVF 
Catfish LHPLDTLDAG RRNRRMLLTA . ILSLLLASP QLFI FRAIKA KGVD ... . . F 
GfB LHPLEALDAG RRNRRMLLAA WILSILLASP QLFI FRAIKA EGVD .. .. . F 
GfA LHPLDSLNAH QRNRRMLLLA WSLSALIASP QLFIFRTVKV KSVD .... . F 
Xl a LYPLSFTSAG QRNRIMLWTA WITSLLLASP QLFLFRLRTA PGVN . ... . F 
Xl b ---------- ---------- ---------- ---------- ----------
201 1--------------TM V----------------1250 
Hgnrhr SQCVTHCSFS QWWHQAFYNF FTFSCLFIIP LFIMLICNAK IIFTLTRVLH 
Catfish VQCATHGSFQ QHWQETAYNM F HFVTLYVFP LL . MSLCYTR ILVEI NRQMH 
GfA VQCVTHGSFR QRWQETAYNM F HFVTLYVFP LLVMSFCYTH ILVEI NRQMP 
GfB TQCVTHGSFH ERWY ETAYNM F HFVTLYVIP LLVMSCCYTC ILI EINRQLH 
Xl a TQCATBGSFT QHWQETAYNM FTFCTLFVTP LVVMIVCYTR ILWEI GKQMK 
Xl b ---------- ----ETI YNM FTF FCL FLLR LLIHVSCYTR I LMEI SHKMK 
2 51 1----------------TM VI ----300 
Hgnrhr Q . . . DPHELQ LNQSKNN . I P RARLKTLKMT VAFATSFTVC WTPYYVLGIW 
Catfish RSKDKAGEPC LRRSGTDMI P KARMKTLKMT IIIVASFVI C WTPYYLLGI W 
GfB RGKGKGGEPC LRRSGTNMI P KARMKTLKMT IIIVASFVVC WTPYYLLGIW 
GfA KSTE . . GE . S LRRSGTDMI P KARMKTLKMT IIIVLSFVVC WTPYYLLGIW 
Xl a HKNE ...... LARSKNDLI S KARLKTLKMT LVIVASFMVC WTPYYLLGLW 
Xlb ATCVSSKEID LRRSSNN . I P RARMRTLKMS LVIVLTF IVC WTPYYLLGI W 
301 --1 1- - ----------TM VII ------------1 350 
Hgnrhr YWF DPEML .. NRLSDPVNHF FFLFAFLNPC FDPLIYGYFS L---------
Catfish YWFQPQML .. HVIPDYVHHV FFVFGNLNTC CDPVI YGFFT PSFRADLSRC 
GfA YWFQPRML .. QSMPEYIHHA LFVFGNLNTC CDPVI YGFFT PSFRADIASC 
GfB YWFQPEML . . KVTPEYIHHL LFVFGNLNTC CDPVI YGLYT PSFRADLARC 
Xl a YWFQPEMI .. NQTPEYLNHS LFLFGLLHTC TDPLVYGLYT PSFKEDLRSW 
Xlb YWFPPEMLTE EKVPPVLSHI LFLFGLLNTC IDPQI YGSSV SRILQISIT-
351 396 
Hgnrhr ---------- ---------- ---------- ----------
Catfish FCWRNQNASA KSLPHFSGHR REVSGEAESD LGSGDQ.SGQ *-----
GfA FCRRNQNSSL KSLDRLSVRR GGASREAESD LGSGDQPSGQ QA* ---
GfB WRCRTPAESP RSLDRIPHEN TSPTRPA*-- ----------
Xla IRRVSTLLSR KEKNSKQLAG SELNIKDLTS MEGPTSTAVT MQSVF* 
Xlb ---------- ---------- ---------- ----------
Figure 5.2. Alignment of the amino acid sequences of the human (hgnrhr) , catfish , 
goldfish A and B (GfA and GfB), X. laevis A and B (XI A and XI B) GnRH receptors. 
Amino acid residues shown in red are conserved between all the GnRH receptors 
shown here. 
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mammalian and the mammalian GnRH receptors. The effect of the positioning of the 
acidic amino acid in EL Ill relative to proline, may be reflected by the reduced 
selectivity of mGnRH, and furthermore in the differences in ligand selectivity of 
cGnRH II versus mGnRH in the non-mammalian and mammalian GnRH receptors. 
The non-mammalian GnRH receptors do not show a high selectivity for mGnRH, 
however, they all seem to be a highly selective for cGnRH II. This is reflected by the 
high potency of this peptide in stimulating inositol phosphate production in COS-1 
cells transiently expressing the receptors. This possibility can be explored further by 
the use of chimeric receptors, whereby the agonist selectivity of the mammalian 
GnRH receptors could be changed by the exchange of extracellular loops of the 
mammalian GnRH receptors with those of non-mammalian receptors, thereby adding 
to our understanding of the agonist binding pocket. 
In addition to showing differences in selectivity for naturally occurring forms of GnRH 
the non-mammalian GnRH receptors tested, all show partial agonism to the 
mammalian GnRH receptor antagonist 135-18 ([Ac-0-Na11, 0-4-CIPhe2, O-Pal3, lle5, 
O-lsopropy1Lys6•8, 0-Ala 10 NH2]GnRH) (data not shown for goldfish GnRH receptor 
subtypes). Although it is not known which residues in the non-mammalian GnRH 
receptors may be responsible for this interaction this difference may be useful in 
defining the antagonist binding site in the mammalian GnRH receptors. The chimeric 
exchange of the extracellular loops of the human GnRH receptor with the X. laevis 
pituitary GnRH receptor, have implicated extracellular loop II [Ott TR, unpublished 
results]. 
A detailed analysis of the sequences of the non-mammalian GnRH receptors, 
coupled to pharmacological characterisations, therefore, lays the foundation for 
future studies involving the receptor structure and stability as well as the delineation 
of agonist and antagonist binding domains. 
The isolation of multiple GnRH subtypes in vertebrates and functional studies of 
these peptides have implicated them in several regulatory roles in addition to the 
regulation of the hypothalamic/pituitary gonadal axis [for review, see King and Millar, 
1997]. The function of the highly conserved cGnRH II, which has only recently been 
described in primates and humans [Lescheid et al., 1997; White et al., 1998] is 
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unclear, but its high conservation throughout evolution suggests a stringent selection, 
possibly due to multiple functions, and possibly constrained by the interaction with 
different receptor subtypes. The occurrence of one or more variants of GnRH, as 
well as the highly conserved cGnRH II lays the foundation for the study of multiple 
GnRH receptor subtypes. 
In amphibia, cGnRH II has been proposed to be involved in neuromodulation or 
neurotransmission [King et al., 1994a] and has been implicated in the inhibition of M-
current [Jan and Jan, 1980; 1982; Jones 1987]. M-current inhibition has been shown 
to have an effect on neuron excitability [Kirkwood and Lissman, 1992]. The 
occurrence of cGnRH II and cGnRH II specific binding sites in extracts of 
sympathetic ganglia, described in this thesis, provides further evidence that cGnRH II 
may be the endogenous neurotransmitter in this response. Thus, in the amphibian 
brain, one would predict the occurrence of two GnRH receptor subtypes. One, which 
is involved in the release of LH and FSH from the pituitary, while the other may inhibit 
M-current in the sympathetic ganglia. Two GnRH receptor subtypes were isolated 
from X. laevis genomic DNA. The full-length cDNA for the one was cloned from the 
pituitary, while a processed, but incomplete transcript was cloned from sympathetic 
ganglia cDNA. Although no full-length transcripts were identified, the fact that a 
processed transcript is present in cDNA from the sympathetic ganglia implies an 
expression of this receptor in these neurons, which is substantiated by the detection 
of specific cGnRH II binding sites. The GnRH dependent M-current inhibition has 
been described in rats [Owen et al., 1990] and may, therefore, be a widespread 
mechanism for controlling neuron excitability. Possible homologues to this receptor 
have been detected in the lizard (Agama atra) by PCR on genomic DNA (Dr E. 
Rumbak) and in the human by database interrogation (Prof. R. Millar). Due to the 
high conservation of these putative GnRH receptor subtypes in amphibians, reptiles 
and mammals, it is unlikely that they are unexpressed pseudogenes. 
The goldfish is also a unique model system in that two distinct GnRH receptor 
subtypes may facilitate the release of GH and GtH from somatotropes and 
gonadotropes respectively. Two GnRH receptor subtypes were identified, which 
have different primary structures and co-ordinated with these differences, distinct 
pharmacologies. There is no clear correlation between the pharmacology of these 
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cloned receptor subtypes and the GtH and GH-releasing activity of GnRH analogues, 
but expression patterns as determined by in situ hybridisations (Dr R.E. Peter, 
University of Alberta, Edmonton), imply a role in pituitary hormone secretion and 
possibly reproductive behaviour. 
Although the occurrence of multiple GnRHs in a single species suggests the co-
ordinated occurrence of multiple receptor subtypes, this is the first description of 
multiple GnRH receptor subtypes in a single species. Although only one full-length 
receptor was isolated from X laevis, there is convincing evidence for the presence of 
a second receptor, although its expression remains to be elucidated. In the goldfish, 
however, two receptors were cloned, and these have distinct pharmacologies and 
differential expression in the brain, gonads and liver. The sequence corresponding to 
EC Ill of two receptor subtypes have also been cloned from the genomic DNA of the 
lizard (Agama atra) and the zebrafish (Brachydanio rerio) by Dr E Rumbak. From the 
sequence alignment of all the receptor subtypes, there appear to be two receptor 
groups, designated type I and type II, which may have arisen via the duplication of an 
ancestral gene (fig. 5.3). The first group, designated type I, includes the mammalian, 
the chicken [Sun et al., in preparation], the X laevis A, one of the lizard receptor 
subtypes, the catfish, and the two goldfish and zebrafish GnRH receptors. Despite 
the fact that no classifications can be made, based on the homology data, these 
receptors have to be grouped into two groups, type la and type lb, due to the multiple 
receptor subtypes in the goldfish and zebrafish. The human GnRH receptor appears 
to be equally unrelated to both the type I and type II receptors (fig. 5.4), but has been 
grouped with the type I receptors due to its sequence similarities in EL Ill. The type II 
receptors include the X /aevis B receptor, the second lizard receptor subtype and the 
second human GnRH receptor (HGnRHRII) (Millar et al., submitted]. These 
receptors show .a high homology to each other and a distinctive sequence in EL Ill 
consisting of two adjacent praline residues (fig. 5.2). Although this classification is 
based on the limited sequence to EL Ill, as the full-length sequences are not 
available for all the receptors, it is likely to be representative of the full-length 
receptors for two reasons. Firstly, because EL Ill is thought to be an important 
determinant in ligand selectivity, and secondly because the sequence information in 
this domain is unbiased by the low conservation in the NH2- and carboxy-termini 
domains and the highly conserved transmembrane domains. A similar pattern is 
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obtained using the full-length sequences of the human, chicken [Sun et al., in 
preparation], catfish [fensen et al., 1997], goldfish A and B and X laevis pituitary 
GnRH receptors (this thesis) as well as the partial clones to the X. laevis B (chapter 3, 
this thesis) and the human type II (HGnRHRII) [Millar et al., submitted] putative GnRH 




Figure 5.3 A possible evolutionary scheme for the putative GnRH receptor 
subtypes. A primitive ancestral gene may have undergone a gene duplication 
forming two receptor groups, designated type I and type II. The type I receptor 
subtype, may have subsequently undergone a further duplication (at least in some 
teleosts) forming the type la and type lb receptor subtypes. 
Cloning and characterisation of multiple GnRH receptor subtypes from the 
amphibian, X. laevis and the teleost, C. auratus, has provided some useful insights 
into the understanding of both non-mammalian and mammalian GnRH receptors. 
This work lays the foundation for the identification of receptor subtypes in other 
vertebrate species, including mammals. The sequence information has already been 
used to identify a possible homologue, to the type II receptor subtype in X laevis, in 
the human. Analysis of the primary structure of the non-mammalian GnRH receptors 
described in this thesis, has revealed several features which are unique from each 
other and the mammalian GnRH receptors. Coupled to these changes are distinct 
pharmacologies and ligand selectivities. Characterisation using GnRH analogues has 
revealed that these receptors, in contrast to previous studies do show a selectivity for 
naturally occurring GnRHs, in particular chicken GnRH II. This work therefore lays the 
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groundwork for future studies on the interaction of GnRH and its receptor, by the use of 
receptor site-directed mutagenesis studies and the analysis of non-

































Figure 5.4. Dendogram of the relatedness between the human GnRH receptors, 
type I (HGnRHR) and type II (HGnRHRII) [Millar et al., submitted], Chicken 
(ChGnRHR) [Sun et al., in preparation], Catfish (CfGnRHR) [Tensen et al., 1997], 
Goldfish A and B receptor subtypes (GfA and GIB) and the X. laevis A and B 
receptor subtypes (X/A and X/8). Full-length sequences were used where available, 
oniy partial sequences of HGriRHRII and X/8 were used: Relatedness determined 
using the Wisconsin Packag~, Version 9.0, Genetics Computer Group (GCG), 
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Appendix 7.1: Map of pMOSB/ue-T PCR cloning vector (Amersham) 
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Appendix 7.2: Map of Bacteriophage Lambda EMBL4 vector, showing the mulitple 
cloning regions 
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Appendix 7.3: Map· of pX/a.1 showing the nucleotide and translated amino acid 
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cctgataccatgaccaa ggtcggactctactagttggtttgaggactcatggaattggtg 









Appendix 7.4: Map of pBluescript II SK(+/-) phagemid, showing the multiple cloning site. 
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Appendix 7.5a: Map of pX/1 a.2 containing a 3 kbp genomic DNA fragment cloned 
into the EcoRI site of pBluescript II SK(+/-). 
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Appendix 7.5b: Sequence of pX/1 a.2, showing the primers used for amplification 
of cDNA 
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Appendix 7. 7: Map of pX/b.1 showing the nucleotide sequence and the translated 
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Appendix 7.Ba: Map of pSPL3 exon trapping vector. The upper region shows the 
HIV-1 tat sequences. Shaded blocks represent exon sequences, where SDv = 
vector splice donor and SAv = vector splice acceptor. solid line represents the intron 
sequence, where soc = cryptic splice donor in the intron region. PCR primers are 
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Appendix 7.Bb: Potential splicing events in the exon trapping procedure. A; 
represents the genomic fragment cloned into the pSPL3 vector. B; RNA 
extracted for transfected COS-1 cells, is converted to cDNA and amplified in 
C. This amplified DNA is reamplified in D. SD
9 
= genomic DNA splice donor, 
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Appendix 7.9: Nucleotide and deduced amino acid sequence of pXb from 5' 
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Appendix 7.10: Nucleotide sequence of the exon trapping subclone aligned to 
the X. laevis 28 S, 18 Sand 5.8 S ribosomal RNAs, to which it showed a 96.4% 
identity 
ET9: Exon trapping subclone number 9 
Accession number of the ribosomal RNA to which ET9 aligns: Gb _ Ov:XlrnO 1 
LOCUS XLRNOl 8153 bp DNA VRT 28-FEB-1992 
DEFINITION Xenopus /aevis genes for 18S, 5.8S and 28S ribosomal RNAs. 
ACCESSION X02995 J00999 J01001 J01002 J01003 J01006 J01007 K01369 K01370 
SCORES 
K01371 K01372 K01373 K01376 K01535 V01444 V01445 V01446 V01447 
V01448 V01449 V01450 V01451 V01452 V01453 V01454 V01456 X00136 
X01071 ... 
96.4% identity in 140 bp overlap 
10 20 30 40 50 60 
Et9 CACTATAGGGCTCGAGCGGCCGCCCGGGCAGGTCCTTTGATCGCTCCATCTGTTACTTGG 
I I I I I I 111 I 111111 11 I I I I I I I I 11 I 
XlrnOl AACTGCGAATGGCTCATTAAATCAGTTATGGTTCCTTTGATCGCTCCATCTGTTACTTGG 
1120 1130 1140 1150 1160 1170 
70 80 90 100 110 120 
Et9 ATAACTGTGGTAATTCTAGAGCTAATACATGCCGACGAGCGCTGACCCCCAGGGATGCGT 
I 1111 I I 11 I I I I I I 11 I I 111 I 111 I I I I I I I I I 11 111 I 1 11 I 11 I I 11 I I 11 11 11 I 
XlrnOl ATAACTGTGGTAATTCTAGAGCTAATACATGCCGACGAGCGCTGACCCCCAGGGATGCGT 
1180 1190 1200 1210 1220 1230 
130 140 150 160 170 
Et9 GCATTTATCAGACCAAAACCAATCCGGGG-CCCCGCG-CCCGCTCGCTTT 
I 1111 I I I I 11 I I I I I I I I 11 11 I I I I I I I I I I 11 I I I I I I 11 I I I 
Xl~nOl GCATTTATCAGACCAAAACCAATCCGGGGCCCCCGCGCCCCGGCCGCTTTGGTGACTCTA 
1240 1250 1260 1270 1280 1290 
160 
Appendix 7.11: Map of pGfA.1 showing the nucleotide and translated amino 

























61 ---------+---------+---------+---------+---------+-- 112 
gacgagaagca9aajgcccttggacttgtggacgajc~~ 
L L F V F G N L N T C C D P L I Y 
GfA.1 as JH 6a2 
161 
Appendix 7.12: Map of pGfB.1 showing the nucleotide and translated 
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E -ca--o:: n,Ec:ug 
ct! > a. ct! 
Ill <( (/) ~ (/) w 
U19 primer 
f1 origin 
Clone GIB.l : 
GfB.2s 
~fit¢jfj~jj3:: c ~ gcctcgtatgctgcagtcg l, tgccagaatacatccatcac 
1 --- -+- ---- --- -+ ---- --- --+- ---- ---- +- ------ --+----- ---- + 60 
ootqataocatqaccaag gtcggagcatacgacgtcagctacggt f ttatgtaggtagtg 
G I W Y W F Q P R M L Q S M P E Y I H H 
JH s s Gf8.3as 
gctctcttcgtcttcggcaatctcaacacatgctgcqatcoocttatotao 
61 
cg aga gaag~ag l, a b ccgt~a gagttg tg ~ acga p gfl\tENif.-dN 
112 
A L F V F G N L N T 
Gf8.1as 
162 
C C D P L I Y 
JH Eia2 
Appendix 7.13: Map of pGEM-T PCR cloning vector (Promega) 
T7 primer 
), 
Multiple cloning site 
- - - N - = _ N - - x Sp6 Primer 
m=~-oo~--==~o~= •4<L---a.ma.(l)oma.o(/)(l)m"Cmui(I) ~ 
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